U.S. patent application number 10/490976 was filed with the patent office on 2008-10-30 for whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof.
Invention is credited to Dean Ervin Cress, Tarlochart Singh Dhadialla, Subba Reddy Palli, Jianzhong Zhang.
Application Number | 20080268499 10/490976 |
Document ID | / |
Family ID | 23268290 |
Filed Date | 2008-10-30 |
United States Patent
Application |
20080268499 |
Kind Code |
A9 |
Zhang; Jianzhong ; et
al. |
October 30, 2008 |
WHITEFLY ECDYSONE RECEPTOR NUCLEIC ACIDS, POLYPEPTIDES, AND USES
THEREOF
Abstract
The present invention relates to a novel isolated whitefly
ecdysone receptor polypeptide. The invention also relates to an
isolated nucleic acid encoding the whitefly ecdysone receptor
polypeptide, to vectors comprising them and to their uses, in
particular in methods for modulating gene expression in an ecdysone
receptor-based gene expression modulation system and methods for
identifying molecules that modulate whitefly ecdysone receptor
activity.
Inventors: |
Zhang; Jianzhong; (North
Wales, PA) ; Cress; Dean Ervin; (Souderton, PA)
; Palli; Subba Reddy; (Lansdale, PA) ; Dhadialla;
Tarlochart Singh; (Chalfont, PA) |
Correspondence
Address: |
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 NEW YORK AVENUE, N.W.
WASHINGTON
DC
20005
US
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20040235097 A1 |
November 25, 2004 |
|
|
Family ID: |
23268290 |
Appl. No.: |
10/490976 |
Filed: |
February 20, 2002 |
PCT Filed: |
February 20, 2002 |
PCT NO: |
PCT/US02/05234 |
371 Date: |
March 25, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60325534 |
Sep 26, 2001 |
|
|
|
Current U.S.
Class: |
514/1.1 ;
435/320.1; 435/348; 530/350; 536/23.5 |
Current CPC
Class: |
A61P 33/14 20180101;
G01N 33/566 20130101; G01N 2333/723 20130101; A61P 43/00 20180101;
C07K 14/43577 20130101 |
Class at
Publication: |
435/069.1 ;
435/348; 435/320.1; 530/350; 536/023.5; 514/002 |
International
Class: |
A01N 37/18 20060101
A01N037/18; C07H 21/04 20060101 C07H021/04; C07K 14/72 20060101
C07K014/72 |
Claims
1. An isolated polynucleotide comprising a nucleic acid sequence
selected from the group consisting of SEQ ID NO: 1, nucleotides
102-1349 of SEQ ID NO: 1, nucleotides 102-258 of SEQ ID NO: 1,
nucleotides 259-457 of SEQ ID NO: 1, nucleotides 458-677 of SEQ ID
NO: 1, nucleotides 678-1349 of SEQ ID NO: 1, nucleotides 259-1349
of SEQ ID NO: 1, nucleotides 458-1349 of SEQ ID NO: 1, and
nucleotides 648-1349 of SEQ ID NO: 1.
2. An isolated polynucleotide encoding a polypeptide comprising an
amino acid sequence selected from the group consisting of SEQ ID
NO: 2, amino acids 1-52 of SEQ ID NO: 2, amino acids 53-118 of SEQ
ID NO: 2, amino acids 119-192 of SEQ ID NO: 2, amino acids 193-416
of SEQ ID NO: 2, amino acids 53-416 of SEQ ID NO: 2, amino acids
119-416 of SEQ ID NO: 2, and amino acids 183-416 of SEQ ID NO:
2.
3. A vector comprising the isolated polynucleotide according to
claims 1 or 2.
4. The vector according to claim 3, wherein the isolated
polynucleotide is operatively linked to an expression control
sequence that permits expression of the isolated polynucleotide in
an expression competent host cell.
5. The vector according to claim 4, wherein the expression control
sequence comprises a promoter that is functional in a mammalian
cell.
6. The vector according to claim 4, wherein the vector is selected
from the group consisting of an RNA molecule, a plasmid, and a
viral vector.
7. The vector according to claim 6, wherein the vector is a
plasmid.
8. An isolated host cell transfected with the vector according to
claim 3.
9. The isolated host cell according to claim 8, wherein the host
cell is selected from the group consisting of a bacterial cell, a
fungal cell, a yeast cell, a nematode cell, an insect cell, a fish
cell, a plant cell, an avian cell, an animal cell, and a mammalian
cell.
10. An isolated polypeptide comprising an amino acid sequence
selected from the group consisting of SEQ ID NO: 2, amino acids
1-52 of SEQ ID NO: 2, amino acids 53-118 of SEQ ID NO: 2, amino
acids 119-192 of SEQ ID NO: 2, amino acids 193-416 of SEQ ID NO: 2,
amino acids 53-416 of SEQ ID NO: 2, amino acids 119-416 of SEQ ID
NO: 2, and amino acids 183-416 of SEQ ID NO: 2.
11. A method for producing a whitefly ecdysone receptor polypeptide
comprising: a) culturing the host cell of claim 8 in culture medium
under conditions permitting expression of a whitefly ecdysone
receptor polypeptide; and b) isolating the whitefly ecdysone
receptor polypeptide from the culture medium.
12. An antibody which specifically binds the isolated polypeptide
of claim 10.
13. The antibody of claim 12, wherein the antibody is a monoclonal
antibody.
14. A composition comprising the isolated polynucleotide according
to claims 1 or 2 and an acceptable carrier.
15. A composition comprising the vector according to claim 3 and an
acceptable carrier.
16. A composition comprising the isolated polypeptide according to
claim 10 and an acceptable carrier.
17. A method of screening for molecules that modulate whitefly
ecdysone receptor activity in a cell, the method comprising: (a)
contacting a cell comprising the isolated polypeptide according to
claim 10 with a candidate molecule; and (b) detecting whitefly
ecdysone receptor activity in the presence of the molecule.
18. The method according to claim 17, wherein the molecule is an
agonist of whitefly ecdysone receptor.
19. The method according to claim 17, wherein the molecule is an
antagonist of whitefly ecdysone receptor.
Description
FIELD OF THE INVENTION
[0001] This invention relates to the field of biotechnology.
Specifically, this invention relates to isolated nucleic acids,
vectors comprising them, and polypeptides encoded by them, and to
their use in the field of gene expression and insecticide
discovery. More specifically, this invention relates to a novel
nucleic acid encoding an ecdysone receptor polypeptide from the
homopteran whitefly (Bamecia argentifoli, "BaEcR") and its use in
methods of modulating the expression of a gene within a host cell
using BaEcR, and in methods of identifying molecules that modulate
the activity of the BaEcR
BACKGROUND OF THE INVENTION
[0002] Various publications are cited herein, the disclosures of
which are incorporated by reference in their entireties. However,
the citation of any reference herein should not be construed as an
admission that such reference is available as "Prior Art" to the
instant application.
[0003] Cultivated agriculture has greatly increased efficiency of
food production in the world. However, various insect pests have
found it advantageous to seek out and exploit cultivated sources of
food to their own advantage. These insect pests typically develop
by a temporal sequence of events which are characteristic of their
order. Many insects initially develop in a caterpillar or
maggot-like larval form. Thereafter, they undergo a significant
metamorphosis from which an adult emerges having characteristic
anatomical features. Anatomic similarity is a reflection of
developmental, physiological and biochemical similarities shared by
these creatures. In particular, the principles of the insect
ecdysteroid-hormone receptors and development, as described by
Ashburner et al. (Cold Spring Harbor Symp. Quant. Biol. 38:655-662,
1974), likely would be shared by many different types of
insects.
[0004] To prevent or reduce the destruction of cultivated crops by
insects, organic molecules with pesticidal properties are used
commonly in attempts to eliminate or reduce the insect populations.
However, the ecological side effects of these pesticides, due in
part to their broad activity and lack of specificity, and in part,
to the fact that some of these pesticides are not easily
biodegradable, significantly affect populations of both insect and
other species of animals. Some of these organisms may be
advantageous from an ecological or other perspective. Furthermore,
as the insect populations evolve in directions to minimize the
effects of the applied pesticides, the amounts of pesticides
applied are often elevated so high as to cause significant effects
on other animals, including humans, which are affected directly or
indirectly by the application of the pesticides. Thus, an important
need exists for both highly specific pesticides or highly active
pesticides which have biological effects only on the species of
animals targeted by the pesticides, and are biodegradable. Novel
insect hormones which, like the ecdysteroids, act by complexing
with insect members of the steroid receptor superfamily to control
insect development, are likely candidates for pesticides with these
desirable properties.
[0005] Growth, molting, and development in insects are regulated by
the ecdysone steroid hormone (molting hormone) and the juvenile
hormones (Dhadialla, et al., 1998, Annu. Rev. Entomol. 43:
545-569). The molecular target for ecdysone in insects consists of
at least ecdysone receptor (EcR) and ultraspiracle protein (USP).
EcR is a member of the nuclear steroid receptor super family that
is characterized by signature DNA and ligand binding domains, and
an activation domain (Koelle et al. 1991, Cell, 67:59-77). EcR
receptors are responsive to a number of steroidal compounds such as
ponasterone A and muristerone A. Recently, non-steroidal compounds
with ecdysteroid agonist activity have been described, including
the commercially available insecticides tebufenozide and
methoxyfenozide (see International Patent Application No.
PCT/EP96/00686 and U.S. Pat. No. 5,530,028). Both analogs have
exceptional safety profiles to other organisms.
[0006] Polynucleotides encoding ecdysone receptors have been cloned
from a variety of insect species, including Dipterans (see U.S.
Pat. Nos. 5,514,578 and 6,245,531 B1), Lepidopterans, Orthopterans,
Hemipterans, and one Homopteran Aphid, all from the class
Arthropod. In particular, EcRs have been cloned from spruce budworm
Choristoneura furniferana EcR ("CfEcR"; Kothapalli et al., 1995 Dev
Genet. 17: 319-30), a yellow meal worm Tenebrio molitor EcR
("TmEcR"; Mouillet et al., 1997, Eur. J. biochem. 248: 856-863), a
tobacco hormworm Manduca sexta EcR ("MsEcR"; Fujiwara et al., 1995,
Insect Biochem. Molec. Biol. 25, 845-856), a tobacco budworm
Heliotliies virescens EcR ("HvEcR"; Martinez et al., 1999, Insect
Biochem Mol. Biol. 29: 915-30), a golmidge Chironomus tentans EcR
("CtEcR"; Imhof et al., 1993, Insect Biochem. Molec. Biol. 23,
115-124), a silkworm Bombyx mori EcR ("BmEcR"; Swevers et al.,
1995, Insect Biochem. Molec. Biol. 25, 857-866), a squinting bush
brown Bicyclus anynana EcR ("BanEcR"), a buckeye Junonia coenia EcR
("JcEcR"), a fruit fly Drosophila melanogaster EcR ("DmEcR"; Koelle
et al., 1991, Cell 67, 59-77), a yellow fever mosquito Aedes
aegypti EcR ("AaEcR"; Cho et al., 1995, Insect Biochem Molec. Biol.
25, 19-27), a blowfly Lucilia capitata ("LcEcR"), a sheep blowfly
Lucilia cuprina EcR ("LucEcR"; Hannan and Hill, 1997, Insect
Biochem. Molec. Biol. 27, 479-488), a blowfly Calliphora vicinia
EcR ("CvEcR"), a Mediterranean fruit fly Ceratitis capitata EcR
("CcEcR"; Verras et al., 1999, Eur J Biochem. 265: 798-808), a
locust Locusta migratoria EcR ("LmEcR"; Saleh et al., 1998, Mol
Cell Endocrinol. 143: 91-9), an aphid Myzus persicae EcR ("MpEcR";
International Patent Application Publication WO99/36520), a fiddler
crab Celuca pugilator EcR ("CpEcR"; Chung et al., 1998, Mol Cell
Endocrinol 139: 209-27), and an ixodid tick Amblyomma americanum
EcR ("AmaEcR"; Guo et al., 1997, Insect Biochem. Molec. Biol. 27:
945-962). The nucleotide and/or amino acid sequences of these
ecdysone receptors have been determined and are publicly
available.
[0007] The ecdysone receptor complex typically includes proteins
that are members of the nuclear receptor superfamily wherein all
members are generally characterized by the presence of an
amino-terminal transactivation domain, a DNA binding domain
("DBD"), and a ligand binding domain ("LBD") separated from the DBD
by a hinge region. As used herein, the term "DNA binding domain"
comprises a minimal polypeptide sequence of a DNA binding protein,
up to the entire length of a DNA binding protein, so long as the
DNA binding domain functions to associate with a particular
response element. Members of the nuclear receptor superfamily are
also characterized by the presence of four or five domains: A/B, C,
D, E, and in some members F (see U.S. Pat. No. 4,981,784 and Evans,
Science 240:889-895 (1988)). The "A/B" domain corresponds to the
transactivation domain, "C" corresponds to the DNA binding domain,
"D" corresponds to the hinge region, and "E" corresponds to the
ligand binding domain. Some members of the family may also have
another tmmsactivation domain on the carboxy-terminal side of the
LBD corresponding to "F".
[0008] The DBD is characterized by the presence of two cysteine
zinc fingers between which are two amino acid motifs, the P-box and
the D-box, which confer specificity for ecdysone response elements.
These domains may be either native, modified, or chimeras of
different domains of heterologous receptor proteins. The EcR
receptor, like a subset of the steroid receptor family, also
possesses less well-defined regions responsible for
heterodimerization properties. Because the domains of nuclear
receptors are modular in nature, the LBD, DBD, and transactivation
domains may be interchanged.
[0009] Gene switch systems are known that incorporate components
from the ecdysone receptor complex. However, in these known
systems, whenever EcR is used it is associated with native or
modified DNA binding domains and transactivation domains on the
same molecule. USP or RXR are typically used as silent partners.
Applicants have previously shown that when DNA binding domains and
transactivation domains are on the same molecule the background
activity in the absence of ligand is high and that such activity is
dramatically reduced when DNA binding domains and transactivation
domains are on different molecules, that is, on each of two
partners of a heterodimeric or homodimeric complex (see
PCT/US01/09050).
[0010] The insect ecdysone receptor (EcR) heterodimerizes with
Ultraspiracle (USP), the insect homologue of the mammalian RXR, and
binds ecdysteroids and ecdysone receptor response elements and
activates transcription of ecdysone responsive genes (Riddiford et
al. 2000, Vitam Horm, 60: 1-73). The EcR/USP/ligand complexes play
important roles during insect development and reproduction. The EcR
is a member of the steroid hormone receptor superfamily and has
five modular domains, A/B (transactivation), C (DNA binding,
heterodimerization), D (Hinge, heterodimerization), E (ligand
binding, heterodimerization and transactivation and in some cases,
F (transactivation), domains. Some of these domains such as A/B, C
and E retain their function when they are fused to other
proteins.
[0011] Recently, ecdysone receptor based gene expression systems
have been developed. Tightly regulated inducible gene expression
systems or "gene switches" are useful for various applications such
as gene therapy, large scale production of proteins in cells, cell
based high throughput screening assays, functional genomics and
regulation of traits in transgenic plants and animals. U.S. Pat.
No. 6,265,173 B1 discloses that various members of the
steroid/thyroid superfamily of receptors can combine with
Drosophila melanogaster ultraspiracle receptor (USP) or fragments
thereof comprising at least the dimerization domain of USP for use
in a gene expression system. U.S. Pat. No. 5,880,333 discloses a
Drosophila melanogaster EcR and ultraspiracle (USP) heterodimer
system used in plants in which the transactivation domain and the
DNA binding domain are positioned on two different hybrid
proteins.
[0012] The first version of an EcR-based gene switch used
Drosophila melanogaster EcR (DmEcR) and Mus musculus RXR (MmRXR)
and showed that these receptors in the presence of steroid,
ponasterone A, transactivate reporter genes in mamalian cell lines
and transgenic mice (Christopherson et al. 1992, PNAS 89:6314-6318;
No et al. 1996, PNAS 93:3346-3351). Later, Suhr et al. (1998, Proc.
Natl. Acad. Sci. U.S.A. 95: 7999-8004) showed that non-steroidal
ecdysone agonist, tebufenozide, induced high level of
transactivation of reporter genes in mammalian cells through Bombyx
mori EcR (BmEcR) in the absence of exogenous heterodimer
partner.
[0013] International Patent Applications Nos. PCT/US97/05330 (WO
97/38117) and PCT/US99/08381 (WO99/58155) disclose methods for
modulating the expression of an exogenous gene in which a DNA
construct comprising the exogenous gene and an ecdysone response
element is activated by a second DNA construct comprising an
ecdysone receptor that, in the presence of a ligand therefor, and
optionally in the presence of a receptor capable of acting as a
silent partner, binds to the ecdysone response element to induce
gene expression. The ecdysone receptor of choice was isolated from
Drosophila melanogaster.
[0014] Typically, such systems require the presence of the silent
partner, preferably retinoid X receptor (RXR), in order to provide
optimum activation. In mammalian cells, insect ecdysone receptor
(EcR) heterodimerizes with retinoid X receptor (RXR) and regulates
expression of target genes in a ligand dependent manner.
International Patent Application No. PCT/US98/14215 (WO 99/02683)
discloses that the ecdysone receptor isolated from the silk moth
Bombyx mori is functional in mammalian systems without the need for
an exogenous dimer partner.
[0015] Unfortunately, these USP-based systems are constitutive in
animal cells and therefore, are not effective for regulating
reporter gene expression. Drawbacks of the above described
EcR-based gene regulation systems include a considerable background
activity in the absence of ligands and non-applicability of these
systems for use in both plants and animals (see U.S. Pat. No.
5,880,333).
[0016] Recently, an improved ecdysone receptor-based inducible gene
expression system has been developed in which the transactivation
and DNA binding domains are separated from each other by placing
them on two different proteins results in greatly reduced
background activity in the absence of a ligand and significantly
increased activity over background in the presence of a ligand
(pending application PCT/US01/09050, incorporated herein in its
entirety by reference). This two-hybrid system is a significantly
improved inducible gene expression modulation system compared to
the two systems disclosed in applications PCT/US97/05330 and
PCT/US98/14215. The two-hybrid system exploits the ability of a
pair of interacting proteins to bring the transcription activation
domain into a more favorable position relative to the DNA binding
domain such that when the DNA binding domain binds to the DNA
binding site on the gene, the transactivation domain more
effectively activates the promoter (see, for example, U.S. Pat. No.
5,283,173). Briefly, the two-hybrid gene expression system
comprises two gene expression cassettes; the first encoding a DNA
binding domain fused to a nuclear receptor polypeptide, and the
second encoding a transactivation domain fused to a different
nuclear receptor polypeptide. In the presence of ligand, the
interaction of the first polypeptide with the second polypeptide
effectively tethers the DNA binding domain to the transactivation
domain. Since the DNA binding and transactivation domains reside on
two different molecules, the background activity in the absence of
ligand is greatly reduced.
[0017] A two-hybrid system also provides improved sensitivity to
non-steroidal ligands for example, diacylhydrazines, when compared
to steroidal ligands for example, ponasterone A ("PonA") or
muristerone A ("MurA"). That is, when compared to steroids, the
non-steroidal ligands provide higher activity at a lower
concentration. In addition, since transactivation based on EcR gene
switches is often cell-line dependent, it is easier to tailor
switching systems to obtain maximum transactivation capability for
each application. Furthermore, the two-hybrid system avoids some
side effects due to overexpression of RXR that often occur when
unmodified RXR is used as a switching partner. In a preferred
two-hybrid system, native DNA binding and transactivation domains
of EcR or RXR are eliminated and as a result, these hybrid
molecules have less chance of interacting with other steroid
hormone receptors present in the cell resulting in reduced side
effects.
[0018] Applicants have now obtained and determined the full-length
coding sequence of an additional homopteran EcR polynucleotide from
whitefly for use in methods of modulating gene expression in a host
cell and methods of identifying molecules that modulate activity of
whitefly EcR. As described herein, Applicants' invention provides
novel whitefly ecdysone receptor polypeptides and novel
polynucleotides encoding these polypeptides that are useful as
components of gene expression systems for highly specific
regulation of recombinant proteins in host cells or in methods for
identifying new molecules which may act as agonists or antagonists
of a homopteran insect ecdysone receptor.
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] FIG. 1: Transactivation of reporter genes through
VP16/BaEcR-CDE construct transfected into L57 cells or CBW cells
along with 5XEcRELacZ and pFREcRE by 20E or GS.TM.-E. The numbers
on top of the bars indicate fold increase over DMSO levels.
[0020] FIG. 2: Transactivation of reporter genes through
GALA/BaEcR-DE construct transfected into NIH3T3 cells along with
VP16/CfUSP-EF, VP16/DmUSP-EF, VP16/MmRXR.alpha.-EF,
VP16/MmRXR.alpha./LmUSP-EF chimera, VP16/AmaRXR1-EF, or
VP16/AmaRX2-EF, and pFRLuc by PonA or GS.TM.-E. The numbers on top
of the bars indicate the maximum fold induction for that group.
DETAILED DESCRIPTION OF THE INVENTION
[0021] The present invention advantageously provides an isolated
polynucleotide encoding a novel whitefly ecdysone receptor
polypeptide. The polynucleotides and polypeptides of the present
invention are useful in methods to regulate gene expression of a
polypeptide of interest in a host cell and in identifying new
molecules that modulate activity of a whitefly EcR.
[0022] The various aspects of the invention will be set forth in
greater detail in the following sections, directed to the nucleic
acids, polypeptides, vectors, antibodies, compositions, and methods
of use of the invention. This organization into various sections is
intended to facilitate understanding of the invention, and is in no
way intended to be limiting thereof.
Definitions
[0023] The following defined terms are used throughout the present
specification, and should be helpful in understanding the scope and
practice of the present invention.
[0024] In a specific embodiment, the term "about" or
"approximately" means within 20%, preferably within 10%, more
preferably within 5%, and even more preferably within 1% of a given
value or range.
[0025] The term "substantially free" means that a composition
comprising "A" (where "A" is a single protein, DNA molecule,
vector, recombinant host cell, etc.) is substantially free of "B"
(where "B" comprises one or more contaminating proteins, DNA
molecules, vectors, etc.) when at least about 75% by weight of the
proteins, DNA, vectors (depending on the category of species to
which A and B belong) in the composition is "A". Preferably, "A"
comprises at least about 90% by weight of the A+B species in the
composition, most preferably at least about 99% by weight. It is
also preferred that a composition, which is substantially free of
contamination, contain only a single molecular weight species
having the activity or characteristic of the species of
interest.
[0026] The term "isolated" for the purposes of the present
invention designates a biological material (nucleic acid or
protein) that has been removed from its original environment (the
environment in which it is naturally present). For example, a
polynucleotide present in the natural state in a plant or an animal
is not isolated, however the same polynucleotide separated from the
adjacent nucleic acids in which it is naturally present, is
considered "isolated". The term "purified" does not require the
material to be present in a form exhibiting absolute purity,
exclusive of the presence of other compounds. It is rather a
relative definition.
[0027] A polynucleotide is in the "purified" state after
purification of the starting material or of the natural material by
at least one order of magnitude, preferably 2 or 3 and preferably 4
or 5 orders of magnitude.
[0028] As used herein, the term "substantially pure" describes a
polypeptide or other material which has been separated from its
native contaminants. Typically, a monomeric polypeptide is
substantially pure when at least about 60 to 75% of a sample
exhibits a single polypeptide backbone. Minor variants or chemical
modifications typically share the same polypeptide sequence.
Usually a substantially pure polypeptide will comprise over about
85 to 90% of a polypeptide sample, and preferably will be over
about 99% pure. Normally, purity is measured on a polyacrylamide
gel, with homogeneity determined by staining. Alternatively, for
certain purposes high resolution will be necessary and HPLC or a
similar means for purification will be used. For most purposes, a
simple chromatography column or polyacrylamide gel will be used to
determine purity.
[0029] The term "substantially free of naturally-associated host
cell components" describes a polypeptide or other material which is
separated from the native contaminants which accompany it in its
natural host cell state. Thus, a polypeptide which is chemically
synthesized or synthesized in a cellular system different from the
host cell from which it naturally originates will be free from its
naturally-associated host cell components.
[0030] The terms "nucleic acid" or "polynucleotide" are used
interchangeably herein to refer to a polymeric compound comprised
of covalently linked subunits called nucleotides. Nucleic acid
includes polyribonucleic acid (RNA) and polydeoxyribonucleic acid
(DNA), both of which may be single-stranded or double-stranded. DNA
includes but is not limited to cDNA, genomic DNA, plasmids DNA,
synthetic DNA, and semi-synthetic DNA. DNA may be linear, circular,
or supercoiled.
[0031] A "nucleic acid molecule" refers to the phosphate ester
polymeric form of ribonucleosides (adenosine, guanosine, uridine or
cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine,
deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules"),
or any phosphoester analogs thereof, such as phosphorothioates and
thioesters, in either single stranded form, or a double-stranded
helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are
possible. The term nucleic acid molecule, and in particular DNA or
RNA molecule, refers only to the primary and secondary structure of
the molecule, and does not limit it to any particular tertiary
forms. Thus, this term includes double-stranded DNA found, inter
alia, in linear or circular DNA molecules (e.g., restriction
fragments), plasmids, and chromosomes. In discussing the structure
of particular double-stranded DNA molecules, sequences may be
described herein according to the normal convention of giving only
the sequence in the 5' to 3' direction along the non-transcribed
strand of DNA (i.e., the strand having a sequence homologous to the
mRNA). A "recombinant DNA molecule" is a DNA molecule that has
undergone a molecular biological mranipulation.
[0032] The term "fragment" will be understood to mean a nucleotide
sequence of reduced length relative to the reference nucleic acid
and comprising, over the common portion, a nucleotide sequence
identical to the reference nucleic acid. Such a nucleic acid
fragment according to the invention may be, where appropriate,
included in a larger polynucleotide of which it is a constituent.
Such fragments comprise, or alternatively consist of,
oligonucleotides ranging in length from at least 6-1100 consecutive
nucleotides of a nucleic acid according to the invention.
[0033] As used herein, an "isolated nucleic acid fragment" is a
polymer of RNA or DNA that is single- or double-stranded,
optionally containing synthetic, non-natural or altered nucleotide
bases. An isolated nucleic acid fragment in the form of a polymer
of DNA may be comprised of one or more segments of cDNA, genomic
DNA or synthetic DNA.
[0034] A "gene" refers to an assembly of nucleotides that encode a
polypeptide, and includes cDNA and genomic DNA nucleic acids.
"Gene" also refers to a nucleic acid fragment that expresses a
specific protein or polypeptide, including regulatory sequences
preceding (5' non-coding sequences) and following (3' non-coding
sequences) the coding sequence. "Native gene" refers to a gene as
found in nature with its own regulatory sequences. "Chimeric gene"
refers to any gene that is not a native gene, comprising regulatory
and/or coding sequences that are not found together in nature.
Accordingly, a chimeric gene may comprise regulatory sequences and
coding sequences that are derived from different sources, or
regulatory sequences and coding sequences derived from the same
source, but arranged in a manner different than that found in
nature. A chimeric gene may comprise coding sequences derived from
different sources and/or regulatory sequences derived from
different sources. "Endogenous gene" refers to a native gene in its
natural location in the genome of an organism. A "foreign" gene or
"heterologous" gene refers to a gene not normally found in the host
organism, but that is introduced into the host organism by gene
transfer. Foreign genes can comprise native genes inserted into a
non-native organism, or chimeric genes. A "transgene" is a gene
that has been introduced into the genome by a transformation
procedure.
[0035] "Heterologous" DNA refers to DNA not naturally located in
the cell, or in a chromosomal site of the cell. Preferably, the
heterologous DNA includes a gene foreign to the cell.
[0036] The term "genome" includes chromosomal as well as
mitochondrial, chloroplast and viral DNA or RNA.
[0037] A nucleic acid molecule is "hybridizable" to another nucleic
acid molecule, such as a cDNA, genomic DNA, or RNA, when a single
stranded form of the nucleic acid molecule can anneal to the other
nucleic acid molecule under the appropriate conditions of
temperature and solution ionic strength (see Sambrook et al., 1989
infra). Hybridization and washing conditions are well known and
exemplified in Sambrook, J., Fritsch, E. F. and Maniatis, T.
Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring
Harbor Laboratory Press, Cold Spring Harbor (1989), particularly
Chapter 11 and Table 11.1 therein (entirely incorporated herein by
reference). The conditions of temperature and ionic strength
determine the "stringency" of the hybridization.
[0038] Stringency conditions can be adjusted to screen for
moderately similar fragments, such as homologous sequences from
distantly related organisms, to highly similar fragments, such as
genes that duplicate functional enzymes from closely related
organisms. For preliminary screening for homologous nucleic acids,
low stringency hybridization conditions, corresponding to a T.sub.m
of 55.degree., can be used, e.g., 5.times.SSC, 0.1% SDS, 0.25%
milk, and no formamide; or 30% formamide, 5.times.SSC, 0.5% SDS).
Moderate stringency hybridization conditions correspond to a higher
T.sub.m, e.g. 40% formamide, with 5.times. or 6.times.SCC. High
stringency hybridization conditions correspond to the highest
T.sub.m, e.g., 50% formamide, 5.times. or 6.times.SCC.
[0039] Hybridization requires that the two nucleic acids contain
complementary sequences, although depending on the stringency of
the hybridization, mismatches between bases are possible. The term
"complementary" is used to describe the relationship between
nucleotide bases that are capable of hybridizing to one another.
For example, with respect to DNA, adenosine is complementary to
thymine and cytosine is complementary to guanine. Accordingly, the
instant invention also includes isolated nucleic acid fragments
that are complementary to the complete sequences as disclosed or
used herein as well as those substantially similar nucleic acid
sequences.
[0040] In a specific embodiment of the invention, polynucleotides
are detected by employing hybridization conditions comprising a
hybridization step at T.sub.m of 55.degree. C., and utilizing
conditions as set forth above. In a preferred embodiment, the
T.sub.m is 60.degree. C.; in a more preferred embodiment, the
T.sub.m is 63.degree. C.; in an even more preferred embodiment, the
T.sub.m is 65.degree. C.
[0041] Post-hybridization washes also determine stringency
conditions. One set of preferred conditions uses a series of washes
starting with 6.times.SSC, 0.5% SDS at room temperature for 15
minutes (min), then repeated with 2.times.SSC, 0.5% SDS at
45.degree. C. for 30 minutes, and then repeated twice with
0.2.times.SSC, 0.5% SDS at 50.degree. C. for 30 minutes. A more
preferred set of stringent conditions uses higher temperatures in
which the washes are identical to those above except for the
temperature of the final two 30 min washes in 0.2.times.SSC, 0.5%
SDS was increased to 60.degree. C. Another preferred set of highly
stringent conditions uses two final washes in 0.1.times.SSC, 0.1%
SDS at 65.degree. C.
[0042] The appropriate stringency for hybridizing nucleic acids
depends on the length of the nucleic acids and the degree of
complementation, variables well known in the art. The greater the
degree of similarity or homology between two nucleotide sequences,
the greater the value of T.sub.m for hybrids of nucleic acids
having those sequences. The relative stability (corresponding to
higher T.sub.m) of nucleic acid hybridizations decreases in the
following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater
than 100 nucleotides in length, equations for calculating T.sub.m
have been derived (see Sambrook et al., supra, 9.50-0.51). For
hybridization with shorter nucleic acids, i.e., oligonucleotides,
the position of mismatches becomes more important, and the length
of the oligonucleotide determines its specificity (see Sambrook et
al., supra, 11.7-11.8).
[0043] Selectivity of hybridization exists when hybridization
occurs which is more selective than total lack of specificity.
Typically, selective hybridization will occur when there is at
least about 55% homology over a stretch of at least about 14/25
nucleotides, preferably at least about 65%, more preferably at
least about 75%, and most preferably at least about 90%. See,
Kanehisa, M. (1984), Nucleic Acids Res. 12:203-213, which is
incorporated herein by reference. Stringent hybridization
conditions will typically include salt concentrations of less than
about 1 M, more usually less than about 500 mM and preferably less
than about 200 mM. Temperature conditions will typically be greater
than 20 degrees Celsius, more usually greater than about 30 degrees
Celsius and preferably in excess of about 37 degrees Celsius. As
other factors may significantly affect the stringency of
hybridization, including, among others, base composition and size
of the complementary strands, presence of organic solvents and
extent of base mismatching, the combination of parameters is more
important than the absolute measure of any one.
[0044] In a specific embodiment of the invention, polynucleotides
of the invention are detected by employing hybridization conditions
comprising a hybridization step in less than 500 mM salt and at
least 37 degrees Celsius, and a washing step in 2.times.SSPE at
least 63 degrees Celsius. In a preferred embodiment, the
hybridization conditions comprise less than 200 mM salt and at
least 37 degrees Celsius for the hybridization step. In a more
preferred embodiment, the hybridization conditions comprise
2.times.SSPE and 63 degrees Celsius for both the hybridization and
washing steps.
[0045] In one embodiment, the length for a hybridizable nucleic
acid is at least about 10 nucleotides. Preferable a minimum length
for a hybridizable nucleic acid is at least about 15 nucleotides;
more preferably at least about 20 nucleotides; and even more
preferably the length is at least 30 nucleotides. Furthermore, the
skilled artisan will recognize that the temperature and wash
solution salt concentration may be adjusted as necessary according
to factors such as length of the probe.
[0046] The term "probe" refers to a single-stranded nucleic acid
molecule that can base pair with a complementary single stranded
target nucleic acid to form a double-stranded molecule.
[0047] As used herein, the term "oligonucleotide" refers to a
nucleic acid, generally of at least 18 nucleotides, that is
hybridizable to a genomic DNA molecule, a cDNA molecule, a plasmid
DNA or an mRNA molecule. Oligonucleotides can be labeled, e.g.,
with .sup.32P-nucleotides or nucleotides to which a label, such as
biotin, has been covalently conjugated. A labeled oligonucleotide
can be used as a probe to detect the presence of a nucleic acid.
Oligonucleotides (one or both of which may be labeled) can be used
as PCR primers, either for cloning full length or a fragment of a
nucleic acid, or to detect the presence of a nucleic acid. An
oligonucleotide can also be used to form a triple helix with a DNA
molecule. Generally, oligonucleotides are prepared synthetically,
preferably on a nucleic acid synthesizer. Accordingly,
oligonucleotides can be prepared with non-naturally occurring
phosphoester analog bonds, such as thioester bonds, etc.
[0048] A "primer" is an oligonucleotide that hybridizes to a target
nucleic acid sequence to create a double stranded nucleic acid
region that can serve as an initiation point for DNA synthesis
under suitable conditions. Such primers may be used in a polymerase
chain reaction.
[0049] "Polymerase chain reaction" is abbreviated PCR and means an
in vitro method for enzymatically amplifying specific nucleic acid
sequences. PCR involves a repetitive series of temperature cycles
with each cycle comprising three stages: denaturation of the
template nucleic acid to separate the strands of the target
molecule, annealing a single stranded PCR oligonucleotide primer to
the template nucleic acid, and extension of the annealed primer(s)
by DNA polymerase. PCR provides a means to detect the presence of
the target molecule and, under quantitative or semi-quantitative
conditions, to determine the relative amount of that target
molecule within the starting pool of nucleic acids.
[0050] "Reverse transcription-polymerase chain reaction" is
abbreviated RT-PCR and means an in vitro method for enzymatically
producing a target cDNA molecule or molecules from an RNA molecule
or molecules, followed by enzymatic amplification of a specific
nucleic acid sequence or sequences within the target cDNA molecule
or molecules as described above. RT-PCR also provides a means to
detect the presence of the target molecule and, under quantitative
or semi-quantitative conditions, to determine the relative amount
of that target molecule within the starting pool of nucleic
acids.
[0051] A DNA "coding sequence" is a double-stranded DNA sequence
that is transcribed and translated into a polypeptide in a cell in
vitro or in vivo when placed under the control of appropriate
regulatory sequences. "Suitable regulatory sequences" refer to
nucleotide sequences located upstream (5' non-coding sequences),
within, or downstream (3' non-coding sequences) of a coding
sequence, and which influence the transcription, RNA processing or
stability, or translation of the associated coding sequence.
Regulatory sequences may include promoters, translation leader
sequences, introns, polyadenylation recognition sequences, RNA
processing site, effector binding site and stem-loop structure. The
boundaries of the coding sequence are determined by a start codon
at the 5' (amino) terminus and a translation stop codon at the 3'
(carboxyl) terminus. A coding sequence can include, but is not
limited to, prokaryotic sequences, cDNA from mRNA, genomic DNA
sequences, and even synthetic DNA sequences. If the coding sequence
is intended for expression in a eukaryotic cell, a polyadenylation
signal and transcription termination sequence will usually be
located 3' to the coding sequence.
[0052] "Open reading frame" is abbreviated ORF and means a length
of nucleic acid sequence, either DNA, cDNA or RNA, that comprises a
translation start signal or initiation codon, such as an ATG or
AUG, and a termination codon and can be potentially translated into
a polypeptide sequence.
[0053] The term "head-to-head" is used herein to describe the
orientation of two polynucleotide sequences in relation to each
other. Two polynucleotides are positioned in a head-to-head
orientation when the 0.5.degree. end of the coding strand of one
polynucleotide is adjacent to the 5' end of the coding strand of
the other polynucleotide, whereby the direction of transcription of
each polynucleotide proceeds away from the 5' end of the other
polynucleotide. The term "head-to-head" may be abbreviated
(5')-to-(5') and may also be indicated by the symbols
(.rarw..fwdarw.) or (3'.rarw.5'5'.fwdarw.3').
[0054] The term "tail-to-tail" is used herein to describe the
orientation of two polynucleotide sequences in relation to each
other. Two polynucleotides are positioned in a tail-to-tail
orientation when the 3' end of the coding strand of one
polynucleotide is adjacent to the 3' end of the coding strand of
the other polynucleotide, whereby the direction of transcription of
each polynucleotide proceeds toward the other polynucleotide. The
term "tail-to-tail" may be abbreviated (3')-to-(3') and may also be
indicated by the symbols (.fwdarw..rarw.) or
(5'.fwdarw.3'3'.rarw.5').
[0055] The term "head-to-tail" is used herein to describe the
orientation of two polynucleotide sequences in relation to each
other. Two polynucleotides are positioned in a head-to-tail
orientation when the 5' end of the coding strand of one
polynucleotide is adjacent to the 3' end of the coding strand of
the other polynucleotide, whereby the direction of transcription of
each polynucleotide proceeds in the same direction as that of the
other polynucleotide. The term "head-to-tail" may be abbreviated
(5')-to-(3') and may also be indicated by the symbols
(.fwdarw..fwdarw.) or (5.fwdarw.3'5'.fwdarw.3').
[0056] The term "downstream" refers to a nucleotide sequence that
is located 3' to reference nucleotide sequence. In particular,
downstream nucleotide sequences generally relate to sequences that
follow the starting point of transcription. For example, the
translation initiation codon of a gene is located downstream of the
start site of transcription.
[0057] The term "upstream" refers to a nucleotide sequence that is
located 5' to reference nucleotide sequence. In particular,
upstream nucleotide sequences generally relate to sequences that
are located on the 5' side of a coding sequence or starting point
of transcription. For example, most promoters are located upstream
of the start site of transcription.
[0058] The terms "restriction endonuclease" and "restriction
enzyme" refer to an enzyme that binds and cuts within a specific
nucleotide sequence within double stranded DNA.
[0059] "Homologous recombination" refers to the insertion of a
foreign DNA sequence into another DNA molecule, e.g., insertion of
a vector in a chromosome. Preferably, the vector targets a specific
chromosomal site for homologous recombination. For specific
homologous recombination, the vector will contain sufficiently long
regions of homology to sequences of the chromosome to allow
complementary binding and incorporation of the vector into the
chromosome. Longer regions of homology, and greater degrees of
sequence similarity, may increase the efficiency of homologous
recombination.
[0060] Several methods known in the art may be used to propagate a
polynucleotide according to the invention. Once a suitable host
system and growth conditions are established, recombinant
expression vectors can be propagated and prepared in quantity. As
described herein, the expression vectors which can be used include,
but are not limited to, the following vectors or their derivatives:
human or animal viruses such as vaccinia virus or adenovirus;
insect viruses such as baculovirus; yeast vectors; bacteriophage
vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name
but a few.
[0061] A "vector" is any means for the cloning of and/or transfer
of a nucleic acid into a host cell. A vector may be a replicon to
which another DNA segment may be attached so as to bring about the
replication of the attached segment. A "replicon" is any genetic
element (e.g., plasmid, phage, cosmid, chromosome, virus) that
functions as an autonomous unit of DNA replication in vivo, i.e.,
capable of replication under its own control. The term "vector"
includes both viral and nonviral means for introducing the nucleic
acid into a cell in vitro, ex vivo or in vivo. A large number of
vectors known in the art may be used to manipulate nucleic acids,
incorporate response elements and promoters into genes, etc.
Possible vectors include, for example, plasmids or modified viruses
including, for example bacteriophages such as lambda derivatives,
or plasmids such as pBR322 or pUC plasmid derivatives, or the
Bluescript vector. For example, the insertion of the DNA fragments
corresponding to response elements and promoters into a suitable
vector can be accomplished by ligating the appropriate DNA
fragments into a chosen vector that has complementary cohesive
termini. Alternatively, the ends of the DNA molecules may be
enzymatically modified or any site may be produced by ligating
nucleotide sequences (linkers) into the DNA termini. Such vectors
may be engineered to contain selectable marker genes that provide
for the selection of cells that have incorporated the marker into
the cellular genome. Such markers allow identification and/or
selection of host cells that incorporate and express the proteins
encoded by the marker.
[0062] Viral vectors, and particularly retroviral vectors, have
been used in a wide variety of gene delivery applications in cells,
as well as living animal subjects. Viral vectors that can be used
include but are not limited to retrovirus, adeno-associated virus,
pox, baculovirus, vaccinia, herpes simplex, Epstein-Barr,
adenovirus, geminivirus, and caulimovirus vectors. Non-viral
vectors include plasmids, liposomes, electrically charged lipids
(cytofectins), DNA-protein complexes, and biopolymers. In addition
to a nucleic acid, a vector may also comprise one or more
regulatory regions, and/or selectable markers useful in selecting,
measuring, and monitoring nucleic acid transfer results (transfer
to which tissues, duration of expression, etc.).
[0063] The term "plasmid" refers to an extra chromosomal element
often carrying a gene that is not part of the central metabolism of
the cell, and usually in the form of circular double-stranded DNA
molecules. Such elements may be autonomously replicating sequences,
genome integrating sequences, phage or nucleotide sequences,
linear, circular, or supercoiled, of a single- or double-stranded
DNA or RNA, derived from any source, in which a number of
nucleotide sequences have been joined or recombined into a unique
construction which is capable of introducing a promoter fragment
and DNA sequence for a selected gene product along with appropriate
3' untranslated sequence into a cell.
[0064] A "cloning vector" is a "replicon", which is a unit length
of a nucleic acid, preferably DNA, that replicates sequentially and
which comprises an origin of replication, such as a plasmid, phage
or cosmid, to which another nucleic acid segment may be attached so
as to bring about the replication of the attached segment. Cloning
vectors may be capable of replication in one cell type and
expression in another ("shuttle vector").
[0065] Vectors may be introduced into the desired host cells by
methods known in the art, e.g., transfection, electroporation,
microinjection, transduction, cell fusion, DEAE dextran, calcium
phosphate precipitation, lipofection (lysosome fusion), particle
bombardment, use of a gene gun, or a DNA vector transporter (see,
e.g., Wu et al., 1992, J. Biol. Chem. 267: 963-967; Wu and Wu,
1988, J. Biol. Chem. 263: 14621-14624; and Hartmut et al., Canadian
Patent Application No. 2,012,311, filed Mar. 15, 1990).
[0066] A polynucleotide according to the invention can also be
introduced in vivo by lipofection. For the past decade, there has
been increasing use of liposomes for encapsulation and transfection
of nucleic acids in vitro. Synthetic cationic lipids designed to
limit the difficulties and dangers encountered with liposome
mediated transfection can be used to prepare liposomes for in vivo
transfection of a gene encoding a marker (Felgner et al., 1987,
Proc. Natl. Acad. Sci. U.S.A. 84: 7413; Mackey, et al., 1988, Proc.
Natl. Acad. Sci. U.S.A. 85: 8027-8031; and Ulmer et al., 1993,
Science 259: 1745-1748). The use of cationic lipids may promote
encapsulation of negatively charged nucleic acids, and also promote
fusion with negatively charged cell membranes (Felgner and Ringold,
1989, Science 337: 387-388). Particularly useful lipid compounds
and compositions for transfer of nucleic acids are described in
International Patent Publications WO95/18863 and WO96/17823, and in
U.S. Pat. No. 5,459,127. The use of lipofection to introduce
exogenous genes into the specific organs in vivo has certain
practical advantages. Molecular targeting of liposomes to specific
cells represents one area of benefit. It is clear that directing
transfection to particular cell types would be particularly
preferred in a tissue with cellular heterogeneity, such as
pancreas, liver, kidney, and the brain. Lipids may be chemically
coupled to other molecules for the purpose of targeting (Mackey, et
al., 1988, supra). Targeted peptides, e.g., hormones or
neurotransmitters, and proteins such as antibodies, or non-peptide
molecules could be coupled to liposomes chemically.
[0067] Other molecules are also useful for facilitating
transfection of a nucleic acid in vivo, such as a cationic
oligopeptide (e.g., WO95/21931), peptides derived from DNA binding
proteins (e.g. WO96/25508), or a cationic polymer (e.g.,
WO95/21931).
[0068] It is also possible to introduce a vector in vivo as a naked
DNA plasmid (see U.S. Pat. Nos. 5,693,622, 5,589,466 and
5,580,859). Receptor-mediated DNA delivery approaches can also be
used (Curiel et al., 1992, Hum Gene Ther. 3: 147-154; and Wu and
Wu, 1987, J. Biol. Chem. 262: 4429-4432).
[0069] The term "transfection" means the uptake of exogenous or
heterologous RNA or DNA by a cell. A cell has been "transfected" by
exogenous or heterologous RNA or DNA when such RNA or DNA has been
introduced inside the cell. A cell has been "transformed" by
exogenous or heterologous RNA or DNA when the transfected RNA or
DNA effects a phenotypic change. The transforming RNA or DNA can be
integrated (covalently linked) into chromosomal DNA making up the
genome of the cell.
[0070] "Transformation" refers to the transfer of a nucleic acid
fragment into the genome of a host organism, resulting in
genetically stable inheritance. Host organisms containing the
transformed nucleic acid fragments are referred to as "transgenic"
or "recombinant" or "transformed" organisms.
[0071] The term "genetic region" will refer to a region of a
nucleic acid molecule or a nucleotide sequence that comprises a
gene encoding a polypeptide.
[0072] In addition, the recombinant vector comprising a
polynucleotide according to the invention may include one or more
origins for replication in the cellular hosts in which their
amplification or their expression is sought, markers or selectable
markers.
[0073] The term "selectable marker" means an identifying factor,
usually an antibiotic or chemical resistance gene, that is able to
be selected for based upon the marker gene's effect, i.e.,
resistance to an antibiotic, resistance to a herbicide,
calorimetric markers, enzymes, fluorescent markers, and the like,
wherein the effect is used to track the inheritance of a nucleic
acid of interest and/or to identify a cell or organism that has
inherited the nucleic acid of interest. Examples of selectable
marker genes known and used in the art include: genes providing
resistance to ampicillin, streptomycin, gentamycin, kanamycin,
hygromycin, bialaphos herbicide, sulfonamide, and the like; and
genes that are used as phenotypic markers, i.e., anthocyanin
regulatory genes, isopentanyl transferase gene, and the like.
Selectable marker genes may also be considered reporter genes.
[0074] The term "reporter gene" means a nucleic acid encoding an
identifying factor that is able to be identified based upon the
reporter gene's effect, wherein the effect is used to track the
inheritance of a nucleic acid of interest, to identify a cell or
organism that has inherited the nucleic acid of interest, and/or to
measure gene expression induction or transcription. Examples of
reporter genes known and used in the art include: luciferase (Luc),
green fluorescent protein (GFP), chloramphenicol acetyltransferase
(CAT), .beta.-galactosidase (LacZ), .beta.-glucuronidase (Gus), and
the like.
[0075] "Promoter" refers to a DNA sequence capable of controlling
the expression of a coding sequence or functional RNA. In general,
a coding sequence is located 3' to a promoter sequence. Promoters
may be derived in their entirety from a native gene, or be composed
of different elements derived from different promoters found in
nature, or even comprise synthetic DNA segments. It is understood
by those skilled in the art that different promoters may direct the
expression of a gene in different tissues or cell types, or at
different stages of development, or in response to different
environmental or physiological conditions. Promoters that cause a
gene to be expressed in most cell types at most times are commonly
referred to as "constitutive promoters". Promoters that cause a
gene to be expressed in a specific cell type are commonly referred
to as "cell-specific promoters" or "tissue-specific promoters".
Promoters that cause a gene to be expressed at a specific stage of
development or cell differentiation are commonly referred to as
"developmentally-specific promoters" or "cell
differentiation-specific promoters". Promoters that are induced and
cause a gene to be expressed following exposure or treatment of the
cell with an agent, biological molecule, chemical, ligand, light,
or the like that induces the promoter are commonly referred to as
"inducible promoters" or "regulatable promoters". It is further
recognized that since in most cases the exact boundaries of
regulatory sequences have not been completely defined, DNA
fragments of different lengths may have identical promoter
activity.
[0076] A "promoter sequence" is a DNA regulatory region capable of
binding RNA polymerase in a cell and initiating transcription of a
downstream (3' direction) coding sequence. For purposes of defining
the present invention, the promoter sequence is bounded at its 3'
terminus by the transcription initiation site and extends upstream
(5' direction) to include the minimum number of bases or elements
necessary to initiate transcription at levels detectable above
background. Within the promoter sequence will be found a
transcription initiation site (conveniently defined for example, by
mapping with nuclease S1), as well as protein binding domains
(consensus sequences) responsible for the binding of RNA
polymerase.
[0077] A coding sequence is "under the control" of transcriptional
and translational control sequences in a cell when RNA polymerase
transcribes the coding sequence into mRNA, which is then trans-RNA
spliced (if the coding sequence contains introns) and translated
into the protein encoded by the coding sequence.
[0078] "Transcriptional and translational control sequences" are
DNA regulatory sequences, such as promoters, enhancers,
terminators, and the like, that provide for the expression of a
coding sequence in a host cell. In eukaryotic cells,
polyadenylation signals are control sequences.
[0079] The term "response element" means one or more cis-acting DNA
elements which confer responsiveness on a promoter mediated through
interaction with the DNA-binding domains of the first chimeric
gene. This DNA element may be either palindromic (perfect or
imperfect) in its sequence or composed of sequence motifs or half
sites separated by a variable number of nucleotides. The half sites
can be similar or identical and arranged as either direct or
inverted repeats or as a single half site or multimers of adjacent
half sites in tandem. The response element may comprise a mininal
promoter isolated from different organisms depending upon the
nature of the cell or organism into which the response element will
be incorporated. The DNA binding domain of the first hybrid protein
binds, in the presence or absence of a ligand, to the DNA sequence
of a response element to initiate or suppress transcription of
downstream gene(s) under the regulation of this response element.
Examples of DNA sequences for response elements of the natural
ecdysone receptor include: RRGG/TTCANTGAC/ACYY (see Cherbas L., et.
al., (1991), Genes Dev. 5, 120-131); AGGTCAN.sub.(n)AGGTCA,where
N.sub.(n) can be one or more spacer nucleotides (see D'Avino PP.,
et. al., (1995), Mol. Cell. Endocrinol, 113, 1-9); and
GGGTTGAATGAATTT (see Antoniewski C., et. al., (1994). Mol. Cell
Biol. 14, 44654474).
[0080] The term "operably linked" refers to the association of
nucleic acid sequences on a single nucleic acid fragment so that
the function of one is affected by the other. For example, a
promoter is operably linked with a coding sequence when it is
capable of affecting the expression of that coding sequence (i.e.,
that the coding sequence is under the transcriptional control of
the promoter). Coding sequences can be operably linked to
regulatory sequences in sense or antisense orientation.
[0081] The term "expression", as used herein, refers to the
transcription and stable accumulation of sense (mRNA) or antisense
RNA derived from a nucleic acid or polynucleotide. Expression may
also refer to translation of mRNA into a protein or
polypeptide.
[0082] The terms "cassette", "expression cassette" and "gene
expression cassette" refer to a segment of DNA that can be inserted
into a nucleic acid or polynucleotide at specific restriction sites
or by homologous recombination. The segment of DNA comprises a
polynucleotide that encodes a polypeptide of interest, and the
cassette and restriction sites are designed to ensure insertion of
the cassette in the proper reading frame for transcription and
translation. "Transformation cassette" refers to a specific vector
comprising a polynucleotide that encodes a polypeptide of interest
and having elements in addition to the polynucleotide that
facilitate transformation of a particular host cell. Cassettes,
expression cassettes, gene expression cassettes and transformation
cassettes of the invention may also comprise elements that allow
for enhanced expression of a polynucleotide encoding a polypeptide
of interest in a host cell. These elements may include, but are not
limited to: a promoter, a minimal promoter, an enhancer, a response
element, a terminator sequence, a polyadenylation sequence, and the
like.
[0083] For purposes of this invention, the term "gene switch"
refers to the combination of a response element associated with a
promoter, and an EcR-based gene expression system which, in the
presence of one or more ligands, modulates the expression of a gene
into which the response element and promoter are incorporated.
[0084] The terms "modulate" and "modulates" mean to induce, reduce
or inhibit nucleic acid or gene expression, resulting in the
respective induction, reduction or inhibition of protein or
polypeptide production.
[0085] The plasmids or vectors according to the invention may
further comprise at least one promoter suitable for driving
expression of a gene in a host cell. The term "expression vector"
means a vector, plasmid or vehicle designed to enable the
expression of an inserted nucleic acid sequence following
transformation into the host. The cloned gene, i.e., the inserted
nucleic acid sequence, is usually placed under the control of
control elements such as a promoter, a minimal promoter, an
enhancer, or the like. Initiation control regions or promoters,
which are useful to drive expression of a nucleic acid in the
desired host cell are numerous and familiar to those skilled in the
art. Virtually any promoter capable of driving these genes is
suitable for the present invention including but not limited to:
viral promoters, bacterial promoters, animal promoters, mammalian
promoters, synthetic promoters, constitutive promoters, tissue
specific promoter, developmental specific promoters, inducible
promoters, light regulated promoters; CYC1, HIS3, GAL1, GAL4,
GAL10, ADH1, PGK, PHO5, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, TPI,
alkaline phosphatase promoters (useful for expression in
Saccharomyces); AOX1 promoter (useful for expression in Pichia);
.beta.-lactamase, lac, ara, tet, trp, IP.sub.L, IP.sub.R, T7, tac,
and trc promoters (useful for expression in Escherichia coli);
light regulated-, seed specific-, pollen specific-, ovary
specific-, pathogenesis or disease related-, cauliflower mosaic
virus 35S, CMV 35S minimal, cassaya vein mosaic virus (CsVMV),
chlorophyll a/b binding protein, ribulose 1,5-bisphosphate
carboxylase, shoot-specific, root specific, chitinase, stress
inducible, rice tungro bacilliform virus, plant super-promoter,
potato leucine aminopeptidase, nitrate reductase, mannopine
synthase, nopaline synthase, ubiquitin, zein protein, and
anthocyanin promoters (useful for expression in plant cells);
animal and mammalian promoters known in the art include, but are
not limited to, the SV40 early (SV40e) promoter region, the
promoter contained in the 3' long terminal repeat (LTR) of Rous
sarcoma virus (RSV), the promoters of the E1A or major late
promoter (MLP) genes of adenoviruses (Ad), the cytomegalovirus
(CMV) early promoter, the herpes simplex virus (HSV) thymidine
kinase (TK) promoter, a baculovirus IE1 promoter, an elongation
factor 1 alpha (EF1) promoter, a phosphoglycerate kinase (PGK)
promoter, a ubiquitin (Ubc) promoter, an albumin promoter, the
regulatory sequences of the mouse metallothionein-L promoter and
transcriptional control regions, the ubiquitous promoters (HPRT,
vimentin, .alpha.-actin, tubulin and the like), the promoters of
the intermediate filaments (desmin, neurofilaments, keratin, GFAP,
and the like), the promoters of therapeutic genes (of the MDR, CFTR
or factor VIII type, and the like), pathogenesis or disease
related-promoters, and promoters that exhibit tissue specificity
and have been utilized in transgenic animals, such as the elastase
I gene control region which is active in pancreatic acinar cells;
insulin gene control region active in pancreatic beta cells,
immunoglobulin gene control region active in lymphoid cells, mouse
mammary tumor virus control region active in testicular, breast,
lymphoid and mast cells; albumin gene, Apo AI and Apo AII control
regions active in liver, alpha-fetoprotein gene control region
active in liver, alpha 1-antitrypsin gene control region active in
the liver, beta-globin gene control region active in myeloid cells,
myelin basic protein gene control region active in oligodendrocyte
cells in the brain, myosin light chain-2 gene control region active
in skeletal muscle, and gonadotropic releasing hormone gene control
region active in the hypothalamus, pyruvate kinase promoter, villin
promoter, promoter of the fatty acid binding intestinal protein,
promoter of the smooth muscle cell .alpha.-actin, and the like. In
addition, these expression sequences may be modified by addition of
enhancer or regulatory sequences and the like.
[0086] Enhancers that may be used in embodiments of the invention
include but are not limited to: an SV40 enhancer, a cytomegalovirus
(CMV) enhancer, an elongation factor 1 (EF1) enhancer, yeast
enhancers, viral gene enhancers, and the like.
[0087] Termination control regions, i.e., terminator or
polyadenylation sequences, may also be derived from various genes
native to the preferred hosts. Optionally, a termination site may
be unnecessary, however, it is most preferred if included. In a
preferred embodiment of the invention, the termination control
region may be comprise or be derived from a synthetic sequence,
synthetic polyadenylation signal, an SV40 late polyadenylation
signal, an SV40 polyadenylation signal, a bovine growth hormone
(BGH) polyadenylation signal, viral terminator sequences, or the
like.
[0088] The terms "3' non-coding sequences" or "3' untranslated
region (UTR)" refer to DNA sequences located downstream (3') of a
coding sequence and may comprise polyadenylation [poly(A)]
recognition sequences and other sequences encoding regulatory
signals capable of affecting mRNA processing or gene expression.
The polyadenylation signal is usually characterized by affecting
the addition of polyadenylic acid tracts to the 3' end of the mRNA
precursor.
[0089] "Regulatory region" means a nucleic acid sequence that
regulates the expression of a second nucleic acid sequence. A
regulatory region may include sequences which are naturally
responsible for expressing a particular nucleic acid (a homologous
region) or may include sequences of a different origin that are
responsible for expressing different proteins or even synthetic
proteins (a heterologous region). In particular, the sequences can
be sequences of prokaryotic, eukaryotic, or viral genes or derived
sequences that stimulate or repress transcription of a gene in a
specific or non-specific manner and in an inducible or
non-inducible manner. Regulatory regions include origins of
replication, RNA splice sites, promoters, enhancers,
transcriptional termination sequences, and signal sequences which
direct the polypeptide into the secretory pathways of the target
cell.
[0090] A regulatory region from a "heterologous source" is a
regulatory region that is not naturally associated with the
expressed nucleic acid. Included among the heterologous regulatory
regions are regulatory regions from a different species, regulatory
regions from a different gene, hybrid regulatory sequences, and
regulatory sequences which do not occur in nature, but which are
designed by one having ordinary skill in the art.
[0091] "RNA transcript" refers to the product resulting from RNA
polymerase-catalyzed transcription of a DNA sequence. When the RNA
transcript is a perfect complementary copy of the DNA sequence, it
is referred to as the primary transcript or it may be a RNA
sequence derived from post-transcriptional processing of the
primary transcript and is referred to as the mature RNA. "Messenger
RNA (mRNA)" refers to the RNA that is without introns and that can
be translated into protein by the cell. "cDNA" refers to a
double-stranded DNA that is complementary to and derived from mRNA.
"Sense" RNA refers to RNA transcript that includes the mRNA and so
can be translated into protein by the cell. "Antisense RNA" refers
to a RNA transcript that is complementary to all or part of a
target primary transcript or mRNA and that blocks the expression of
a target gene. The complementarity of an antisense RNA may be with
any part of the specific gene transcript, i.e., at the 5'
non-coding sequence, 3' non-coding sequence, or the coding
sequence. "Functional RNA" refers to antisense RNA, ribozyme RNA,
or other RNA that is not translated yet has an effect on cellular
processes.
[0092] A "polypeptide" is a polymeric compound comprised of
covalently linked amino acid residues. Amino acids have the
following general structure: ##STR1## Amino acids are classified
into seven groups on the basis of the side chain R: (1) aliphatic
side chains, (2) side chains containing a hydroxylic (OH) group,
(3) side chains containing sulfur atoms, (4) side chains containing
an acidic or amide group, (5) side chains containing a basic group,
(6) side chains containing an aromatic ring, and (7) proline, an
imino acid in which the side chain is fused to the amino group. A
polypeptide of the invention preferably comprises at least about 14
amino acids.
[0093] A "protein" is a polypeptide that performs a structural or
functional role in a living cell.
[0094] An "isolated polypeptide" or "isolated protein" is a
polypeptide or protein that is substantially free of those
compounds that are normally associated therewith in its natural
state (e.g., other proteins or polypeptides, nucleic acids,
carbohydrates, lipids). "Isolated" is not meant to exclude
artificial or synthetic mixtures with other compounds, or the
presence of impurities which do not interfere with biological
activity, and which may be present, for example, due to incomplete
purification, addition of stabilizers, or compounding into a
pharmaceutically acceptable preparation.
[0095] A "fragment" of a polypeptide according to the invention
will be understood to mean a polypeptide whose amino acid sequence
is shorter than that of the reference polypeptide and which
comprises, over the entire portion with these reference
polypeptides, an identical amino acid sequence. Such fragments may,
where appropriate, be included in a larger polypeptide of which
they are a part. Such fragments of a polypeptide according to the
invention may have a length of at least 2-300 amino acids.
[0096] A "heterologous protein" refers to a protein not naturally
produced in the cell.
[0097] A "mature protein" refers to a post-translationally
processed polypeptide; i.e., one from which any pre- or propeptides
present in the primary translation product have been removed.
"Precursor" protein refers to the primary product of translation of
mRNA; i.e., with pre- and propeptides still present. Pre- and
propeptides may be but are not limited to intracellular
localization signals.
[0098] The term "signal peptide" refers to an amino terminal
polypeptide preceding the secreted mature protein. The signal
peptide is cleaved from and is therefore not present in the mature
protein. Signal peptides have the function of directing and
translocating secreted proteins across cell membranes. Signal
peptide is also referred to as signal protein.
[0099] A "signal sequence" is included at the beginning of the
coding sequence of a protein to be expressed on the surface of a
cell. This sequence encodes a signal peptide, N-terminal to the
mature polypeptide, that directs the host cell to translocate the
polypeptide. The term "translocation signal sequence" is used
herein to refer to this sort of signal sequence. Translocation
signal sequences can be found associated with a variety of proteins
native to eukaryotes and prokaryotes, and are often functional in
both types of organisms.
[0100] The term "homology" refers to the percent of identity
between two polynucleotide or two polypeptide moieties. The
correspondence between the sequence from one moiety to another can
be determined by techniques known to the art. For example, homology
can be determined by a direct comparison of the sequence
information between two polypeptide molecules by aligning the
sequence information and using readily available computer programs.
Alternatively, homology can be determined by hybridization of
polynucleotides under conditions that form stable duplexes between
homologous regions, followed by digestion with
single-stranded-specific nuclease(s) and size determination of the
digested fragments.
[0101] As used herein, the term "homologous" in all its grammatical
forms and spelling variations refers to the relationship between
proteins that possess a "common evolutionary origin," including
proteins from superfamilies (e.g., the immunoglobulin superfamily)
and homologous proteins from different species (e.g., myosin light
chain, etc.) (Reeck et al., 1987, Cell 50: 667.). Such proteins
(and their encoding genes) have sequence homology, as reflected by
their high degree of sequence similarity. However, in common usage
and in the instant application, the term "homologous," when
modified with an adverb such as "highly," may refer to sequence
similarity and not a common evolutionary origin.
[0102] Accordingly, the term "sequence similarity" in all its
grammatical forms refers to the degree of identity or
correspondence between nucleic acid or amino acid sequences of
proteins that may or may not share a common evolutionary origin
(see Reeck et al., 1987, Cell 50: 667).
[0103] In a specific embodiment, two DNA sequences are
"substantially homologous" or "substantially similar" when at least
about 50% (preferably at least about 75%, and most preferably at
least about 90 or 95%) of the nucleotides match over the defined
length of the DNA sequences. Sequences that are substantially
homologous can be identified by comparing the sequences using
standard software available in sequence data banks, or in a
Southern hybridization experiment under, for example, stringent
conditions as defined for that particular system. Defining
appropriate hybridization conditions is within the skill of the
art. See, e.g., Sambrook et al., 1989, supra.
[0104] As used herein, "substantially similar" refers to nucleic
acid fragments wherein changes in one or more nucleotide bases
results in substitution of one or more amino acids, but do not
affect the functional properties of the protein encoded by the DNA
sequence. "Substantially similar" also refers to nucleic acid
fragments wherein changes in one or more nucleotide bases does not
affect the ability of the nucleic acid fragment to mediate
alteration of gene expression by antisense or co-suppression
technology. "Substantially similar" also refers to modifications of
the nucleic acid fragments of the instant invention such as
deletion or insertion of one or more nucleotide bases that do not
substantially affect the functional properties of the resulting
transcript. It is therefore understood that the invention
encompasses more than the specific exemplary sequences. Each of the
proposed modifications is well within the routine skill in the art,
as is determination of retention of biological activity of the
encoded products.
[0105] Moreover, the skilled artisan recognizes that substantially
similar sequences encompassed by this invention are also defined by
their ability to hybridize, under stringent conditions
(0.1.times.SSC, 0.1% SDS, 65.degree. C. and washed with
2.times.SSC, 0.1% SDS followed by 0.1.times.SSC, 0.1% SDS), with
the sequences exemplified herein. Substantially similar nucleic
acid fragments of the instant invention are those nucleic acid
fragments whose DNA sequences are at least 70% identical to the DNA
sequence of the nucleic acid fragments reported herein. Preferred
substantially nucleic acid fragments of the instant invention are
those nucleic acid fragments whose DNA sequences are at least 80%
identical to the DNA sequence of the nucleic acid fragments
reported herein. More preferred nucleic acid fragments are at least
90% identical to the DNA sequence of the nucleic acid fragments
reported herein. Even more preferred are nucleic acid fragments
that are at least 95% identical to the DNA sequence of the nucleic
acid fragments reported herein.
[0106] Two amino acid sequences are "substantially homologous" or
"substantially similar" when greater than about 40% of the amino
acids are identical, or greater than 60% are similar (functionally
identical). Preferably, the similar or homologous sequences are
identified by alignment using, for example, the GCG (Genetics
Computer Group, Program Manual for the GCG Paclcage, Version 7,
Madison, Wis.) pileup program.
[0107] The term "corresponding to" is used herein to refer to
similar or homologous sequences, whether the exact position is
identical or different from the molecule to which the similarity or
homology is measured. A nucleic acid or amino acid sequence
alignment may include spaces. Thus, the term "corresponding to"
refers to the sequence similarity, and not the numbering of the
amino acid residues or nucleotide bases.
[0108] A "substantial portion" of an amino acid or nucleotide
sequence comprises enough of the amino acid sequence of a
polypeptide or the nucleotide sequence of a gene to putatively
identify that polypeptide or gene, either by manual evaluation of
the sequence by one skilled in the art, or by computer-automated
sequence comparison and identification using algorithms such as
BLAST (Basic Local Alignment Search Tool; Altschul, S. F., et al.,
(1993) J. Mol. Biol. 215: 403-410; see also
www.ncbi.nlm.nih.gov/BLAST/). In general, a sequence of ten or more
contiguous amino acids or thirty or more nucleotides is necessary
in order to putatively identify a polypeptide or nucleic acid
sequence as homologous to a known protein or gene. Moreover, with
respect to nucleotide sequences, gene specific oligonucleotide
probes comprising 20-30 contiguous nucleotides may be used in
sequence-dependent methods of gene identification (e.g., Southern
hybridization) and isolation (e.g., in situ hybridization of
bacterial colonies or bacteriophage plaques). In addition, short
oligonucleotides of 12-15 bases may be used as amplification
primers in PCR in order to obtain a particular nucleic acid
fragment comprising the primers. Accordingly, a "substantial
portion" of a nucleotide sequence comprises enough of the sequence
to specifically identify and/or isolate a nucleic acid fragment
comprising the sequence.
[0109] The term "percent identity", as known in the art, is a
relationship between two or more polypeptide sequences or two or
more polynucleotide sequences, as determined by comparing the
sequences. In the art, "identity" also means the degree of sequence
relatedness between polypeptide or polynucleotide sequences, as the
case may be, as determined by the match between strings of such
sequences. "Identity" and "similarity" can be readily calculated by
known methods, including but not limited to those described in:
Computational Molecular Biology (Lesk, A. M., ed.) Oxford
University Press, New York (1988); Biocomputing: Informatics and
Genome Projects (Smith, D. W., ed.) Academic Press, New York
(1993); Computer Analysis of Sequence Data, Part I (Griffin, A. M.,
and Griffin, H. G., eds.) Humana Press, New Jersey (1994); Sequence
Analysis in Molecular Biology (von Heinje, G., ed.) Academic Press
(1987); and Sequence Analysis Primer (Gribskov, M. and Devereux,
J., eds.) Stockton Press, New York (1991). Preferred methods to
determine identity are designed to give the best match between the
sequences tested. Methods to determine identity and similarity are
codified in publicly available computer programs. Sequence
alignments and percent identity calculations may be performed using
the Megalign program of the LASERGENE bioinformatics computing
suite (DNASTAR Inc., Madison, Wis.). Multiple alignment of the
sequences may be performed using the Clustal method of alignment
(Higgins and Sharp (1989) CABIOS. 5:151-153) with the default
parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default
parameters for pairwise alignments using the Clustal method may be
selected: KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS
SAVED=5.
[0110] The term "sequence analysis software" refers to any computer
algorithm or software program that is useful for the analysis of
nucleotide or amino acid sequences. "Sequence analysis software"
may be commercially available or independently developed. Typical
sequence analysis software will include but is not limited to the
GCG suite of programs (Wisconsin Package Version 9.0, Genetics
Computer Group (GCG), Madison, Wis.), BLASTP, BLASTN, BLASTX
(Altschul et al., J. Mol. Biol. 215:403-410 (1990), and DNASTAR
(DNASTAR, Inc. 1228 S. Park St. Madison, Wis. 53715 USA). Within
the context of this application it will be understood that where
sequence analysis software is used for analysis, that the results
of the analysis will be based on the "default values" of the
program referenced, unless otherwise specified. As used herein
"default values" will mean any set of values or parameters which
originally load with the software when first initialized.
[0111] "Synthetic genes" can be assembled from oligonucleotide
building blocks that are chemically synthesized using procedures
known to those skilled in the art. These building blocks are
ligated and annealed to form gene segments that are then
enzymatically assembled to construct the entire gene. "Chemically
synthesized", as related to a sequence of DNA, means that the
component nucleotides were assembled in vitro. Manual chemical
synthesis of DNA may be accomplished using well-established
procedures, or automated chemical synthesis can be performed using
one of a number of commercially available machines. Accordingly,
the genes can be tailored for optimal gene expression based on
optimization of nucleotide sequence to reflect the codon bias of
the host cell. The skilled artisan appreciates the likelihood of
successful gene expression if codon usage is biased towards those
codons favored by the host. Determination of preferred codons can
be based on a survey of genes derived from the host cell where
sequence information is available.
Polynucleotides Encoding Whitefly Ecdysone Receptor
Polypeptides
[0112] The present invention provides novel polynucleotides
encoding a whitefly ecdysone receptor polypeptide of the invention,
including a full-length whitefly ecdysone receptor protein, and any
whitefly ecdysone receptor-specific fragments thereof.
[0113] In accordance with specific embodiments of the present
invention, nucleic acid sequences encoding portions of a novel
ecdysone receptor polypeptide have been elucidated and
characterized. Specifically, polynucleotides encoding a homopteran
ecdysone receptor from whitefly (BaEcR) has been characterized. The
full-length encoding sequence has been determined and is presented
herein as nucleotides 102-1349 of SEQ ID NO: 1. In addition,
domains within this polynucleotide encoding the full-length BaEcR
polypeptide have been defined and are presented herein as described
in Table 1. TABLE-US-00001 TABLE 1 Nucleotide and amino acid
sequences corresponding to various domains and helices of whitefly
ecdysone receptor ("BaEcR"). Full Length BaEcR or BaEcR Nucleotides
of Amino Acids of Domains SEQ ID NO: 1 SEQ ID NO: 2 A/BCDE (Full
length) 102-1349 1-416 A/B 102-258 1-52 C 259-457 53-118 D 458-677
119-192 E 678-1349 193-416 CDE 259-1349 53-416 DE 458-1349 119-416
Helices 1-12 648-1349 183-416
[0114] Thus, a first subject of the invention relates to an
isolated polynucleotide encoding a novel ecdysone receptor
polypeptide. More specifically, the invention relates to an
isolated polynucleotide encoding a whitefly ecdysone receptor
polypeptide. In a specific embodiment, the isolated polynucleotide
comprises a nucleic acid sequence selected from the group
consisting of SEQ ID NO: 1, nucleotides 102-1349 of SEQ ID NO: 1,
nucleotides 102-258 of SEQ ID NO: 1, nucleotides 259-457 of SEQ ID
NO: 1, nucleotides 458-677 of SEQ ID NO: 1, nucleotides 678-1349 of
SEQ ID NO: 1, nucleotides 259-1349 of SEQ ID NO: 1, nucleotides
458-1349 of SEQ ID NO: 1, and nucleotides 648-1349 of SEQ ID NO: 1.
In another specific embodiment, the isolated polynucleotide
comprises a nucleic acid sequence as depicted in SEQ ID NO: 1. In
another specific embodiment, the isolated polynucleotide comprises
a nucleic acid sequence as depicted in nucleotides 102-1349 of SEQ
ID NO: 1. In another specific embodiment, the isolated
polynucleotide further comprises a region permitting expression of
the polypeptide in a host cell.
[0115] The present invention also relates to an isolated
polynucleotide encoding a polypeptide comprising an amino acid
sequence selected from the group consisting of SEQ ID NO: 2, amino
acids 1-52 of SEQ ID NO: 2, amino acids 53-118 of SEQ ID NO: 2,
amino acids 119-192 of SEQ ID NO: 2, amino acids 193-416 of SEQ ID
NO: 2, amino acids 53-416 of SEQ ID NO: 2, amino acids 119416 of
SEQ ID NO: 2, and amino acids 183-416 of SEQ ID NO: 2. In a
specific embodiment, the isolated polynucleotide encodes a whitefly
ecdysone receptor polypeptide comprising an amino acid sequence as
depicted in SEQ ID NO: 2.
[0116] The present invention provides novel isolated
polynucleotides encoding whitefly ecdysone receptor polypeptides.
Having elucidated the sequence and structure of this ecdysone
receptor, an isolated polynucleotide encoding a whitefly receptor
polypeptide comprising a ligand-binding domain may be used
individually or in combination to screen for new ligands that bind
this ligand binding domain. Thus, for example, an ecdysone receptor
polypeptide according to the invention may be used to control
expression of reporter genes for which sensitive assays exist. The
ligand binding domain may serve as a reagent for screening new
molecules, useful as either agonists or antagonists of the whitefly
ecdysone receptor. Either new classes of molecules may be screened,
or selected modifications from known ligands may be used. These new
ligands find use as highly specific and highly active, naturally
occurring pesticides. Thus, the present invention provides for
screening for new ligand molecules.
[0117] The polynucleotides of the present invention also provide
probes for screening for homologous nucleic acid sequences, both in
Bamecia and other genetic sources. This screening allows isolation
of homologous genes from both vertebrates and invertebrates.
[0118] Accordingly, any whitefly cell potentially can serve as the
nucleic acid source for the molecular cloning of a whitefly
ecdysone receptor polynucleotide. The polynucleotide may be
obtained by standard procedures known in the art from cloned DNA
(e.g., a DNA "library"), and preferably is obtained from a cDNA
library prepared from tissues with high level expression of the
protein, by chemical synthesis, by cDNA cloning, or by the cloning
of genomic DNA, or fragments thereof, purified from the desired
cell (See, for example, Sambrook et al., 1989, supra; Glover, D. M.
(ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd.,
Oxford, U.K. Vol. I, II). Clones derived from genomic DNA may
contain regulatory and intron DNA regions in addition to coding
regions; clones derived from cDNA will not contain intron
sequences. Whatever the source, the polynucleotide should be
molecularly cloned into a suitable vector for propagation of the
polynucleotide.
[0119] Once the DNA fragments are generated, identification of the
specific DNA fragment containing the desired whitefly ecdysone
receptor polynucleotide may be accomplished in a number of ways.
For example, DNA fragments may be screened by nucleic acid
hybridization to a labeled probe (Benton and Davis, 1977, Science
196: 180; Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci.
U.S.A. 72: 3961). Those DNA fragments with substantial homology to
the probe will hybridize. As noted above, the greater the degree of
homology, the more stringent hybridization conditions can be
used.
[0120] Further selection can be carried out on the basis of the
properties of the polynucleotide, e.g., if the polynucleotide
encodes a polypeptide having the isoelectric, electrophoretic,
amino acid composition, or partial amino acid sequence of the
whitefly ecdysone receptor polypeptide as disclosed herein. Thus,
the presence of the polynucleotide may be detected by assays based
on the physical, chemical, or immunological properties of its
expressed product. For example, cDNA clones, or DNA clones which
hybrid-select the proper mRNAs, can be selected which produce a
polypeptide that, e.g., has similar or identical electrophoretic
migration, isoelectric focusing or non-equilibrium pH gel
electrophoresis behavior, proteolytic digestion maps, or antigenic
properties as known for a whitefly ecdysone receptor polypeptide.
In a specific embodiment, the expressed polypeptide is recognized
by a polyclonal antibody that is generated against an epitope
specific for a whitefly ecdysone receptor polypeptide.
[0121] Due to the degeneracy of nucleotide coding sequences, other
polynucleotides that encode substantially the same amino acid
sequence as a whitefly ecdysone receptor polynucleotide disclosed
herein, including an amino acid sequence that contains a single
amino acid variant, may be used in the practice of the present
invention. These include but are not limited to allelic genes,
homologous genes from other species, and nucleotide sequences
comprising all or portions of whitefly ecdysone receptor
polynucleotides that are altered by the substitution of different
codons that encode the same amino acid residue within the sequence,
thus producing a silent change. Likewise, the whitefly ecdysone
receptor derivatives of the invention include, but are not limited
to, those comprising, as a primary amino acid sequence, all or part
of the amino acid sequence of a whitefly ecdysone receptor
polypeptide including altered sequences in which functionally
equivalent amino acid residues are substituted for residues within
the sequence resulting in a conservative amino acid substitution.
For example, one or more amino acid residues within the sequence
can be substituted by another amino acid of a similar polarity,
which acts as a functional equivalent, resulting in a silent
alteration. Substitutes for an amino acid within the sequence may
be selected from other members of the class to which the amino acid
belongs. For example, the nonpolar (hydrophobic) amino acids
include alanine, leucine, isoleucine, valine, proline,
phenylalanine, tryptophan and methionine. Amino acids containing
aromatic ring structures are phenylalanine, tryptophan, and
tyrosine. The polar neutral amino acids include glycine, serine,
threonine, cysteine, tyrosine, asparagine, and glutamine. The
positively charged (basic) amino acids include arginine, lysine and
histidine. The negatively charged (acidic) amino acids include
aspartic acid and glutamic acid. Such alterations can be produced
by various methods known in the art (see Sambrook et al., 1989,
infra) and are not expected to affect apparent molecular weight as
determined by polyacrylamide gel electrophoresis, or isoelectric
point.
[0122] The present invention also relates to an isolated whitefly
ecdysone receptor polypeptide encoded by a polynucleotide according
to the invention.
Whitefly Ecdysone Receptor Polypeptides
[0123] The present invention provides novel isolated whitefly
ecdysone receptor polypeptides, including a full-length whitefly
ecdysone receptor protein, and any whitefly ecdysone
receptor-specific polypeptide fragments thereof.
[0124] Thus, the invention relates to an isolated ecdysone receptor
polypeptide. More specifically, the invention relates to an
isolated whitefly ecdysone receptor polypeptide. In a specific
embodiment, the isolated ecdysone receptor polypeptide comprises an
amino acid sequence selected from the group consisting of SEQ ID
NO: 2, amino acids 1-52 of SEQ ID NO: 2, amino acids 53-118 of SEQ
ID NO: 2, amino acids 119-192 of SEQ ID NO: 2, amino acids 193-416
of SEQ ID NO: 2, amino acids 53-416 of SEQ ID NO: 2, amino acids
119-416 of SEQ ID NO: 2, and amino acids 183-416 of SEQ ID NO: 2.
In another specific embodiment, the isolated ecdysone receptor
polypeptide comprises an amino acid sequence as depicted in SEQ ID
NO: 2.
[0125] In another specific embodiment, the isolated ecdysone
receptor polypeptide is encoded by a polynucleotide comprising a
nucleic acid sequence selected from the group consisting of SEQ ID
NO: 1, nucleotides 102-1349 of SEQ ID NO: 1, nucleotides 102-258 of
SEQ ID NO: 1, nucleotides 259-457 of SEQ ID NO: 1, nucleotides
458-677 of SEQ ID NO: 1, nucleotides 678-1349 of SEQ ID NO: 1,
nucleotides 259-1349 of SEQ ID NO: 1, nucleotides 458-1349 of SEQ
ID NO: 1, and nucleotides 648-1349 of SEQ ID NO: 1. In another
specific embodiment, the isolated ecdysone receptor polypeptide is
encoded by a polynucleotide comprising a nucleic acid sequence as
depicted in SEQ ID NO: 1. In another specific embodiment, the
isolated ecdysone receptor polypeptide is encoded by a
polynucleotide comprising a nucleic acid sequence as depicted in
nucleotides 102-1349 of SEQ ID NO: 1.
[0126] One of skill in the art is able to produce other
polynucleotides to encode the polypeptides of the invention, by
making use of the present invention and the degeneracy or
non-universality of the genetic code as described herein.
[0127] Additional embodiments of the present invention include an
ecdysone receptor polypeptide according to the invention, wherein
the ecdysone receptor polypeptide is substantially free of
naturally associated cell components. Such polypeptides will
typically be either full-length proteins, functional fragments, or
fusion proteins comprising segments from an ecdysone receptor
polypeptide of the present invention fused to a heterologous, or
normally non-contiguous, protein domain. Preferably, the ecdysone
receptor polypeptide comprises a transactivation domain, a DNA
binding domain, a ligand binding domain, a hinge region, or a
heterodimerization domain. More preferably, the ecdysone receptor
polypeptide comprises a ligand binding domain that is capable of
binding to a ligand selected from the group consisting of a steroid
ligand and a non-steroid ligand. As desired, the ecdysone receptor
polypeptide may be fused to a second polypeptide to generate a
hybrid polypeptide. Preferably, the second polypeptide is a
heterologous polypeptide from the steroid hormone nuclear receptor
superfamily.
[0128] Besides substantially full-length polypeptides, the present
invention provides for biologically active fragments of the
polypeptides. Significant biological activities include
transactivation activity, ligand binding, DNA binding,
heterodimerization activity, immunological activity and other
biological activities characteristic of steroid receptor
superfamily members immunological activities include both
immunogenic function in a target immune system, as well as sharing
of immunological epitopes for binding, serving as either a
competitor or substitute antigen for an ecdysone receptor
epitope.
[0129] For example, transactivation, ligand binding, or DNA-binding
domains may be "swapped" between different new fusion polypeptides
or fragments. Thus, novel hybrid polypeptides exhibiting new
combinations of specificities result from the functional linkage of
transactivation, ligand-binding specificities, or DNA-binding
domains. This is extremely useful in the design of inducible
expression systems.
[0130] For immunological purposes, immunogens may be produced that
tandemly repeat polypeptide segments, thereby producing highly
antigenic proteins. Alternatively, such polypeptides will serve as
highly efficient competitors for specific binding. Production of
antibodies to BaEcR is described below.
[0131] The present invention also provides for other polypeptides
comprising fragments of BaEcR Thus, fusion polypeptides between the
BaEcR segments and other homologous or heterologous proteins are
provided. Homologous polypeptides may be fusions between different
steroid receptor superfamily members, resulting in, for instance, a
hybrid protein exhibiting ligand specificity of one member and
DNA-binding specificity of another. Likewise, heterologous fusions
may be constructed which would exhibit a combination of properties
or activities of the derivative proteins. Typical examples are
fusions of a reporter polypeptide, e.g., luciferase, with another
domain of a receptor, e.g., a DNA-binding domain, so that the
presence or location of a desired ligand may be easily determined.
See, e.g., Dull et al., U.S. Pat. No. 4,859,609, which is hereby
incorporated herein by reference. Other typical gene fusion
partners include "zinc finger" segment swapping between DNA-binding
proteins, bacterial beta-galactosidase, trpE Protein A,
beta-lactamase, alpha amylase, alcohol dehydrogenase and yeast
alpha mating factor. See, e.g., Godowski et al. (1988), Science
241: 812-816.
[0132] Thus, the present invention also provides an isolated
polypeptide selected from the group consisting of a) an isolated
polypeptide comprising a transactivation domain, a DNA-binding
domain, and a whitefly ecdysone receptor ligand binding domain; b)
an isolated polypeptide comprising a DNA-binding domain and a
whitefly ecdysone receptor ligand binding domain; and c) an
isolated polypeptide comprising a transactivation domain and a
whitefly ecdysone receptor ligand binding domain. Preferably, the
whitefly ecdysone receptor ligand binding domain comprises an amino
acid sequence selected from the group consisting of SEQ ID NO: 2,
amino acids 193-416 of SEQ ID NO: 2, amino acids 53-416 of SEQ ID
NO: 2, amino acids 119-416 of SEQ ID NO: 2, and amino acids 183-416
of SEQ ID NO: 2. In another preferred embodiment, the whitefly
ecdysone receptor ligand binding domain is encoded by a
polynucleotide comprising a nucleic acid sequence selected from the
group consisting of SEQ ID NO: 1, nucleotides 102-1349 of SEQ ID
NO: 1, nucleotides 678-1349 of SEQ ID NO: 1, nucleotides 259-1349
of SEQ ID NO: 1, nucleotides 458-1349 of SEQ ID NO: 1, and
nucleotides 648-1349 of SEQ ID NO: 1.
[0133] The present invention also provides an isolated hybrid
polypeptide selected from the group consisting of a) an isolated
hybrid polypeptide comprising a transactivation domain, a
DNA-binding domain, and a whitefly ecdysone receptor ligand binding
domain; b) an isolated hybrid polypeptide comprising a DNA-binding
domain and a whitefly ecdysone receptor ligand binding domain; and
c) an isolated hybrid polypeptide comprising a transactivation
domain and a whitefly ecdysone receptor ligand binding domain.
Preferably, the whitefly ecdysone receptor ligand binding domain
comprises an amino acid sequence selected from the group consisting
of SEQ ID NO: 2, amino acids 193-416 of SEQ ID NO: 2, amino acids
53-416 of SEQ ID NO: 2, amino acids 119-416 of SEQ ID NO: 2, and
amino acids 183-416 of SEQ ID NO: 2. In another preferred
embodiment, the whitefly ecdysone receptor ligand binding domain is
encoded by a polynucleotide comprising a nucleic acid sequence
selected from the group consisting of SEQ ID NO: 1, nucleotides
102-1349 of SEQ ID NO: 1, nucleotides 678-1349 of SEQ ID NO: 1,
nucleotides 259-1349 of SEQ ID NO: 1, nucleotides 458-1349 of SEQ
ID NO: 1, and nucleotides 648-1349 of SEQ ID NO: 1.
[0134] The present invention also relates to compositions
comprising an isolated polypeptide according to the invention.
Compositions
[0135] The present invention also relates to compositions
comprising the isolated polynucleotides or polypeptides according
to the invention. Such compositions may comprise a whitefly
ecdysone receptor polypeptide or a polynucleotide encoding a
whitefly ecdysone receptor polypeptide, as defined above, and an
acceptable carrier or vehicle. The compositions of the invention
are particularly suitable for formulation of biological material
for use in a gene expression modulation system or a
ligand-screening assay according to the invention. Thus, in a
preferred embodiment, the composition comprises a polynucleotide
encoding a whitefly ecdysone receptor polypeptide. In another
preferred embodiment, the composition comprises a whitefly ecdysone
receptor polypeptide according to the invention.
[0136] The phrase "acceptable" refers to molecular entities and
compositions that are physiologically tolerable to the cell or
organism when administered. The term "carrier" refers to a diluent,
adjuvant, excipient, or vehicle with which the composition is
administered. Such carriers can be sterile liquids, such as water
and oils, including those of petroleum, animal, vegetable or
synthetic origin, such as peanut oil, soybean oil, mineral oil,
sesame oil and the like. Examples of acceptable carriers are
saline, buffered saline, isotonic saline (e.g., monosodium or
disodium phosphate, sodium, potassium, calcium or magnesium
chloride, or mixtures of such salts), Ringer's solution, dextrose,
water, sterile water, glycerol, ethanol, and combinations thereof.
1,3-butanediol and sterile fixed oils are conveniently employed as
solvents or suspending media. Any bland fixed oil can be employed
including synthetic mono- or di-glycerides. Fatty acids such as
oleic acid also find use in the preparation of injectables. Water
or aqueous solution saline solutions and aqueous dextrose and
glycerol solutions are preferably employed as carriers,
particularly for injectable solutions. Suitable pharmaceutical
carriers are described in "Remington's Pharmaceutical Sciences" by
E. W. Martin. Pharmaceutical compositions of the invention may be
formulated for the purpose of topical, oral, parenteral,
intranasal, intravenous, intramuscular, subcutaneous, intraocular,
and the like, administration.
[0137] Preferably, the compositions comprise an acceptable vehicle
for an injectable formulation. This vehicle can be, in particular,
a sterile, isotonic saline solution (monosodium or disodium
phosphate, sodium, potassium, calcium or magnesium chloride, and
the like, or mixtures of such salts), or dry, in particular
lyophilized, compositions which, on addition, as appropriate, of
sterilized water or of physiological saline, enable injectable
solutions to be formed. The preferred sterile injectable
preparations can be a solution or suspension in a nontoxic
parenterally acceptable solvent or diluent.
[0138] In yet another embodiment, a composition comprising a
whitefly ecdysone receptor polypeptide, or polynucleotide encoding
the polypeptide, can be delivered in a controlled release system.
For example, the polynucleotide or polypeptide may be administered
using intravenous infusion, an implantable osmotic pump, a
transdemmal patch, liposomes, or other modes of administration.
Other controlled release systems are discussed in a review by
Langer [Science 249: 1527-1533 (1990)].
Expression of Whitefly Ecdysone Receptor Polypeptides
[0139] With the sequence of the receptor polypeptides and the
polynucleotides encoding them, large quantities of whitefly
ecdysone receptor polypeptides may be prepared. By the appropriate
expression of vectors in cells, high efficiency production may be
achieved. Thereafter, standard purification methods may be used,
such as ammonium sulfate precipitations, column chromatography,
electrophoresis, centrifugation, crystallization and others. See
various volumes of Methods in Enzymology for techniques typically
used for protein purification. Alternatively, in some embodiments
high efficiency of production is unnecessary, but the presence of a
known inducing protein within a carefully engineered expression
system is quite valuable. For instance, a combination of: (1) a
ligand-responsive enhancer or response element operably linked to
(2) a desired gene sequence with (3) the corresponding whitefly
ecdysone receptor polypeptide together in an expression system
provides a specifically inducible expression system. Typically, the
expression system will be a cell, but an in vitro expression system
may also be constructed.
[0140] A polynucleotide encoding a whitefly ecdysone receptor, or
fragment, derivative or analog thereof, or a functionally active
derivative, including a chimeric protein, thereof, can be inserted
into an appropriate expression vector, i.e., a vector which
comprises the necessary elements for the transcription and
translation of the inserted protein-coding sequence. Thus, the
polynucleotide of the invention is operationally linked with a
transcriptional control sequence in an expression vector of the
invention. Both cDNA and genomic sequences can be cloned and
expressed under control of such regulatory sequences. An expression
vector also preferably includes a replication origin.
[0141] The isolated polynucleotides of the invention may be
inserted into any appropriate cloning vector. A large number of
vector-host systems known in the art may be used. Possible vectors
include, but are not limited to, plasmids or modified viruses, but
the vector system must be compatible with the host cell used.
Examples of vectors include, but are not limited to, Escherichia
coli, bacteriophages such as lambda derivatives, or plasmids such
as pBR322 derivatives or pUC plasmid derivatives, e.g. pGEX
vectors, pmal-c, pFLAG, etc. The insertion into a cloning vector
can, for example, be accomplished by ligating the polynucleotide
into a cloning vector that has complementary cohesive termini.
However, if the complementary restriction sites used to fragment
the polynucleotide are not present in the cloning vector, the ends
of the polynucleotide molecules may be enzymatically modified.
Alternatively, any site desired may be produced by ligating
nucleotide sequences (linkers) onto the DNA termini; these ligated
linkers may comprise specific chemically synthesized
oligonucleotides encoding restriction endonuclease recognition
sequences. Preferably, the cloned gene is contained on a shuttle
vector plasmid, which provides for expansion in a cloning cell,
e.g., E. coli, and purification for subsequent insertion into an
appropriate expression cell line, if such is desired. For example,
a shuttle vector, which is a vector that can replicate in more than
one type of organism, can be prepared for replication in both E.
coli and Saccharomyces cerevisiae by linking sequences from an E.
coli plasmid with sequences form the yeast 2.mu. plasmid.
[0142] In addition, the present invention relates to an expression
vector comprising a polynucleotide according the invention,
operatively linked to a transcription regulatory element.
Preferably, the polynucleotide is operatively linked with an
expression control sequence permitting expression of the nuclear
receptor ligand binding domain in an expression competent host
cell. The expression control sequence may comprise a promoter that
is functional in the host cell in which expression is desired. The
vector may be a plasmid DNA molecule or a viral vector. Preferred
viral vectors include retrovirus, adenovirus, adeno-associated
virus, herpes virus, and vaccinia virus. The invention further
relates to a replication defective recombinant virus comprising in
its genome, a polynucleotide according to the invention. Thus, the
present invention also relates to an isolated host cell comprising
such an expression vector, wherein the transcription regulatory
element is operative in the host cell.
[0143] The desired genes will be inserted into any of a wide
selection of expression vectors. The selection of an appropriate
vector and cell line depends upon the constraints of the desired
product. Typical expression vectors are described in Sambrook et
al. (1989). Suitable cell lines may be selected from a depository,
such as the ATCC. See, ATCC Catalogue of Cell Lines and Hybridomas
(6th ed.) (1988); ATCC Cell Lines, Viruses, and Antisera, each of
which is hereby incorporated herein by reference. The vectors are
introduced to the desired cells by standard transformation or
transfection procedures as described, for instance, in Sambrook et
al. (1989).
[0144] Fusion proteins will typically be made by either recombinant
nucleic acid methods or by synthetic polypeptide methods.
Techniques for nucleic acid manipulation are described generally,
for example, in Sambrook et al. (1989), Molecular Cloning: A
Laboratory Manual (2d ed.), Vols. 1-3, Cold Spring Harbor
Laboratory, which are incorporated herein by reference. Techniques
for synthesis of polypeptides are described, for example, in
Merrifield, J. Amer. Chem Soc. 85: 2149-2156 (1963).
[0145] The nucleotide sequences used to produce fusion proteins of
the present invention may be derived from natural or synthetic
sequences. Many natural gene sequences are obtainable from various
cDNA or from genomic libraries using appropriate probes. See,
GenBank.TM., National Institutes of Health. Typical probes for
whitefly ecdysone receptors may be selected from the sequences of
Table 1 in accordance with standard procedures. Suitable synthetic
DNA fragments may be prepared by the phosphoramidite method
described by Beaucage and Carruthers, Tetra. Letts. 22: 1859-1862
(1981). A double stranded fragment may then be obtained either by
synthesizing the complementary strand and annealing the strand
together under appropriate conditions or by adding the
complementary strand using DNA polymerase with an appropriate
primer sequence.
[0146] The natural or synthetic polynucleotide fragments encoding a
desired whitefly ecdysone receptor polypeptide fragment will be
incorporated into nucleic acid constructs capable of introduction
to and expression in an in vitro cell culture. Usually the nucleic
acid constructs will be suitable for replication in a unicellular
host, such as yeast or bacteria, but may also be intended for
introduction to, with and without and integration within the
genome, cultured mammalian or plant or other eukaryotic cell lines.
Nucleic acid constructs prepared for introduction into bacteria or
yeast will typically include a replication system recognized by the
host, the intended DNA fragment encoding the desired receptor
polypeptide, transcription and translational initiation regulatory
sequences operably linked to the polypeptide encoding segment and
transcriptional and translational termination regulatory sequences
operably linked to the polypeptide encoding segment. The
transcriptional regulatory sequences will typically include a
heterologous enhancer, response element, or promoter which is
recognized by the host. The selection of an appropriate promoter
will depend upon the host, but promoters such as the trp, lac and
phage promoters, tRNA promoters and glycolytic enzyme promoters are
known. See, Sambrook et al. (1989). Conveniently available
expression vectors which include the replication system and
transcriptional and translational regulatory sequences together
with the insertion site for the steroid receptor DNA sequence may
be employed. Examples of workable combinations of cell lines and
expression vectors are described in Sambrook et al. (1989); see
also, Metzger et al. (1988), Nature 334: 31-36.
[0147] Once a particular recombinant DNA molecule is identified and
isolated, several methods known in the art may be used to propagate
it. Once a suitable host system and growth conditions are
established, recombinant expression vectors can be propagated and
prepared in quantity. As previously explained, the expression
vectors which can be used include, but are not limited to, the
following vectors or their derivatives: human or animal viruses
such as vaccinia virus or adenovirus; insect viruses such as
baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda),
and plasmid and cosmid DNA vectors, to name but a few.
[0148] In addition, a host cell strain may be chosen which
modulates the expression of the inserted sequences, or modifies and
processes the gene product in the specific fashion desired.
Different host cells have characteristic and specific mechanisms
for the translational and post-translational processing and
modification of proteins. Appropriate cell lines or host systems
can be chosen to ensure the desired modification and processing of
the foreign protein expressed. Expression in yeast can produce a
biologically active product. Expression in eukaryotic cells can
increase the likelihood of "native" folding. Moreover, expression
in mammalian cells can provide a tool for reconstituting, or
constituting, whitefly ecdysone receptor activity. Furthermore,
different vector/host expression systems may affect processing
reactions, such as proteolytic cleavages, to a different
extent.
[0149] Vectors are introduced into the desired host cells by
methods known in the art, e.g., transfection, electroporation,
microinjection, transduction, cell fusion, DEAE dextran, calcium
phosphate precipitation, lipofection (lysosome fusion), particle
bombardment, use of a gene gun, or a DNA vector transporter (see,
e.g., Wu et al., 1992, J. Biol. Chem. 267:963-967; Wu and Wu, 1988,
J. Biol. Chen. 263:14621-14624; Hartmut et al., Canadian Patent
Application No. 2,012,311, filed Mar. 15, 1990).
[0150] Soluble forms of the protein can be obtained by collecting
culture fluid, or solubilizing inclusion bodies, e.g., by treatment
with detergent, and if desired sonication or other mechanical
processes, as described above. The solubilized or soluble protein
can be isolated using various techniques, such as polyacrylamide
gel electrophoresis (PAGE), isoelectric focusing, 2-dimensional gel
electrophoresis, chromatography (e.g., ion exchange, affinity,
immunoaffinity, and sizing column chromatography), centrifugation,
differential solubility, immunoprecipitation, or by any other
standard technique for the purification of proteins.
Vectors and Gene Expression Cassettes Comprising a Whitefly
Ecdysone Receptor Polynucleotide
[0151] Thus, the present invention also relates to a vector
comprising a polynucleotide encoding a whitefly ecdysone receptor
polypeptide according to the invention. The present invention also
provides a gene expression cassette comprising a polynucleotide
encoding a whitefly ecdysone receptor polypeptide according to the
invention. The polynucleotides of the invention, where appropriate
incorporated in vectors or gene expression cassettes, and the
compositions comprising them, are useful for regulating gene
expression in an ecdysone receptor-based gene expression system.
They may be used for the transfer and expression of genes in vitro
or in vivo in any type of cell or tissue. The transformation can,
moreover, be targeted (transfer to a particular tissue can, in
particular, be determined by the choice of a vector, and expression
by the choice of a particular promoter). The polynucleotides and
vectors of the invention are advantageously used for the production
in vivo and intracellularly, of polypeptides of interest.
[0152] The polynucleotides encoding the whitefly ecdysone receptor
polypeptides of the invention will typically be used in a plasmid
vector. Preferably, an expression control sequence is operably
linked to the whitefly ecdysone receptor polynucleotide coding
sequence for expression of the whitefly ecdysone receptor
polypeptide. The expression control sequence may be any enhancer,
response element, or promoter system in vectors capable of
transforming or transfecting a host cell. Once the vector has been
incorporated into the appropriate host, the host, depending on the
use, will be maintained under conditions suitable for high-level
expression of the polynucleotides.
[0153] Polynucleotides will normally be expressed in hosts after
the sequences have been operably linked to (i.e., positioned to
ensure the functioning of) an expression control sequence. These
expression vectors are typically replicable in the host organisms
either as episomes or as an integral part of the host chromosomal
DNA. Commonly, expression vectors will contain selection markers,
e.g., tetracycline or neomycin, to permit detection of those cells
transformed with the desired DNA sequences (see, e.g., U.S. Pat.
No. 4,704,362, which is incorporated herein by reference).
[0154] Escherichia coli is one prokaryotic host useful for cloning
the polynucleotides of the present invention. Other microbial hosts
suitable for use include bacilli, such as Bacillus subtilis, and
other enterobacteriaceae, such as Salmonella, Serratia, and various
Pseudomonas species.
[0155] Other eukaryotic cells may be used, including yeast cells,
insect tissue culture cells, avian cells or the like. Preferably,
mammalian tissue cell culture will be used to produce the
polypeptides of the present invention (see, Winnacker, From Genes
to Clones, VCH Publishers, N.Y. (1987), which is incorporated
herein by reference). Yeast and mammalian cells are preferred cells
in which to use whitefly ecdysone receptor-based inducible gene
expression systems because they naturally lack the molecules which
confer responsiveness to the ligands for ecdysone receptor.
[0156] Expression vectors may also include expression control
sequences, such as an origin of replication, a promoter, an
enhancer, a response element, and necessary processing information
sites, such as ribosome-binding sites, RNA splice sites,
polyadenylation sites, and transcriptional terminator sequences.
Preferably, the enhancers or promoters will be those naturally
associated with genes encoding the steroid receptors, although it
will be understood that in many cases others will be equally or
more appropriate. Other preferred expression control sequences are
enhancers or promoters derived from viruses, such as SV40,
Adenovirus, Bovine Papilloma Virus, and the like.
[0157] The vectors comprising the polynucleotides of the present
invention can be transferred into the host cell by well-known
methods, which vary depending on the type of cellular host. For
example, calcium chloride transfection is commonly utilized for
procaryotic cells, whereas calcium phosphate treatment may be used
for other cellular hosts. (See, generally, Sambrook et al. (1989),
Molecular Cloning: A Laboratory Manual (2d ed.), Cold Spring Harbor
Press, which is incorporated herein by reference.) The term
"transformed cell" is meant to also include the progeny of a
transformed cell.
[0158] The necessary transcriptional and translational signals can
be provided on a recombinant expression vector, or they may be
supplied by the native gene encoding whitefly ecdysone receptor
and/or its flanking regions. Potential host-vector systems include
but are not limited to mammalian cell systems infected with virus
(e.g., vaccinia virus, adenovirus, etc.); insect cell systems
infected with virus (e.g., baculovirus); microorganisms such as
yeast containing yeast vectors; or bacteria transformed with
bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression
elements of vectors vary in their strengths and specificities.
Depending on the host-vector system utilized, any one of a number
of suitable transcription and translation elements may be used.
[0159] A recombinant whitefly ecdysone receptor protein of the
invention, or functional fragment, derivative, chimeric construct,
or analog thereof, may be expressed chromosomally, after
integration of the coding sequence by recombination. In this
regard, any of a number of amplification systems may be used to
achieve high levels of stable gene expression (See Sambrook et al.,
1989, supra).
[0160] The cell into which the recombinant vector comprising the
polynucleotide encoding whitefly ecdysone receptor is cultured in
an appropriate cell culture medium under conditions that provide
for expression of whitefly ecdysone receptor by the cell. Any of
the methods previously described for the insertion of DNA fragments
into a cloning vector may be used to construct expression vectors
containing a gene consisting of appropriate
transcriptional/translational control signals and the protein
coding sequences. These methods may include in vitro recombinant
DNA and synthetic techniques and in vivo recombination (genetic
recombination).
[0161] A polynucleotide encoding a whitefly ecdysone receptor
polypeptide may be operably linked and controlled by any regulatory
region, i.e., promoter/enhancer element known in the art, but these
regulatory elements must be functional in the host cell selected
for expression. The regulatory regions may comprise a promoter
region for functional transcription in the host cell, as well as a
region situated 3' of the gene of interest, and which specifies a
signal for termination of transcription and a polyadenylation site.
All these elements constitute an expression cassette.
[0162] Expression vectors comprising a polynucleotide encoding a
whitefly ecdysone receptor polypeptide of the invention can be
identified by five general approaches: (a) PCR amplification of the
desired plasmid DNA or specific mRNA, (b) nucleic acid
hybridization, (c) presence or absence of selection marker gene
functions, (d) analyses with appropriate restriction endonucleases,
and (e) expression of inserted sequences. In the first approach,
the nucleic acids can be amplified by PCR to provide for detection
of the amplified product. In the second approach, the presence of a
foreign gene inserted in an expression vector can be detected by
nucleic acid hybridization using probes comprising sequences that
are homologous to an inserted marker gene. In the third approach,
the recombinant vector/host system can be identified and selected
based upon the presence or absence of certain "selection marker"
gene functions (e.g., .beta.-galactosidase activity, thymidine
kinase activity, resistance to antibiotics, transformation
phenotype, occlusion body formation in baculovirus, etc.) caused by
the insertion of foreign genes in the vector. In another example,
if the nucleic acid encoding a whitefly ecdysone receptor
polypeptide is inserted within the "selection marker" gene sequence
of the vector, recombinants comprising the whitefly ecdysone
receptor nucleic acid insert can be identified by the absence of
the gene function. In the fourth approach, recombinant expression
vectors are identified by digestion with appropriate restriction
enzymes. In the fifth approach, recombinant expression vectors can
be identified by assaying for the activity, biochemical, or
immunological characteristics of the gene product expressed by the
recombinant, provided that the expressed protein assumes a
functionally active conformation.
[0163] A wide variety of host/expression vector combinations may be
employed in expressing the DNA sequences of this invention. Useful
expression vectors, for example, may consist of segments of
chromosomal, non-chromosomal and synthetic DNA sequences. Suitable
vectors include but are not limited to derivatives of SV40 and
known bacterial plasmids, e.g. E. coli plasmids col El, pCR1,
pBR322, pMal-C2, pET, pGEX (Smith et al., 1988, Gene 67: 31-40),
pMB9 and their derivatives, plasmids such as RP4; phage DNAS, e.g.,
the numerous derivatives of phage 1, e.g., NM989, and other phage
DNA, e.g., M13 and filamentous single stranded phage DNA; yeast
plasmids such as the 2m plasmid or derivatives thereof; vectors
useful in eukaryotic cells, such as vectors useful in insect or
mammalian cells; vectors derived from combinations of plasmids and
phage DNAs, such as plasmids that have been modified to employ
phage DNA or other expression control sequences; and the like.
[0164] The present invention also provides a gene expression
cassette that is capable of being expressed in a host cell, wherein
the gene expression cassette comprises a polynucleotide that
encodes a whitefly ecdysone receptor polypeptide according to the
invention. Thus, Applicants' invention also provides novel gene
expression cassettes useful in an ecdysone receptor-based gene
expression system.
[0165] In a specific embodiment, the gene expression cassette that
is capable of being expressed in a host cell comprises a
polynucleotide that encodes a polypeptide selected from the group
consisting of a) a polypeptide comprising a transactivation domain,
a DNA-binding domain, and a whitefly ecdysone receptor ligand
binding domain; b) a polypeptide comprising a DNA-binding domain
and a whitefly ecdysone receptor ligand binding domain; and c) a
polypeptide comprising a transactivation domain and a whitefly
ecdysone receptor ligand binding domain.
[0166] In another specific embodiment, the present invention
provides a gene expression cassette that is capable of being
expressed in a host cell, wherein the gene expression cassette
comprises a polynucleotide that encodes a hybrid polypeptide
selected from the group consisting of a) a hybrid polypeptide
comprising a transactivation domain, a DNA-binding domain, and a
whitefly ecdysone receptor ligand binding domain; b) a hybrid
polypeptide comprising a DNA-binding domain and a whitefly ecdysone
receptor ligand binding domain; and c) a hybrid polypeptide
comprising a transactivation domain and a whitefly ecdysone
receptor ligand binding domain. A hybrid polypeptide according to
the invention comprises at least two polypeptide fragments, wherein
each polypeptide fragment is from a different source, i.e., a
different polypeptide, a different nuclear receptor, a different
species, etc. The hybrid polypeptide according to the invention may
comprise at least two polypeptide domains, wherein each polypeptide
domain is from a different source.
[0167] Preferably, the whitefly ecdysone receptor ligand binding
domain is from a whitefly Bamecia argentifoli EcR ("BaEcR").
[0168] In a specific embodiment, the whitefly ecdysone receptor
ligand binding domain is encoded by a polynucleotide comprising a
nucleic acid sequence selected from the group consisting of SEQ ID
NO: 1, nucleotides 102-1349 of SEQ ID NO: 1, nucleotides 678-1349
of SEQ ID NO: 1, nucleotides 259-1349 of SEQ ID NO: 1, nucleotides
458-1349 of SEQ ID NO: 1, and nucleotides 648-1349 of SEQ ID NO:
1.
[0169] In a specific embodiment, the whitefly ecdysone receptor
ligand binding domain comprises an amino acid sequence selected
from the group consisting of SEQ ID NO: 2, amino acids 193-416 of
SEQ ID NO: 2, amino acids 53-416 of SEQ ID NO: 2, amino acids
119-416 of SEQ ID NO: 2, and amino acids 183-416 of SEQ ID NO:
2.
[0170] The DNA binding domain can be any DNA binding domain with a
known response element, including synthetic and chimeric DNA
binding domains, or analogs, combinations, or modifications
thereof. Preferably, the DBD is a GAL4 DBD, a LexA DBD, a
transcription factor DBD, a steroid/thyroid hormone nuclear
receptor superfamily member DBD, such as an EcR DBD, or a bacterial
LacZ DBD.
[0171] The transactivation domain (abbreviated "AD" or "TA") may be
any steroid/thyroid hormone nuclear receptor AD, synthetic or
chimeric AD, polyglutamine AD, basic or acidic amino acid AD, a
VP16 AD, a GALA AD, an NF-.kappa.B AD, a BP64 AD, a B42 acidic
activation domain (B42AD), a p65 transactivation domain (p65AD), or
an analog, combination, or modification thereof. In a specific
embodiment, the AD is a synthetic or chimeric AD, or is obtained
from an EcR, a glucocorticoid receptor, VP16, GAL4, NF-KB, or B42
acidic activation domain AD.
[0172] In a specific embodiment, the gene expression cassette
encodes a hybrid polypeptide comprising either a) a DNA-binding
domain, or b) a transactivation domain; and a BaEcR ligand binding
domain according to the invention.
[0173] The present invention also provides a gene expression
cassette comprising: i) a response element comprising a domain
recognized by a polypeptide comprising a DNA binding domain; ii) a
promoter that is activated by a polypeptide comprising a
transactivation domain; and iii) a gene whose expression is to be
modulated.
[0174] The response element ("RE") may be any response element with
a known DNA binding domain, or an analog, combination, or
modification thereof. A single RE may be employed or multiple REs,
either multiple copies of the same RE or two or more different REs,
may be used in the present invention. In a specific embodiment, the
RE is an RE from GAL4 ("GAL4RE"), LexA, a steroid/thyroid hormone
nuclear receptor RE, such as an ecdysone response element (EcRE),
or a synthetic RE that recognizes a synthetic DNA binding
domain.
[0175] A steroid/thyroid hormone nuclear receptor DNA binding
domain, activation domain or response element according to the
invention may be obtained from a steroid/thyroid hormone nuclear
receptor selected from the group consisting of ecdysone receptor
(EcR), ubiquitous receptor (UR), orphan receptor 1 (OR-1), steroid
hormone nuclear receptor 1 (NER-1), RXR interacting protein-15
(RIP-15), liver x receptor .beta. (LXR.beta.), steroid hormone
receptor like protein (RLD-1), liver x receptor (LXR), liver x
receptor .alpha. (LXR.alpha.), farnesoid x receptor XR), receptor
interacting protein 14 (RIP-14), farnesol receptor (HRR-1), thyroid
hormone receptor .alpha. (TR.alpha.), thyroid receptor 1
(c-erbA-1), thyroid hormone receptor .beta. (TR.beta.), retinoic
acid receptor .alpha. (RAR.alpha.), retinoic acid receptor .beta.
(RAR.beta., HAP), retinoic acid receptor .gamma. (RAR.gamma.),
retinoic acid receptor gamma-like (RARD), peroxisome
proliferator-activated receptor .alpha. (PPAR.alpha.), peroxisome
proliferator-activated receptor .beta. (PPAR.beta.), peroxisome
proliferator-activated receptor .delta. (PPAR.delta., NUC-1),
peroxisome proliferator-activator related receptor (FFAR),
peroxisome proliferator-activated receptor .gamma. (PPAR.gamma.),
orphan receptor encoded by non-encoding strand of thyroid hormone
receptor .alpha. (REVERB.alpha.), v-erb A related receptor (EAR-1),
v-erb related receptor (EAR-1A), .gamma.), orphan receptor encoded
by non-encoding strand of thyroid hormone receptor .beta.
(REVERB.beta.), v-erb related receptor (EAR-1.beta.), orphan
nuclear receptor BD73 (BD73), rev-erbA-related receptor (RVR), zinc
finger protein 126 (HZF2), ecdysone-inducible protein E75 (E75),
ecdysone-inducible protein E78 (E78), Drosophila receptor 78
(DR-78), retinoid-related orphan receptor .alpha. (ROR.alpha.),
retinoid Z receptor .alpha. (RZR.alpha.), retinoid related orphan
receptor .beta. (ROR.beta.), retinoid Z receptor .beta.
(RZR.beta.), retinoid-related orphan receptor .gamma. (ROR.gamma.),
retinoid Z receptor .gamma. (RZR.gamma.), retinoid-related orphan
receptor (TOR), hormone receptor 3 (HR-3), Drosophila hormone
receptor 3 (DHR-3), Manduca hormone receptor 3 (MHR-3), Gallaria
hormone receptor 3 (GHR-3), C. elegans nuclear receptor 3 (CNR-3),
Choristoneura hormone receptor 3 (CHR-3), C. elegans nuclear
receptor 14 (CNR-14), vitamin D receptor (VDR), orphan nuclear
receptor (ONR-1), pregnane X receptor (PXR), steroid and xenobiotic
receptor (SXR), benzoate X receptor (BXR), nuclear receptor
(MB-67), constitutive androstane receptor 1 (CAR-1), constitutive
androstane receptor .alpha. (CAR.alpha.), constitutive androstane
receptor 2 (CAR-2), constitutive androstane receptor .beta.
(CAR.beta.), Drosophila hormone receptor 96 (DHR-96), nuclear
hormone receptor 1 (NHR-1), hepatocyte nuclear factor 4 (HNF-4),
hepatocyte nuclear factor 4G (HNF-4G), hepatocyte nuclear factor 4B
(HNF-4B), hepatocyte nuclear factor 4D (HNF-4D, DHNF-4), retinoid X
receptor .alpha. (RXR.alpha.), retinoid X receptor .beta.
(RXR.beta.), H-2 region II binding protein (H-2RIIBP), nuclear
receptor co-regulator-1 (RCOR-1), retinoid X receptor .gamma.
(RXR.gamma.), Ultraspiracle (USP), 2C1 nuclear receptor, chorion
factor 1 (CF-1), testicular receptor 2 (TR-2), testicular receptor
2-11 (TR2-11), testicular receptor 4 (TR4), TAK-1, Drosophila
hormone receptor (DHR78), Tailless (TLL), tailless homolog (TLX),
XTLL, chicken ovalbumin upstream promoter transcription factor I
(COUP-TFI), chicken ovalbuniin upstream promoter transcription
factor A (COUP-TFA), EAR-3, SVP44, chicken ovalbumin upstream
promoter transcription factor II (COUP-TFII), chicken ovalbumin
upstream promoter transcription factor B (COUP-TFB), ARP-1, SVP-40,
SVP, chicken ovalbumin upstream promoter transcription factor m
(COUP-TFIII), chicken ovalburnin upstream promoter transcription
factor G (COUP-TFG), SVP-46, EAR-2, estrogen receptor .alpha.
(ER.alpha.), estrogen receptor .beta. (ERR.beta.), estrogen related
receptor 1 (ERR1), estrogen related receptor .alpha. (ERR.alpha.),
estrogen related receptor 2 (ERR2), estrogen related receptor
.beta. (ERR.beta.), glucocorticoid receptor (GR), mineralocorticoid
receptor (MR), progesterone receptor (PR), androgen receptor (AR),
nerve growth factor induced gene B (NGFI-B), nuclear receptor
similar to Nur-77 (TRS), N10, Orphan receptor (NUR-77), Human early
response gene (NAK-1), Nurr related factor 1 (NURR-1), a human
immediate-early response gene (NOT), regenerating liver nuclear
receptor 1 (RNR-1), hematopoietic zinc finger 3 (HZF-3), Nur
related protein -1 (TINOR), Nuclear orphan receptor 1 (NOR-1), NOR1
related receptor (MINOR), Drosophila hormone receptor 38 (DHR-38),
C. elegans nuclear receptor 8 (CNR-8), C48D5, steroidogenic factor
1 (SF1), endozepine-like peptide (ELP), fushi tarazu factor 1
(FTZ-F1), adrenal 4 binding protein (AD4BP), liver receptor homolog
(LRH-1), Ftz-F1-related orphan receptor A (xFFrA), Ftz-F1-related
orphan receptor B (xFFrB), nuclear receptor related to LRH-1
(FFLR), nuclear receptor related to LRH-1 (PHR), fetoprotein
transcription factor (FTF), germ cell nuclear factor (GCNFM),
retinoid receptor-related testis-associated receptor (RTR), knirps
(KNI), knirps related (KNRL), Embryonic gonad (EGON), Drosophila
gene for ligand dependent nuclear receptor (EAGLE), nuclear
receptor similar to trithorax (ODR7), Trithorax, dosage sensitive
sex reversal adrenal hypoplasia congenita critical region
chromosome X gene (DAX-1), adrenal hypoplasia congenita and
hypogonadotropic hypogonadism (AHCH), and short heterodimer partner
(SHP).
[0176] For purposes of this invention, nuclear receptors and
whitefly ecdysone receptors also include synthetic and chimeric
nuclear receptors and whitefly ecdysone receptors and their
homologs.
Antibodies to Whitefly Ecdysone Receptor
[0177] According to the invention, a whitefly ecdysone receptor
polypeptide produced recombinantly or by chemical synthesis, and
fragments or other derivatives or analogs thereof, including fusion
proteins, may be used as an antigen or immunogen to generate
antibodies. Preferably, the antibodies specifically bind homopteran
ecdysone receptor polypeptides, but do not bind other ecdysone
receptor polypeptides. More preferably, the antibodies specifically
bind a whitefly ecdysone receptor polypeptide, but do not bind
other ecdysone receptor polypeptides.
[0178] The present invention also relates to antigenic peptides and
antibodies thereto. More particularly, the invention relates to
antigenic peptides comprising a fragment of a whitefly ecdysone
receptor polypeptide according to the invention, wherein the
fragment has a property selected from the group consisting of:
[0179] (a) it is encoded by a polynucleotide comprising a nucleic
acid sequence selected from the group consisting of nucleotides
102-258 of SEQ ID NO: 1, nucleotides 259-457 of SEQ ID NO: 1,
nucleotides 458-677 of SEQ ID NO: 1, nucleotides 678-1349 of SEQ ID
NO: 1, nucleotides 259-1349 of SEQ ID NO: 1, nucleotides 458-1349
of SEQ ID NO: 1, and nucleotides 648-1349 of SEQ ID NO: 1; [0180]
(b) it comprises an amino acid sequence selected from the group
consisting of amino acids 1-52 of SEQ ID NO: 2, amino acids 53-118
of SEQ ID NO: 2, amino acids 119-192 of SEQ ID NO: 2, amino acids
193-416 of SEQ ID NO: 2, amino acids 53-416 of SEQ ID NO: 2, amino
acids 119-416 of SEQ ID NO: 2, and amino acids 183-416 of SEQ ID
NO: 2; and [0181] (c) it specifically binds to an antibody
generated against an epitope within a polypeptide comprising an
amino acid sequence selected from the group consisting of SEQ ID
NO: 2, amino acids 1-52 of SEQ ID NO: 2, amino acids 53-118 of SEQ
ID NO: 2, amino acids 119-192 of SEQ ID NO: 2, amino acids 193-416
of SEQ ID NO: 2, amino acids 53-416 of SEQ ID NO: 2, amino acids
119-416 of SEQ ID NO: 2, and amino acids 183-416 of SEQ ID NO:
2.
[0182] In another embodiment, the invention relates to an antibody
which specifically binds an antigenic peptide comprising a fragment
of a whitefly ecdysone receptor polypeptide according to the
invention as described above. The antibody may be polyclonal or
monoclonal and may be produced by in vitro or in vivo
techniques.
[0183] The antibodies of the invention possess specificity for
binding to particular homopteran ecdysone receptors. Thus, reagents
for determining qualitative or quantitative presence of these or
homologous polypeptides may be produced. Alternatively, these
antibodies may be used to separate or purify receptor
polypeptides.
[0184] For production of polyclonal antibodies, an appropriate
target imnune system is selected, typically a mouse or rabbit. The
substantially purified antigen is presented to the immune system in
a fashion determined by methods appropriate for the animal and
other parameters well known to immunologists. Typical sites for
injection are in the footpads, intramuscularly, intraperitoneally,
or intradermally. Of course, another species may be substituted for
a mouse or rabbit.
[0185] An immunological response is usually assayed with an
immunoassay. Normally such immunoassays involve some purification
of a source of antigen, for example, produced by the same cells and
in the same fashion as the antigen was produced. The immunoassay
may be a radioimmunoassay, an enzyme-linked assay (ELISA), a
fluorescent assay, or any of many other choices, most of which are
functionally equivalent but may exhibit advantages under specific
conditions.
[0186] Monoclonal antibodies with high affinities are typically
made by standard procedures as described, e.g., in Harlow and Lane
(1988), Antibodies: A Laboratory Manual, Cold Spring Harbor
Laboratory; or Goding (1986), Monoclonal Antibodies: Principles and
Practice (2d ed) Academic Press, New York, which are hereby
incorporated herein by reference. Briefly, appropriate animals will
be selected and the desired immunization protocol followed. After
the appropriate period of time, the spleens of such animals are
excised and individual spleen cells fused, typically, to
immortalized myeloma cells under appropriate selection conditions.
Thereafter, the cells are clonally separated and the supernatants
of each clone are tested for their production of an appropriate
antibody specific for the desired region of the antigen.
[0187] Other suitable techniques involve in vitro exposure of
lymphocytes to the antigenic polypeptides or alternatively to
selection of libraries of antibodies in phage or similar vectors.
See, Huse et al., (1989) "Generation of a Large Combinatorial
Library of the Immunoglobulin Repertoire in Phage Lambda," Science
246: 1275-1281, hereby incorporated herein by reference.
[0188] The polypeptides and antibodies of the present invention may
be used with or without modification. Frequently, the polypeptides
and antibodies will be labeled by joining, either covalently or
non-covalently, a substance which provides for a detectable signal.
A wide variety of labels and conjugation techniques are known and
are reported extensively in both the scientific and patent
literature. Suitable labels include radionuclides, enzymes,
substrates, cofactors, inhibitors, fluorescence, chemiluminescence,
magnetic particles and the like. Patents, teaching the use of such
labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350;
3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant
immunoglobulins may be produced, see Cabilly, U.S. Pat. No.
4,816,567.
[0189] A molecule is "antigenic" when it is capable of specifically
interacting with an antigen recognition molecule of the immune
system, such as an immunoglobulin (antibody) or T cell antigen
receptor. An antigenic polypeptide contains at least about 5, and
preferably at least about 10 amino acids. An antigenic portion of a
molecule can be that portion that is immunodominant for antibody or
T cell receptor recognition, or it can be a portion used to
generate an antibody to the molecule by conjugating the antigenic
portion to a carrier molecule for immunization. A molecule that is
antigenic need not be itself immunogenic, i.e., capable of
eliciting an immune response without a carrier.
[0190] Such antibodies include but are not limited to polyclonal,
monoclonal, chimeric, single chain, Fab fragments, and a Fab
expression library. The anti-whitefly ecdysone receptor antibodies
of the invention may be cross-reactive, e.g., they may recognize
whitefly ecdysone receptor from different species. Polyclonal
antibodies have greater likelihood of cross reactivity.
Alternatively, an antibody of the invention may be specific for a
single form of whitefly ecdysone receptor, such as whitefly
ecdysone receptor. Preferably, such an antibody is specific for
whitefly ecdysone receptor.
[0191] Various procedures known in the art may be used for the
production of polyclonal antibodies. For the production of
antibody, various host animals can be immunized by injection with
the whitefly ecdysone receptor polypeptide, or a derivative (e.g.,
fragment or fusion protein) thereof, including but not limited to
rabbits, mice, rats, sheep, goats, etc. In one embodiment, the
whitefly ecdysone receptor polypeptide or fragment thereof can be
conjugated to an immunogenic carrier, e.g., bovine serum albumin
(BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be
used to increase the immunological response, depending on the host
species, including but not limited to Freund's (complete and
incomplete), mineral gels such as aluminum hydroxide, surface
active substances such as lysolecithin, pluronic polyols,
polyanions, peptides, oil emulsions, keyhole limpet hemocyanins,
dinitrophenol, and potentially useful human adjuvants such as BCG
(bacille Calmette-Guerin) and Corynebacterium parvum.
[0192] For preparation of monoclonal antibodies directed toward the
whitefly ecdysone receptor polypeptide, or fragment, analog, or
derivative thereof, any technique that provides for the production
of antibody molecules by continuous cell lines in culture may be
used. These include but are not limited to the hybridoma technique
originally developed by Kohler and Milstein [Nature 256: 495497
(1975)], as well as the trioma technique, the human B-cell
hybridoma technique [Kozbor et al., Immunology Today 4: 72 1983);
Cote et al., Proc. Natl. Acad. Sci. U.S.A. 80: 2026-2030 (1983)],
and the EBV-hybridoma technique to produce human monoclonal
antibodies [Cole et al., in Monoclonal Antibodies and Cancer
Therapy, Alan R. Liss, Inc., pp. 77-96 (1985)]. In an additional
embodiment of the invention, monoclonal antibodies can be produced
in germ-free animals [International Patent Publication No. WO
89/12690, published 28 Dec. 1989]. In fact, according to the
invention, techniques developed for the production of "chimeric
antibodies" [Morrison et al., J. Bacteriol. 159: 870 (1984);
Neuberger et al., Nature 312: 604-608 (1984); Takeda et al., Nature
314: 452-454 (1985)] by splicing the genes from a mouse antibody
molecule specific for a whitefly ecdysone receptor polypeptide
together with genes from a human antibody molecule of appropriate
biological activity can be used; such antibodies are within the
scope of this invention. Such human or humanized chimeric
antibodies are preferred for use in therapy of human diseases or
disorders (described infra), since the human or humanized
antibodies are much less likely than xenogenic antibodies to induce
an immune response, in particular an allergic response,
themselves.
[0193] According to the invention, techniques described for the
production of single chain Fv (scFv) antibodies [U.S. Pat. Nos.
5,476,786 and 5,132,405 to Huston; U.S. Pat. No. 4,946,778] can be
adapted to produce whitefly ecdysone receptor polypeptide-specific
single chain antibodies. An additional embodiment of the invention
utilizes the techniques described for the construction of Fab
expression libraries [Huse et al., Science 246: 1275-1281 (1989)]
to allow rapid and easy identification of monoclonal Fab fragments
with the desired specificity for a whitefly ecdysone receptor
polypeptide, or its derivatives, or analogs.
[0194] Antibody fragments which contain the idiotype of the
antibody molecule can be generated by known techniques. For
example, such fragments include but are not limited to: the
F(ab').sub.2 fragment which can be produced by pepsin digestion of
the antibody molecule; the Fab' fragments which can be generated by
reducing the disulfide bridges of the F(ab').sub.2 fragment, and
the Fab fragments which can be generated by treating the antibody
molecule with papain and a reducing agent.
[0195] In the production of antibodies, screening for the desired
antibody can be accomplished by techniques known in the art, e.g.,
radioinimmunoassay, ELISA (enzyme-linked immunosorbent assay),
"sandwich" immunoassays, immunoradiometric assays, gel diffusion
precipitin reactions, immunodiffusion assays, in situ immunoassays
(using colloidal gold, enzyme or radioisotope labels, for example),
western blots, precipitation reactions, agglutination assays (e.g.,
gel agglutination assays, hemagglutination assays), complement
fixation assays, immunofluorescence assays, protein A assays, and
immunoelectrophoresis assays, etc. In one embodiment, antibody
binding is detected by detecting a label on the primary antibody.
In another embodiment, the primary antibody is detected by
detecting binding of a secondary antibody or reagent to the primary
antibody. In a further embodiment, the secondary antibody is
labeled. Many means are known in the art for detecting binding in
an immunoassay and are within the scope of the present invention.
For example, to select antibodies which recognize a specific
epitope of a whitefly ecdysone receptor polypeptide, one may assay
generated hybridomas for a product which binds to a whitefly
ecdysone receptor polypeptide fragment containing such epitope. For
selection of an antibody specific to a whitefly ecdysone receptor
polypeptide from a particular species of animal, one can select on
the basis of positive binding with whitefly ecdysone receptor
polypeptide expressed by or isolated from cells of that species of
animal.
[0196] The foregoing antibodies can be used in methods known in the
art relating to the localization and activity of the whitefly
ecdysone receptor polypeptide, e.g., for western blotting, imaging
whitefly ecdysone receptor polypeptide in situ, measuring levels
thereof in appropriate physiological samples, etc. using any of the
detection techniques mentioned above or known in the art.
[0197] In a specific embodiment, antibodies that agonize or
antagonize the activity of whitefly ecdysone receptor polypeptide
can be generated. Such antibodies can be tested using the assays
described infra for identifying ligands. In particular, such
antibodies can be scFv antibodies expressed intracellularly.
Uses of Novel Polynucleotides and Polypeptides of the Invention
[0198] The present invention further provides a number of uses for
the whitefly ecdysone receptor polynucleotides of the present
invention and their encoded polypeptides.
[0199] The whitefly ecdysone receptor polypeptides of the present
invention have a variety of utilities. For example, the
polynucleotides and polypeptides of the invention are useful in
methods of modulating gene expression in an ecdysone receptor-based
gene expression system. Also included are methods for identifying
and selecting ligands specific for binding to a ligand binding
domain of a polypeptide of the invention, methods for identifying
and selecting compounds exhibiting specific binding to the ligand
binding domain and methods for modulating insect physiology or
development (e.g., killing).
Methods of Modulating Gene Expression
[0200] As presented herein, Applicants' novel polynucleotides and
polypeptides are useful in an ecdysone receptor-based gene
expression system to provide a regulatable gene expression system
in both prokaryotic and eukaryotic host cells. Thus, the present
invention also relates to the use of the novel whitefly ecdysone
receptor polynucleotides and polypeptides of the present invention
in an ecdysone receptor-based gene expression system, and methods
of modulating the expression of a gene within a host cell using
such an ecdysone receptor-based gene expression system.
[0201] This gene expression system may be a "single switch"-based
gene expression system in which the transactivation domain,
DNA-binding domain and ligand binding domain are on one encoded
polypeptide. Alternatively, the gene expression modulation system
may be a "dual switch"- or "two-hybrid"-based gene expression
modulation system in which the transactivation domain and
DNA-binding domain are located on two different encoded
polypeptides. Applicants' have demonstrated for the first time that
whitefly ecdysone receptor polynucleotides and polypeptides of the
invention can be used as a component of an ecdysone receptor-based
inducible gene expression system to modify gene expression in a
host cell.
[0202] In particular, the present invention relates to a gene
expression modulation system comprising at least one gene
expression cassette that is capable of being expressed in a host
cell comprising a polynucleotide that encodes a whitefly ecdysone
receptor polypeptide. Preferably, the whitefly ecdysone receptor
polypeptide comprises an amino acid sequence selected from the
group consisting of SEQ ID NO: 2, amino acids 1-52 of SEQ ID NO: 2,
amino acids 53-118 of SEQ ID NO: 2, amino acids 119-192 of SEQ ID
NO: 2, amino acids 193-416 of SEQ ID NO: 2, amino acids 53-416 of
SEQ ID NO: 2, amino acids 119-416 of SEQ ID NO: 2, and amino acids
183-416 of SEQ ID NO: 2. More preferably, the whitefly ecdysone
receptor polypeptide comprises amino acids 193-416 of SEQ ID NO: 2,
amino acids 53-416 of SEQ ID NO: 2, amino acids 119-416 of SEQ ID
NO: 2, or amino acids 183-416 of SEQ ID NO: 2.
[0203] In a specific embodiment, the gene expression modulation
system comprises a gene expression cassette comprising a
polynucleotide that encodes a polypeptide comprising a
transactivation domain, a DNA-binding domain that recognizes a
response element associated with a gene whose expression is to be
modulated; and a whitefly ecdysone receptor ligand binding domain
(referred to herein as "BaEcR LBD"). The gene expression modulation
system may further comprise a second gene expression cassette
comprising: i) a response element recognized by the DNA-binding
domain of the encoded polypeptide of the first gene expression
cassette; ii) a promoter that is activated by the transactivation
domain of the encoded polypeptide of the first gene expression
cassette; and iii) a gene whose expression is to be modulated.
[0204] In another specific embodiment, the gene expression
modulation system comprises a gene expression cassette comprising
a) a polynucleotide that encodes a polypeptide comprising a
transactivation domain, a DNA-binding domain that recognizes a
response element associated with a gene whose expression is to be
modulated; and an BaEcR LBD, and b) a second nuclear receptor
ligand binding domain selected from the group consisting of a
vertebrate retinoid X receptor ligand binding domain, an
invertebrate retinoid X receptor ligand binding domain, an
ultraspiracle protein ligand binding domain, and a chimeric ligand
binding domain comprising two polypeptide fragments, wherein the
first polypeptide fragment is from a vertebrate retinoid X receptor
ligand binding domain, an invertebrate retinoid X receptor ligand
binding domain, or an ultraspiracle protein ligand binding domain,
and the second polypeptide fragment is from a different vertebrate
retinoid X receptor ligand binding domain, invertebrate retinoid X
receptor ligand binding domain, or ultraspiracle protein ligand
binding domain. The gene expression modulation system may further
comprise a second gene expression cassette comprising: i) a
response element recognized by the DNA-binding domain of the
encoded polypeptide of the first gene expression cassette; ii) a
promoter that is activated by the transactivation domain of the
encoded polypeptide of the first gene expression cassette; and iii)
a gene whose expression is to be modulated.
[0205] In another specific embodiment, the gene expression
modulation system comprises a first gene expression cassette
comprising a polynucleotide that encodes a first polypeptide
comprising a DNA-binding domain that recognizes a response element
associated with a gene whose expression is to be modulated and a
nuclear receptor ligand binding domain, and a second gene
expression cassette comprising a polynucleotide that encodes a
second polypeptide comprising a transactivation domain and a
nuclear receptor ligand binding domain, wherein one of the nuclear
receptor ligand binding domains is an BaEcR LBD. In a preferred
embodiment, the first polypeptide is substantially free of a
transactivation domain and the second polypeptide is substantially
free of a DNA binding domain. For purposes of the invention,
"substantially free of a DNA binding domain" means that the protein
in question does not contain a sufficient sequence of the domain in
question to provide activation or binding activity. The gene
expression modulation system may further comprise a third gene
expression cassette comprising: i) a response element recognized by
the DNA-binding domain of the first polypeptide of the first gene
expression cassette; ii) a promoter that is activated by the
transactivation domain of the second polypeptide of the second gene
expression cassette; and iii) a gene whose expression is to be
modulated.
[0206] Wherein when only one nuclear receptor ligand binding domain
is an BaEcR LBD, the other nuclear receptor ligand binding domain
may be from any other nuclear receptor that forms a dimer with the
BaEcR LBD. For example, the other nuclear receptor ligand binding
domain ("partner") may be from another ecdysone receptor, a
vertebrate retinoid X receptor (RXR), an invertebrate RXR, an
ultraspiracle protein (USP), or a chimeric nuclear receptor
comprising at least two different nuclear receptor ligand binding
domain polypeptide fragments selected from the group consisting of
a vertebrate RXR, an invertebrate RXR, and a USP (see co-pending
applications PCT/US01/09050, U.S. 60/294,814, and U.S. 60/294,819,
incorporated herein by reference in their entirety). The "partner"
nuclear receptor ligand binding domain may further comprise a
truncation mutation, a deletion mutation, a substitution mutation,
or another modification.
[0207] In a specific embodiment, the whitefly ecdysone receptor
ligand binding domain comprises an amino acid sequence selected
from the group consisting of SEQ ID NO: 2, amino acids 193-416 of
SEQ ID NO: 2, amino acids 53-416 of SEQ ID NO: 2, amino acids
119-416 of SEQ ID NO: 2, and amino acids 183-416 of SEQ ID NO: 2.
In another embodiment, the whitefly ecdysone receptor ligand
binding domain is encoded by a polynucleotide comprising a nucleic
acid sequence selected from the group consisting of SEQ ID NO: 1,
nucleotides 102-1349 of SEQ ID NO: 1, nucleotides 678-1349 of SEQ
ID NO: 1, nucleotides 259-1349 of SEQ ID NO: 1, nucleotides
458-1349 of SEQ ID NO: 1, and nucleotides 648-1349 of SEQ ID NO:
1.
[0208] In a specific embodiment, the gene whose expression is to be
modulated is a homologous gene with respect to the host cell. In
another specific embodiment, the gene whose expression is to be
modulated is a heterologous gene with respect to the host cell.
[0209] The ligands for use in the methods of modulating gene
expression are described below, when combined with the ligand
binding domain of the nuclear receptor(s), which in turn are bound
to the response element linked to a gene, provide the means for
external temporal regulation of expression of the gene. The binding
mechanism or the order in which the various components of this
invention bind to each other, that is, for example, ligand to
ligand binding domain, DNA-binding domain to response element,
transactivation domain to promoter, etc., is not critical.
[0210] Thus, Applicants' invention is useful in methods of
modulating gene expression in a host cell using a whitefly ecdysone
receptor according to the invention. Specifically, Applicants'
invention provides a method of modulating the expression of a gene
in a host cell comprising the steps of: a) introducing into the
host cell an ecdysone receptor-based gene expression modulation
system comprising a whitefly ecdysone receptor according to the
invention; and b) introducing into the host cell a ligand; wherein
the gene to be modulated is a component of a gene expression
cassette comprising: i) a response element comprising a domain
recognized by the DNA binding domain of the gene expression system;
ii) a promoter that is activated by the transactivation domain of
the gene expression system; and iii) a gene whose expression is to
be modulated, whereby upon introduction of the ligand into the host
cell, expression of the gene is modulated.
[0211] The invention also provides a method of modulating the
expression of a gene in a host cell comprising the steps of: a)
introducing into the host cell an ecdysone receptor-based gene
expression modulation system comprising a whitefly ecdysone
receptor according to the invention; b) introducing into the host
cell a gene expression cassette, wherein the gene expression
cassette comprises i) a response element comprising a domain
recognized by the DNA binding domain from the gene expression
system; ii) a promoter that is activated by the transactivation
domain of the gene expression system; and iii) a gene whose
expression is to be modulated; and c) introducing into the host
cell a ligand; whereby upon introduction of the ligand into the
host cell, expression of the gene is modulated.
[0212] Genes of interest for expression in a host cell using
Applicants' methods may be endogenous genes or heterologous genes.
Nucleic acid or amino acid sequence information for a desired gene
or protein can be located in one of many public access databases,
for example, GENBANK, EMBL, Swiss-Prot, and PIR, or in many biology
related journal publications. Thus, those skilled in the art have
access to nucleic acid sequence information for virtually all known
genes. Such information can then be used to construct the desired
constructs for the insertion of the gene of interest within the
gene expression cassettes used in the methods described herein.
[0213] Examples of genes of interest for expression in a host cell
using these methods include, but are not limited to: antigens
produced in plants as vaccines, enzymes like alpha-amylase,
phytase, glucanes, xylase and xylanase, genes for resistance
against insects, nematodes, fungi, bacteria, viruses, and abiotic
stresses, nutraceuticals, pharmaceuticals, vitamins, genes for
modifying amino acid content, herbicide resistance, cold, drought,
and heat tolerance, industrial products, oils, protein,
carbohydrates, antioxidants, male sterile plants, flowers, fuels,
other output traits, genes encoding therapeutically desirable
polypeptides or products that may be used to treat a condition, a
disease, a disorder, a dysfunction, a genetic defect, such as
monoclonal antibodies, enzymes, proteases, cytokines, interferons,
insulin, erthropoietin, clotting factors, other blood factors or
components, viral vectors for gene therapy, virus for vaccines,
targets for drug discovery, functional genomics, and proteomics
analyses and applications, and the like.
[0214] The term "ligand" is meant herein to refer to a molecule
that binds the domain described here as the "ligand binding
domain." Also, a ligand for a whitefly ecdysone receptor is a
ligand which serves either as the natural ligand to which the
ecdysone receptor binds, or a functional analogue which may serve
as an agonist or antagonist.
[0215] Acceptable ligands are any that modulate expression of the
gene when binding of the DNA binding domain of the gene expression
system according to the invention to the response element in the
presence of the ligand results in activation or suppression of
expression of the genes. Preferred ligands include an ecdysteroid,
such as ecdysone, 20-hydroxyecdysone, ponasterone A, muristerone A,
and the like, 9-cis-retinoic acid, synthetic analogs of retinoic
acid, N,N'-diacylhydrazines such as those disclosed in U.S. Pat.
Nos. 6,013,836; 5,117,057; 5,530,028; and 5,378,726; dibenzoylalkyl
cyanohydrazines such as those disclosed in European Application No.
461,809; N-alkyl-N,N'-diaroylhydrazines such as those disclosed in
U.S. Pat. No. 5,225,443; N-acyl-N-alkylcarbonylhydrazines such as
those disclosed in European Application No. 234,994;
N-aroyl-N-alkyl-N'-aroylhydrazines such as those described in U.S.
Pat. No. 4,985,461; each of which is incorporated herein by
reference and other similar materials including
3,5-di-tert-butyl4-hydroxy-N-isobutyl-benzamide,
8-O-acetylharpagide, and the like.
[0216] In a preferred embodiment, the ligand for use in the method
of modulating expression of gene is a compound of the fortnula:
##STR2## wherein: [0217] E is a (C.sub.4-C.sub.6)alkyl containing a
tertiary carbon or a cyano(C.sub.3-C.sub.5)alkyl containing a
tertiary carbon; [0218] R.sup.1 is H, Me, Et, i-Pr, F, formyl,
CF.sub.3, CHF.sub.2, CHCl.sub.2, CH.sub.2F, CH.sub.2Cl, CH.sub.2OH,
CH.sub.2OMe, CH.sub.2CN, CN, C.degree.CH, 1-propynyl, 2-propynyl,
vinyl, OH, OMe, OEt, cyclopropyl, CF.sub.2CF.sub.3, CH.dbd.CHCN,
allyl, azido, SCN, or SCHF.sub.2; [0219] R.sup.2 is H, Me, Et,
n-Pr, i-Pr, formyl, CF.sub.3, CHF.sub.2, CHCl.sub.2, CH.sub.2F,
CH.sub.2Cl, CH.sub.2OH, CH.sub.2OMe, CH.sub.2CN, CN, C.degree.CH,
1-propynyl, 2-propynyl, vinyl, Ac, F, Cl, OH, OMe, OEt, O-n-Pr,
OAc, NMe.sub.2, NEt.sub.2, SMe, SEt, SOCF.sub.3,
OCF.sub.2CF.sub.2H, COEt, cyclopropyl, CF.sub.2CF.sub.3,
CH.dbd.CHCN, allyl, azido, OCF.sub.3, OCHF.sub.2, O-i-Pr, SCN,
SCHF.sub.2, SOMe, NH--CN, or joined with R.sup.3 and the phenyl
carbons to which R.sup.2 and R.sup.3 are attached to form an
ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent to a
phenyl carbon, or a dihydropyryl ring with the oxygen adjacent to a
phenyl carbon; [0220] R.sup.3 is H, Et, or joined with R.sup.2 and
the phenyl carbons to which R.sup.2 and R.sup.3 are attached to
form an ethylenedioxy, a dihydrofuryl ring with the oxygen adjacent
to a phenyl carbon, or a dihydropyryl ring with the oxygen adjacent
to a phenyl carbon; [0221] R.sup.4, R.sup.5, and R.sup.6 are
independently H, Me, Et, F, Cl, Br, formyl, CF.sub.3, CHF.sub.2,
CHCl.sub.2, CH.sub.2F, CH.sub.2Cl, CH.sub.2OH, CN, C.degree.CH,
1-propynyl, 2-propynyl, vinyl, OMe, OEt, SMe, or SEt.
[0222] In another preferred embodiment, the ligand for use in the
method of modulating expression of gene is an ecdysone,
20-hydroxyecdysone, ponasterone A, or muristerone A.
[0223] In another preferred embodiment, a second ligand may be used
in addition to the first ligand discussed above in the method of
modulating expression of a gene. Preferably, this second ligand is
9-cis-retinoic acid or a synthetic analog of retinoic acid.
Screening Assays
[0224] Identification and isolation of a polynucleotide encoding a
whitefly ecdysone receptor polypeptide of the invention provides
for expression of whitefly ecdysone receptor in quantities greater
than can be isolated from natural sources, or in indicator cells
that are specially engineered to indicate the activity of whitefly
ecdysone receptor expressed after transfection or transformation of
the cells. Accordingly, in addition to rational design of agonists
and antagonists based on the structure of whitefly ecdysone
receptor polypeptide, the present invention contemplates an
alternative method for identifying specific ligands of whitefly
ecdysone receptor using various screening assays known in the
art.
[0225] Thus, the present invention also relates to methods of
screening for a compound that induces or represses transactivation
of a whitefly ecdysone receptor polypeptide in a cell by contacting
a whitefly ecdysone receptor polypeptide with a candidate molecule
and detecting reporter gene activity in the presence of the ligand.
Candidate compounds may be either agonists or antagonists of the
whitefly ecdysone receptor polypeptide. In a preferred embodiment,
the whitefly ecdysone receptor polypeptide is expressed from a
polynucleotide in the cell and the transactivation activity (i.e.,
expression or repression of a reporter gene) or compound binding
activity is measured.
[0226] In a specific embodiment, the present invention relates to
methods of screening for molecules that stimulate or inhibit
whitefly ecdysone receptor activity in a cell by contacting a
whitefly ecdysone receptor polypeptide with a candidate molecule
and detecting whitefly ecdysone receptor activity in the presence
of the molecule. Candidate molecules may be either agonists or
antagonists of whitefly ecdysone receptor. In a preferred
embodiment, the whitefly ecdysone receptor is expressed from a
polynucleotide in the cell and the whitefly ecdysone receptor
activity measured is by induction of expression or transactivation
of a reporter gene. Induction of reporter gene expression can be
measured as described herein.
[0227] Thus, one aspect of the present invention is a method for
selecting molecules or ligands that modulate the activity of a
whitefly ecdysone receptor polypeptide. In a specific embodiment,
the present invention provides a method for identifying a ligand
specific for binding to a ligand binding domain of a whitefly
ecdysone receptor comprising [0228] (a) combining (i) a hybrid
polypeptide comprising a whitefly ecdysone receptor ligand binding
domain and a DNA binding domain from a steroid hormone nuclear
receptor superfamily; and (ii) a polynucleotide encoding a second
polypeptide, wherein the polynucleotide is operably linked to a
transcriptional control element that is responsive to the DNA
binding domain of the hybrid polypeptide; [0229] (b) exposing the
hybrid polypeptide and the polynucleotide of (a) to a compound;
[0230] (c) determining ligand activity of the compound of (b) by
determining induction of expression of the second polypeptide; and
[0231] (d) identifying the compound that results in the induction
of expression of the second polypeptide.
[0232] The present invention is also useful to search for
orthogonal ligands and orthogonal receptor-based gene expression
systems such as those described in co-pending U.S. application
60/237,446, which is incorporated herein by reference in its
entirety.
[0233] The ligand binding domain ("LBD") of the ecdysone receptor,
specifically binds steroid and non-steroidal agonist ligands,
thereby providing a means to screen for new molecules possessing
the property of binding with high affinity to the ligand binding
domain. Thus, the ligand binding domain of a whitefly ecdysone
receptor polypeptide may be used as a reagent to develop a binding
assay. On one level, the LBD can be used as an affinity reagent for
a batch or in a column selective process, to selectively retain
ligands which bind. Alternatively, a functional assay is preferred
for its greater sensitivity to ligand-binding. By using a reporter
molecule for binding, either through a direct assay for binding, or
through an expression or other functional linkage between binding
and another function, an assay for binding may be developed. For
example, by operable linkage of an easily assayable reporter gene
to a controlling element responsive to binding by an ecdysone
receptor, and where ligand-binding is functionally linked to
protein induction, an extremely sensitive assay for the presence of
a ligand or of a receptor results. Such a construct is useful for
assaying the presence of 20-hydroxyecdysone is described below.
This construct is useful for screening for agonists or antagonists
of homopteran ecdysone receptors, in particular, whitefly ecdysone
receptors.
[0234] As presented herein, a whitefly ecdysone receptor can
transactivate gene expression of an ecdysone receptor-based gene
expression modulation system. Therefore, agonists of whitefly
ecdysone receptor that enhance its ability to transactivate gene
expression will be expected to improve its activity in an ecdysone
receptor-based gene expression modulation system. Inhibitors
(antagonists) of whitefly ecdysone receptor activity are useful to
reduce its ability to transactivate an ecdysone receptor-based gene
expression modulation system.
[0235] Any screening technique known in the art can be used to
screen for whitefly ecdysone receptor agonists or antagonists. For
example, a suitable cell line expressing both whitefly ecdysone
receptor and an ecdysone receptor-based gene expression modulation
system, can be transfected with a nucleic acid encoding a marker
gene, such as .beta.-galactosidase. Cells are then exposed to a
test solution comprising an agonist or antagonist, and then stained
for .beta.-galactosidase activity. The presence of more .beta.-gal
positive cells relative to control cells not exposed to the test
solution is an indication of the presence of a whitefly ecdysone
receptor agonist in the test solution. Conversely, the presence of
less .beta.-gal positive cells relative to control cells not
exposed to the test solution is an indication of the presence of a
whitefly ecdysone receptor antagonist in the test solution.
[0236] The present invention contemplates screens for small
molecule ligands or ligand analogs and mimics, as well as screens
for natural ligands that bind to and agonize or antagonize whitefly
ecdysone receptor in vivo. For example, natural products libraries
can be screened using assays of the invention for molecules that
agonize or antagonize whitefly ecdysone receptor activity.
[0237] Knowledge of the primary sequence of whitefly ecdysone
receptor, and the similarity of that sequence with proteins of
known function, can provide an initial clue as the inhibitors or
antagonists of the protein. Identification and screening of
antagonists is further facilitated by determining structural
features of the protein, e.g., using X-ray crystallography, neutron
diffraction, nuclear magnetic resonance spectrometry, and other
techniques for structure determination. These techniques provide
for the rational design or identification of agonists and
antagonists.
[0238] Another approach uses recombinant bacteriophage to produce
large libraries. Using the "phage method" [Scott and Smith, 1990,
Science 249: 386-390 (1990); Cwirla, et al., Proc. Natl. Acad.
Sci., 87: 6378-6382 (1990); Devlin et al., Science, 249: 404-406
(1990)], very large libraries can be constructed (10.sup.6-10.sup.8
chemical entities). A second approach uses primarily chemical
methods, of which the Geysen method [Geysen et al., Molecular
Immunology 23: 709-715 (1986); Geysen et al. J. Immunologic Method
102: 259-274 (1987)] and the method of Fodor et al. [Science 251:
767-773 (1991)] are examples. Furka et al. [14th International
Congress of Biochemistry, Volume 5, Abstract FR:013 (1988); Furka,
Int. J. Peptide Protein Res. 37: 487-493 (1991)], Houghton [U.S.
Pat. No. 4,631,211, issued December 1986] and Rutter et al. [U.S.
Pat. No. 5,010,175, issued Apr. 23, 1991] describe methods to
produce a mixture of peptides that can be tested as agonists or
antagonists.
[0239] In another aspect, synthetic libraries [Needels et al.,
Proc. Natl. Acad. Sci. USA 90: 10700-4 (1993); Ohlmeyer et al.,
Proc. Natl. Acad. Sci. USA 90: 10922-10926 (1993); Lam et al.,
International Patent Publication No. WO 92/00252; Kocis et al.,
International Patent Publication No. WO 9428028, each of which is
incorporated herein by reference in its entirety], and the like can
be used to screen for whitefly ecdysone receptor ligands according
to the present invention.
[0240] The screening can be performed with recombinant cells that
express the whitefly ecdysone receptor, or alternatively, using
purified protein, e.g., produced recombinantly, as described above.
For example, labeled, soluble whitefly ecdysone receptor can be
used to screen libraries, as described in the foregoing
references.
[0241] In one embodiment, whitefly ecdysone receptor may be
directly labeled. In another embodiment, a labeled secondary
reagent may be used to detect binding of a whitefly ecdysone
receptor to a molecule of interest, e.g., a molecule attached to a
solid phase support. Binding may be detected by in situ formation
of a chromophore by an enzyme label. Suitable enzymes include, but
are not limited to, alkaline phosphatase and horseradish
peroxidase. In a further embodiment, a two-color assay, using two
chromogenic substrates with two enzyme labels on different acceptor
molecules of interest, may be used. Cross-reactive and singly
reactive ligands may be identified with a two-color assay.
[0242] Other labels for use in the invention include colored latex
beads, magnetic beads, fluorescent labels (e.g., fluorescene
isothiocyanate (FITC), phycoerythrin (PE), Texas red (TR),
rhodamine, free or chelated lanthanide series salts, especially
Eu.sup.3+, to name a few fluorophores), chemiluminescent molecules,
radio-isotopes, or magnetic resonance imaging labels. Two-color
assays may be performed with two or more colored latex beads, or
fluorophores that emit at different wavelengths. Labeled may be
detected visually or by mechanical/optical means.
Mechanical/optical means include fluorescence activated sorting,
i.e., analogous to FACS, and micromanipulator removal means.
[0243] As exemplified herein, the level of a whitefly ecdysone
receptor polypeptide can be evaluated by metabolic labeling of the
proteins. As the metabolic labeling occurs during in vitro
incubation of the tissue biopsy in the presence of culture medium
supplemented with [.sup.35S]-methionine, the level of each of the
markers detected may be affected by the in vitro conditions. In
addition to metabolic (or biosynthetic) labeling with
[.sup.35S]-methionine, the invention further contemplates labeling
with [.sup.14C]-amino acids and [.sup.3H]-amino acids (with the
tritium substituted at non-labile positions). Thus, a sample or
library of compounds can be directly analyzed after labeling of the
proteins therein, e.g. by calorimetric staining using silver, gold,
coomassie blue, or amido-schwartz, to mention a few techniques;
isotopic labeling, e.g., with [.sup.32P]-orthophosphate,
[.sup.125I], [.sup.131I]; fluorescent or chemiluminescent tags; and
immunological detection with labeled antibody or specific binding
partner of a marker.
Modulating Insect Physiology or Development
[0244] The isolation of a whitefly ecdysone receptor provides for
isolation or screening of new ligands for receptor binding. Some of
these will interfere with, or disrupt, normal insect development.
It may sometimes be important to either accelerate or decelerate
insect development, for instance, in preparing sterile adults for
release. Alternatively, in certain circumstances, a delay or change
in the timing of development may be lethal or may dramatically
modify the ability of an insect to affect an agricultural crop.
Thus, naturally occurring, biodegradable and highly active
molecules to disrupt the timing of insect development will
result.
[0245] The present invention provides a means for disrupting insect
development where new ligand agonists or antagonists are
discovered. These compounds are prime candidates as agonists or
antagonists to interfere with the normal insect development. By
application of new analogues of ligands for a whitefly ecdysone
receptor, it is possible to modify the normal temporal sequence of
developmental events. For example, accelerating insect development
will minimize generation time. This may be very important in
circumstances where large numbers of insects are desired finally,
for instance, in producing sterile males. Alternatively, it may be
useful to slow development in a pest infestation, such that the
insects reach destructive stages of development only after
commercial crops may have passed sensitive stages. In another
commercial application, ligands discovered by methods provided by
the present invention may be used to artificially maintain insects
in a specific developmental stage. The development of larvae may
also be accelerated to reach a particular developmental stage in
their life cycle earlier than naturally.
[0246] Other analogues of ligands for a whitefly ecdysone receptor
may be selected which, upon application, may be completely
disruptive of normal development, leading to a lethal result and
pest control. Indeed, there may be new ligands for a whitefly
ecdysone receptor which may be species specific or may exhibit a
particularly useful spectrum of effectiveness. The greater
specificity of the ligands will allow avoidance of use of
non-specific pesticides possessing undesired deleterious ecological
side effects. Furthermore, compounds having structures closely
analogous to natural compounds may be susceptible to natural
mechanisms of biological degradation.
[0247] Thus, the present invention also provides a method for
identifying and selecting compounds exhibiting specific binding to
the ligand binding domain to modulate insect physiology or
development (e.g., killing) comprising the steps of screening
compounds for binding to a homopteran ecdysone receptor, selecting
compounds exhibiting said binding and administering the ligand to a
homopteran insect. In a specific embodiment, a method for
modulating insect physiology or development comprises the steps of
screening compounds for binding to a whitefly ecdysone receptor,
selecting compounds exhibiting said binding and administering the
ligand to a whitefly.
Polypeptide Production
[0248] A purified whitefly ecdysone receptor polypeptide of the
invention is also useful in a method for determining the structural
and biosynthetic aspects of the purified whitefly ecdysone receptor
polypeptide. Structural studies of interactions of the
ligand-binding domains with selected ligands may be performed by
various methods. The preferred method for structural determination
is X-ray crystallography but may include various other forms of
spectroscopy or chromatography. See, e.g., Connolly, M. L., J.
Appl. Crystall. 16: 548 (1983); and Connolly, M. L., Science 221:
709 (1983), which are hereby incorporated herein by reference. For
example, the structure of the interaction between ligand and
ligand-binding domain may be determined to high resolution.
[0249] Having provided for the substantially pure polypeptides,
biologically active fragments thereof and recombinant
polynucleotides encoding them, the present invention also provides
cells comprising each of them. By appropriate introduction
techniques well known in the field, cells comprising them may be
produced. See, e.g., Sambrook et al. (1989).
Host Cells and Non-Human Organisms
[0250] Another aspect of the present invention involves cells
comprising an isolated polynucleotide encoding a whitefly ecdysone
receptor polypeptide of the present invention. In a specific
embodiment, the invention relates to an isolated host cell
comprising a vector comprising a polynucleotide encoding a whitefly
ecdysone receptor polypeptide of the present invention. The present
invention also relates to an isolated host cell comprising an
expression vector according to the invention. In another specific
embodiment, the invention relates to an isolated host cell
comprising a gene expression cassette comprising a polynucleotide
encoding a whitefly ecdysone receptor polypeptide of the present
invention. In another specific embodiment, the invention relates to
an isolated host cell transfected with a gene expression modulation
system comprising a polynucleotide encoding a whitefly ecdysone
receptor polypeptide of the present invention. In another specific
embodiment, the invention also provides an isolated host cell
comprising an ecdysone receptor-based gene expression system
comprising a whitefly ecdysone receptor polypeptide according to
the invention. In another specific embodiment, the invention
relates to an isolated host cell comprising a whitefly ecdysone
receptor polypeptide of the present invention. In still another
embodiment, the invention relates to a method for producing a
whitefly ecdysone receptor polypeptide, wherein the method
comprises culturing an isolated host cell comprising a
polynucleotide encoding a whitefly ecdysone receptor polypeptide of
the present invention in culture medium under conditions permitting
expression of the polynucleotide encoding the whitefly ecdysone
receptor polypeptide, and isolating the whitefly ecdysone receptor
polypeptide from the culture.
[0251] As described above, the polypeptides of the present
invention and the polynucleotides encoding them may be used to
modulate gene expression in a host cell. Expression in transgenic
host cells may be useful for the expression of various genes of
interest. Applicants' invention provides for modulation of gene
expression in prokaryotic and eukaryotic host cells. Expression in
transgenic host cells is useful for the expression of various
polypeptides of interest including but not limited to antigens
produced in plants as vaccines, enzymes like alpha-amylase,
phytase, glucanase, xylase and xylanase, genes for resistance
against insects, nematodes, fungi, bacteria, viruses, and abiotic
stresses, antigens, nutraceuticals, pharmaceuticals, vitamins,
genes for modifying amino acid content, herbicide resistance, cold,
drought, and heat tolerance, industrial products, oils, protein,
carbohydrates, antioxidants, male sterile plants, flowers, fuels,
other output traits, therapeutic polypeptides, pathway
intermediates; for the modulation of pathways already existing in
the host for the synthesis of new products heretofore not possible
using the host; cell based assays; functional genomics assays,
biotherapeutic protein production, proteomics assays, and the like.
Additionally the gene products may be useful for conferring higher
growth yields of the host or for enabling an alternative growth
mode to be utilized.
[0252] In a specific embodiment, the isolated host cell is a
prokaryotic host cell or a eukaryotic host cell. In another
specific embodiment, the isolated host cell is an invertebrate host
cell or a vertebrate host cell. Preferably, the isolated host cell
is selected from the group consisting of a bacterial cell, a fungal
cell, a yeast cell, a nematode cell, an insect cell, a fish cell, a
plant cell, an avian cell, an animal cell, and a mammalian cell.
More preferably, the isolated host cell is a yeast cell, a nematode
cell, an insect cell, a plant cell, a zebrafish cell, a chicken
cell, a hamster cell, a mouse cell, a rat cell, a rabbit cell, a
cat cell, a dog cell, a bovine cell, a goat cell, a cow cell, a pig
cell, a horse cell, a sheep cell, a simian cell, a monkey cell, a
chimpanzee cell, or a human cell.
[0253] Examples of preferred host cells include, but are not
limited to, fungal or yeast species such as Aspergillus,
Trichoderma, Saccharomyces, Pichia, Candida, Hansenula, or
bacterial species such as those in the genera Synechocystis,
Synechococcus, Salmonella, Bacillus, Acinetobacter, Rhodococcus,
Streptomyces, Escherichia, Pseudomonas, Metlylomonas,
Methylobacter, Alcaligenes, Synechocystis, Anabaena, Thiobacillus,
Methanobacterium and Klebsiella; plant species selected from the
group consisting of an apple, Arabidopsis, bajra, banana, barley,
beans, beet, blackgram, chickpea, chili, cucumber, eggplant,
favabean, maize, melon, millet, mungbean, oat, okra, Panicum,
papaya, peanut, pea, pepper, pigeonpea, pineapple, Phaseolus,
potato, pumpkin, rice, sorghum, soybean, squash, sugarcane,
sugarbeet, sunflower, sweet potato, tea, tomato, tobacco,
watermelon, and wheat; animal; and mammalian host cells.
[0254] In a specific embodiment, the isolated host cell is a yeast
cell selected from the group consisting of a Sacciaromyces, a
Pichia, and a Candida host cell.
[0255] In another specific embodiment, the isolated host cell is a
Caenorhabdus elegans nematode cell.
[0256] In another specific embodiment, the isolated host cell is a
plant cell selected from the group consisting of an apple,
Arabidopsis, bajra, banana, barley, beans, beet, blackgram,
chickpea, chili, cucumber, eggplant, favabean, maize, melon,
millet, mungbean, oat, okra, Panicum, papaya, peanut, pea, pepper,
pigeonpea, pineapple, Phaseolus, potato, pumpkin, rice, sorghum,
soybean, squash, sugarcane, sugarbeet, sunflower, sweet potato,
tea, tomato, tobacco, watermelon, and wheat cell.
[0257] In another specific embodiment, the isolated host cell is a
zebrafish cell.
[0258] In another specific embodiment, the isolated host cell is a
chicken cell.
[0259] In another specific embodiment, the isolated host cell is a
mammalian cell selected from the group consisting of a hamster
cell, a mouse cell, a rat cell, a rabbit cell, a cat cell, a dog
cell, a bovine cell, a goat cell, a cow cell, a pig cell, a horse
cell, a sheep cell, a monkey cell, a chimpanzee cell, and a human
cell.
[0260] Host cell transformation is well known in the art and may be
achieved by a variety of methods including but not limited to
electroporation, viral infection, plasmid/vector transfection,
non-viral vector mediated transfection, Agrobacterium-mediated
transformation, particle bombardment, and the like. Expression of
desired gene products involves culturing the transformed host cells
under suitable conditions and inducing expression of the
transformed gene. Culture conditions and gene expression protocols
in prokaryotic and eukaryotic cells are well known in the art (see
General Methods section of Examples). Cells may be harvested and
the gene products isolated according to protocols specific for the
gene product.
[0261] In addition, a host cell may be chosen that modulates the
expression of the transfected polynucleotide, or modifies and
processes the polypeptide product in a specific fashion desired.
Different host cells have characteristic and specific mechanisms
for the translational and post-translational processing and
modification [e.g., glycosylation, cleavage (e.g., of signal
sequence)] of proteins. Appropriate cell lines or host systems can
be chosen to ensure the desired modification and processing of the
foreign protein expressed. For example, expression in a bacterial
system can be used to produce a non-glycosylated core protein
product. However, a polypeptide expressed in bacteria may not be
properly folded. Expression in yeast can produce a glycosylated
product. Expression in eukaryotic cells can increase the likelihood
of "native" glycosylation and folding of a heterologous protein.
Moreover, expression in mammalian cells can provide a tool for
reconstituting, or constituting, the polypeptide's activity.
Furthermore, different vector/host expression systems may affect
processing reactions, such as proteolytic cleavages, to a different
extent.
[0262] Applicants' invention also relates to a non-human organism
comprising an isolated host cell according to the invention. In a
specific embodiment, the non-human organism is a prokaryotic
organism or a eukaryotic organism. In another specific embodiment,
the non-human organism is an invertebrate organism or a vertebrate
organism.
[0263] Preferably, the non-human organism is selected from the
group consisting of a bacterium, a fungus, a yeast, a nematode, an
insect, a fish, a plant, a bird, an animal, and a mammal. More
preferably, the non-human organism is a yeast, a nematode, an
insect, a plant, a zebrafish, a chicken, a hamster, a mouse, a rat,
a rabbit, a cat, a dog, a bovine, a goat, a cow, a pig, a horse, a
sheep, a simian, a monkey, or a chimpanzee.
[0264] In a specific embodiment, the non-human organism is a yeast
selected from the group consisting of Saccharomyces, Pichia, and
Candida.
[0265] In another specific embodiment, the non-human organism is a
Caenorhabdus elegans nematode.
[0266] In another specific embodiment, the non-human organism is a
plant selected from the group consisting of an apple, Arabidopsis,
bajra, banana, barley, beans, beet, blackgram, chickpea, chili,
cucumber, eggplant, favabean, maize, melon, millet, mungbean, oat,
okra, Panicum, papaya, peanut, pea, pepper, pigeonpea, pineapple,
Phaseolus, potato, pumpkin, rice, sorghum, soybean, squash,
sugarcane, sugarbeet, sunflower, sweet potato, tea, tomato,
tobacco, watermelon, and wheat.
[0267] In another specific embodiment, the non-human organism is a
Mus musculus mouse.
Measuring Gene Expression/Transcription
[0268] One useful measurement of the methods of modulating gene
expression using the novel polynucleotides, polypeptides, vectors,
and/or gene expression cassettes of the present invention is that
of the transcriptional state of the cell including the identities
and abundances of RNA, preferably mRNA species. Such measurements
are conveniently conducted by measuring cDNA abundances by any of
several existing gene expression technologies.
[0269] Nucleic acid array technology is a useful technique for
determining differential mRNA expression. Such technology includes,
for example, oligonucleotide chips and DNA microarrays. These
techniques rely on DNA fragments or oligonucleotides which
correspond to different genes or cDNAs which are immobilized on a
solid support and hybridized to probes prepared from total mRNA
pools extracted from cells, tissues, or whole organisms and
converted to cDNA. Oligonucleotide chips are arrays of
oligonucleotides synthesized on a substrate using photolithographic
techniques. Chips have been produced which can analyze for up to
1700 genes. DNA microarrays are arrays of DNA samples, typically
PCR products, that are robotically printed onto a microscope slide.
Each gene is analyzed by a full-or partial-length target DNA
sequence. Microarrays with up to 10,000 genes are now routinely
prepared commercially. The primary difference between these two
techniques is that oligonucleotide chips typically utilize 25-mer
oligonucleotides which allow fractionation of short DNA molecules
whereas the larger DNA targets of microarrays, approximately 1000
base pairs, may provide more sensitivity in fractionating complex
DNA mixtures.
[0270] Another useful measurement of Applicants' methods of the
invention is that of determining the translation state of the cell
by measuring the abundances of the constituent protein species
present in the cell using processes well known in the art.
[0271] Where identification of genes associated with various
physiological functions is desired, an assay may be employed in
which changes in such functions as cell growth, apoptosis,
senescence, differentiation, adhesion, binding to a specific
molecules, binding to another cell, cellular organization,
organogenesis, intracellular transport, transport facilitation,
energy conversion, metabolism, myogenesis, neurogenesis, and/or
hematopoiesis is measured.
[0272] In addition, selectable marker or reporter gene expression
may be used to measure gene expression modulation using Applicants'
invention.
[0273] Other methods to detect the products of gene expression are
well known in the art and include Southern blots (DNA detection),
dot or slot blots (DNA, RNA), northern blots (RNA), RT-PCR(RNA),
western blots (polypeptide detection), and ELISA (polypeptide)
analyses. Although less preferred, labeled proteins can be used to
detect a particular nucleic acid sequence to which it
hybridizes.
[0274] In some cases it is necessary to amplify the amount of a
nucleic acid sequence. This may be carried out using one or more of
a number of suitable methods including, for example, polymerase
chain reaction ("PCR"), ligase chain reaction ("LCR"), strand
displacement amplification ("SDA"), transcription-based
amplification, and the like. PCR is carried out in accordance with
known techniques in which, for example, a nucleic acid sample is
treated in the presence of a heat stable DNA polymerase, under
hybridizing conditions, with one pair of oligonucleotide primers,
with one primer hybridizing to one strand (template) of the
specific sequence to be detected. The primers are sufficiently
complementary to each template strand of the specific sequence to
hybridize therewith. An extension product of each primer is
synthesized and is complementary to the nucleic acid template
strand to which it hybridized. The extension product synthesized
from each primer can also serve as a template for further synthesis
of extension products using the same primers. Following a
sufficient number of rounds of synthesis of extension products, the
sample may be analyzed as described above to assess whether the
sequence or sequences to be detected are present.
[0275] The present invention may be better understood by reference
to the following non-limiting Examples, which are provided as
exemplary of the invention.
EXAMPLES
General Molecular Biology Techniques
[0276] In accordance with the present invention there may be
employed conventional molecular biology, microbiology, and
recombinant DNA techniques within the skill of the art. Such
techniques are explained fully in the literature. See, e.g.,
Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory
Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, N.Y. (herein "Sambrook et al., 1989"); DNA
Cloning: A Practical Approach, Volumes I and II (D. N. Glover ed.
1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic
Acid Hybridization [B. D. Hames & S. J. Higgins eds. (1985)];
Transcription And Translation [B. D. Hames & S. J. Higgins,
eds. (1984)]; Animal Cell Culture [R. I. Freshney, ed. (1986)];
Immobilized Cells And Enzymes [IRL Press, (1986)]; B. Perbal, A
Practical Guide To Molecular Cloning (1984); F. M. Ausubel et al.
(eds.), Current Protocols in Molecular Biology, John Wiley &
Sons, Inc. (1994).
[0277] Conventional cloning vehicles include pBR322 and pUC type
plasmids and phages of the M13 series. These may be obtained
commercially (Bethesda Research Laboratories).
[0278] For ligation, DNA fragments may be separated according to
their size by agarose or acrylamide gel electrophoresis, extracted
with phenol or with a phenol/chloroform mixture, precipitated with
ethanol and then incubated in the presence of phage T4 DNA ligase
(Biolabs) according to the supplier's recommendations.
[0279] The filling in of 5' protruding ends may be performed with
the Klenow fragment of E. coli DNA polymerase I (Biolabs) according
to the supplier's specifications. The destruction of 3' protruding
ends is performed in the presence of phage T4 DNA polymerase
(Biolabs) used according to the manufacturer's recommendations. The
destruction of 5' protruding ends is performed by a controlled
treatment with S1 nuclease.
[0280] Mutagenesis directed in vitro by synthetic
oligodeoxynucleotides may be performed according to the method
developed by Taylor et al. [Nucleic Acids Res. 13 (1985) 8749-8764]
using the kit distributed by Amersham.
[0281] The enzymatic amplification of DNA fragments by PCR
[Polymerase-catalyzed Chain Reaction, Saiki R. K. et al., Science
230 (1985) 1350-1354; Mullis K. B. and Faloona F. A., Meth. Enzym.
155 (1987) 335-350] technique may be performed using a "DNA thermal
cycler" (Perkin Elmer Cetus) according to the manufacturer's
specifications.
[0282] Verification of nucleotide sequences may be performed by the
method developed by Sanger et al. [Proc. Natl. Acad. Sci. USA 74:
5463-5467 (1977)] using the kit distributed by Amersham.
[0283] Plasmid DNAs may be purified by the Qiagen Plasmid
Purification System according to the manufacture's instruction.
Example 1
[0284] This Example describes the cloning of full-length cDNA
encoding whitefly Bamecia argentifoli ecdysone receptor
polypeptide. To isolate the full length coding sequence of this
previously unknown whitefly ecdysone receptor isoform (herein named
"BaEcR"), a whitefly cDNA library prepared from total RNA obtained
from mixed stage whitefly nymphs (first to fourth instars) and pupa
was used. Briefly, the cDNA library was constructed in the UNI-Zap
XR.TM. vector using Zap Express cDNA Gigapack II Gold.TM. cloning
kit (Stratagene, La Jolla, Calif.) following the manufacturer's
instructions. Applicants used degenerate oligonucleotides (see
Table 2; SEQ ID NOs: 3 and 4) designed based on conserved regions
of ecdysone receptor C (KKCLSVGM; SEQ ID NO: 5) and E (KLIREDQI;
SEQ ID NO: 6) domains to amplify and obtain a 441 base pair (bp)
cDNA fragment (SEQ ID NO: 7) from whitefly total RNA using RT-PCR.
TABLE-US-00002 Primer Nucleic Primer and SEQ ID NO: Acid Sequence
Primer 1 (SEQ ID NO: 3) 5'-aa(a/g)aa(a/g)tg(t/c)ct
(t/c/a/g)ag(t/c)gt(t/c/a/ g)gg(t/c/a/g)atg-3' Primer 2 (SEQ ID NO:
4) 5'-(a/g/t)at(t/c)tg(a/g)tc (t/c)tc(t/a/c/g)cg(a/g/t)a
t(t/c/a/g)ag(t/c)tt-3'
[0285] Reverse transcription was performed by THERMOSCRIPT RT-PCR
System (LifeTechnologies). Polymerase chain reaction (PCR)
amplification was performed using the TaqPlus polymerase
(Stratagene) and the reaction conditions and cycling parameters as
follows. PCR was performed using 1.times.reaction buffer
(Stratagene), 50 ng of dsDNA template, 125 ng of forward primer
(Primer 1), 125 ng of reverse complementary primer (Primer 2), and
1 .mu.l of dNTP mix (LifeTechnologies) in a final reaction volume
of 50 .mu.L. The cycling parameters used consisted of 35 cycles of
denaturing at 95.degree. C. for 1 minute, annealing at 55.degree.
C. for 50 seconds, and extending at 72.degree. C. for 50 seconds,
followed by a final elongation cycle at 72.degree. C. for 10
minutes.
[0286] The resulting 441 bp cDNA fragment (SEQ ID NO: 7) was then
used as a probe to screen the whitefly cDNA library following high
stringency hybridization and washing protocols for the full length
BaEcR cDNA clone. The hybridization conditions and phage infection
methods were performed according to the manufacturer's instructions
in the Zap Express cDNA Gigapack II Gold.TM. cloning kit
(Stratagene, La Jolla, Calif.) and as recommended by Maniatis et
al., supra. One positive clone was isolated, purified, in-vivo
excised, and both strands of its corresponding whitefly cDNA insert
sequenced using standard protocols (see Maniatis et al.,
supra).
[0287] The polynucleotide sequence of this isolated cDNA clone,
which encodes the full length BaEcR, is presented as SEQ ID NO: 1.
The deduced amino acid sequence of the full length BaEcR is
presented herein as SEQ ID NO: 2 and showed high similarity with
the deduced amino acid sequence of other EcRs (data not shown).
Example 2
[0288] This Example describes the construction of whitefly ecdysone
receptor gene expression cassettes and their use in an ecdysone
receptor-based gene expression modulation system. The results
presented herein demonstrate that a whitefly ecdysone receptor is
functional in an ecdysone receptor-based gene expression modulation
system in both insect and mammalian cells.
A) Insect Cells:
[0289] Briefly, the BaEcR CDE domains (amino acids 53416 of SEQ ID
NO: 2) were fused to a VP16 transactivation domain (SEQ ID NO: 8)
as follows. A construct was prepared by fusing a polynucleotide
(nucleotides 259-1349 of SEQ ID NO: 1) encoding a BaEcR-CDE
polypeptide to a polynucleotide (SEQ ID NO: 9) encoding a VP16
activation domain at the NH2 terminal end. This VP16BaEcR fusion
was then cloned under the control of baculovirus IE1 promoter (SEQ
ID NO: 10). The VP16BaEcR gene expression cassette was transfected
into L57 cell line (Drosophila cell line that lacks endogenous EcR)
and a cotton boll weevil ("CBW"; Anthonomus grandis) BRL-AG-2 cell
line (generously provided by USDA, ARS, Bioscience Research
Laboratory, Fargo, N. Dak.) along with a reporter construct
EcRELaCZ that comprises a 6.times.ECRE response element
(1.times.EcRE is shown in SEQ ID NO: 11), an ADH distal promoter
(see Heberlein et al., 1985, Cell 41: 965-977 and Koelle et al.
1991, Cell 67: 59-77) and a LacZ reporter gene (SEQ ID NO: 12). The
reporter gene activity was quantified in the presence of 0, 0.0001,
0.001, 0.01, 0.1, 1, 10, and 100 .mu.M 20-hydroxyecdysone (20E)
ligand or
N-(2-ethyl-3-methoxybenzoyl)-N'-(3,5-dimethylbenzoyl)-N'-tert-butylhydraz-
ine (GS.TM.-E) ligand.
[0290] Ligands: The steroid ligand 20-hydroxyecdysone (20E) was
purchased from Sigma Chemical Company. The non-steroidal ligand
N-(2-ethyl-3-methoxybenzoyl)-N'-(3,5-dimethylbenzoyl)-N'-tert-butylhydraz-
ine (GS.TM.-E) is a synthetic stable ecdysteroid ligand that was
synthesized at Rohm and Haas Company. The ligands were dissolved in
DMSO and the final concentration of DMSO was maintained at 0.1% in
both controls and treatments.
[0291] Transfections: DNAs corresponding to the gene constructs
described above were transfected into L57 or the CBW cells as
follows. L57 cells were grown in HyQ-CCM3 medium (Hyclone labs) and
transfected with lipofectomine (Life Technologies). The CBW cells
were grown in Ex-Cell 401 (JRH Sciences) and transfected with
Celfectin (Invitrogen). Standard methods for culture and
maintenance of the cells were followed. Cells were harvested when
they reached 50% confluency and plated in 6-, 12- or 24-well plates
at 125,000, 50,000, or 25,000 cells, respectively, in 2.5, 1.0, or
0.5 ml of growth medium, respectively. The next day, the cells were
rinsed with growth medium and transfected for four hours. For
12-well plates, 4 .mu.l of the appropriate transfection reagent was
mixed with 100 .mu.l of growth medium One .mu.g of reporter
construct and 0.25 .mu.g of each receptor construct of the receptor
pair to be analyzed were added to the transfection mix. A second
reporter construct was added [pTKRL (Promega), 0.1 .mu.g
transfection mix] that comprises a Renilla luciferase gene operably
linked and placed under the control of a thymidine kinase (TK)
constitutive promoter and was used for normalization. The contents
of the transfection mix were mixed in a vortex mixer and let stand
at room temperature for 30 minutes. At the end of incubation, the
transfection mix was added to the cells maintained in 400 .mu.l
growth medium. The cells were maintained at 37.degree. C. and 5%
CO.sub.2 for four hours. At the end of incubation, 500 .mu.l of
growth medium and either dimethylsulfoxide (DMSO; control) or a
DMSO solution of steroidal ligand or non-steroidal ligand was added
and the cells were maintained at 37.degree. C. and 5% CO.sub.2 for
48 hours. The cells were harvested and reporter activity was
assayed. The same procedure was followed for 6 and 24 well plates
as well except all the reagents were doubled for 6 well plates and
reduced to half for 24-well plates.
[0292] Reporter Assays: Cells were harvested 48 hours after adding
ligand. 125 .mu.l of passive lysis buffer (part of
Dual-luciferase.TM. reporter assay system from Promega Corporation)
were added to each well of the 24-well plate. The plates were
placed on a rotary shaker for 15 minutes. Twenty .mu.l of lysate
were assayed. Luciferase activity was measured using
Dual-luciferase.TM. reporter assay system from Promega Corporation
following the manufacturer's instructions. .beta.-Galactosidase was
measured using Galacto-Star.TM. assay kit from TROPIX following the
manufacturer's instructions. All luciferase and
.beta.-galactosidase activities were normalized using Renilla
luciferase as a standard. Fold activities were calculated by
dividing normalized relative light units ("RLU") in ligand treated
cells with normalized RLU in DMSO treated cells (untreated
control). The results are presented in FIG. 1 and the numbers on
the top of each bar show the maximum fold induction for that
group.
[0293] As shown in FIG. 1, the BaEcR construct was able to
transactivate reporter gene activity in a dose-dependent manner
with both ligands tested in the CBW cells. However, in L57cells
there was very little transactivation in the presence of either
ligand. Applicants' previous studies have shown that both CfEcR and
DmEcR cause good transactivation in L57 but BaEcR was a poor
transactivator in these cells.
B) Mammalian Cells:
[0294] Briefly, the BaEcR DE domains (amino acids 119-416 of SEQ ID
NO: 2) were fused to a GAL4 DNA binding domain (SEQ ID NO: 13) as
follows. A construct was prepared by fusing a polynucleotide
(nucleotides 458-1349 of SEQ ID NO: 1) encoding a BaEcR-DE
polypeptide to a polynucleotide (SEQ ID NO: 14) encoding a GAL4
DNA-binding domain at the NH2 terminal end. This GAL4/BaEcR fusion
was then cloned under the control of a cytomegalovirus (CMV)
promoter/enhancer (SEQ ID NO: 15). In addition, a polynucleotide
encoding the EF domains of seven RXR/USPs from a moth Choristoneura
fumifeiana ultraspiracle protein ("CfUSP", SEQ ID NO: 16), a fruit
fly Drosophila melanogaster ultraspiracle protein ("DmUSP"; SEQ ID
NO: 17), a locust Locusta migratoria ultraspiracle protein (LmUSP;
SEQ ID NO: 18), a mouse Mus musculus retinoid X receptor isoform
.alpha. (MmRXR.alpha.; SEQ ID NO: 19), a chimeric RXR/USP between
MmRXR.alpha. and LmUSP (Chimera; SEQ ID NO: 20), a tick Amblyomma
americanum retinoid X receptor homolog 1 (AmaRXR1; SEQ ID NO: 21),
and a tick Amblyomma americanum retinoid X receptor homolog
2(AmaRXR2; SEQ ID NO: 22) were each fused to a polynucleotide (SEQ
ID NO: 9) encoding a VP16 activation domain.
[0295] The GAL4/BaEcR gene expression cassette was transfected into
NIH3T3 cells (ATCC) along with each of the seven VP16RXR/USP gene
expression cassettes and a reporter construct pFRLuc that comprises
a 5XGAL4RE (1.times. GAIARE is shown in SEQ ID NO: 23), a synthetic
TATA (SEQ ID NO: 24) and a luciferase reporter gene (SEQ ID NO: 25)
as described above except the cells were cultured in growth media
comprising 10% fetal bovine serum (FBS), Superfect.TM. (Qiagen
Inc.) was used as the transfection reagent, and at the end of
incubation/transfection, 500 .mu.l of growth medium containing 20%
FBS was added to the cells.
[0296] The receptor combinations were compared for their ability to
transactivate pFRLuc in NIH3T3 cells in the presence of 0, 0.2,
1.0, or 10 .mu.M steroid ponasteroneA (PonA; Invitrogen) or 0,
0.04, 0.2, 1.0, or 10 .mu.M GS.TM.-E. The ligands were dissolved in
DMSO and the final concentration of DMSO was maintained at 0.1% in
both controls and treatments. The results are presented in FIG. 2
and the numbers on the top of each bar show the maximum fold
induction for that group.
[0297] As shown in FIG. 2, BaEcR in combination with any of the
RXR/USP receptor constructs tested induced reporter gene activity,
indicating that BaEcR is functional in mammalian cells.
[0298] The present invention is not to be limited in scope by the
specific embodiments described herein. Indeed, various
modifications of the invention in addition to those described
herein will become apparent to those skilled in the art from the
foregoing description. Such modifications are intended to fall
within the scope of the appended claims.
[0299] It is further to be understood that all base sizes or amino
acid sizes, and all molecular weight or molecular mass values,
given for nucleic acids or polypeptides are approximate, and are
provided for description.
[0300] Various publications are cited herein, the disclosures of
which are incorporated by reference in their entireties.
Sequence CWU 1
1
25 1 1586 DNA Bamecia argentifoli 1 gaattcgcgg ccgctcgcaa
acttccgtac ctctcacccc ctcgccagga ccccccgcca 60 accagttcac
cgtcatctcc tccaatggat actcatcccc catgtcttcg ggcagctacg 120
acccttatag tcccaccaat ggaagaatag ggaaagaaga gctttcgccg gcgaatagtc
180 tgaacgggta caacgtggat agctgcgatg cgtcgcggaa gaagaaggga
ggaacgggtc 240 ggcagcagga ggagctgtgt ctcgtctgcg gggaccgcgc
ctccggctac cactacaacg 300 ccctcacctg cgaaggctgc aagggcttct
tccgtcggag catcaccaag aatgccgtct 360 accagtgtaa atatggaaat
aattgtgaaa ttgacatgta catgaggcga aaatgccaag 420 agtgtcgtct
caagaagtgt ctcagcgttg gcatgaggcc agaatgtgta gttcccgaat 480
tccagtgtgc tgtgaagcga aaagagaaaa aagcgcaaaa ggacaaagat aaacctaact
540 caacgacgag ttgttctcca gatggaatca aacaagagat agatcctcaa
aggctggata 600 cagattcgca gctattgtct gtaaatggag ttaaacccat
tactccagag caagaagagc 660 tcatccatag gctagtttat tttcaaaatg
aatatgaaca tccatcccca gaggatatca 720 aaaggatagt taatgctgca
ccagaagaag aaaatgtagc tgaagaaagg tttaggcata 780 ttacagaaat
tacaattctc actgtacagt taattgtgga attttctaag cgattacctg 840
gttttgacaa actaattcgt gaagatcaaa tagctttatt aaaggcatgt agtagtgaag
900 taatgatgtt tagaatggca aggaggtatg atgctgaaac agattcgata
ttgtttgcaa 960 ctaaccagcc gtatacgaga gaatcataca ctgtagctgg
catgggtgat actgtggagg 1020 atctgctccg attttgtcga catatgtgtg
ccatgaaagt cgataacgca gaatatgctc 1080 ttctcactgc cattgtaatt
ttttcagaac gaccatctct aagtgaaggc tggaaggttg 1140 agaagattca
agaaatttac atagaagcat taaaagcata tgttgaaaat cgaaggaaac 1200
catatgcaac aaccattttt gctaagttac tatctgtttt aactgaacta cgaacattag
1260 ggaatatgaa ttcagaaaca tgcttctcat tgaagctgaa gaatagaaag
gtgccatcct 1320 tcctcgagga gatttgggat gttgtttcat aaacagtctt
acctcaattc catgttactt 1380 ttcatatttg atttatctca gcaggtggct
cagtacttat cctcacatta ctgagctcac 1440 ggtatgctca tacaattata
acttgtaata tcatatcggt gatgacaaat ttgttacaat 1500 attctttgtt
accttaacac aatgttgatc tcataatgat gtatgaattt ttctgttttt 1560
gcaaaaaaaa aagcggccgc gaattc 1586 2 416 PRT Bamecia argentifoli 2
Met Ser Ser Gly Ser Tyr Asp Pro Tyr Ser Pro Thr Asn Gly Arg Ile 1 5
10 15 Gly Lys Glu Glu Leu Ser Pro Ala Asn Ser Leu Asn Gly Tyr Asn
Val 20 25 30 Asp Ser Cys Asp Ala Ser Arg Lys Lys Lys Gly Gly Thr
Gly Arg Gln 35 40 45 Gln Glu Glu Leu Cys Leu Val Cys Gly Asp Arg
Ala Ser Gly Tyr His 50 55 60 Tyr Asn Ala Leu Thr Cys Glu Gly Cys
Lys Gly Phe Phe Arg Arg Ser 65 70 75 80 Ile Thr Lys Asn Ala Val Tyr
Gln Cys Lys Tyr Gly Asn Asn Cys Glu 85 90 95 Ile Asp Met Tyr Met
Arg Arg Lys Cys Gln Glu Cys Arg Leu Lys Lys 100 105 110 Cys Leu Ser
Val Gly Met Arg Pro Glu Cys Val Val Pro Glu Phe Gln 115 120 125 Cys
Ala Val Lys Arg Lys Glu Lys Lys Ala Gln Lys Asp Lys Asp Lys 130 135
140 Pro Asn Ser Thr Thr Ser Cys Ser Pro Asp Gly Ile Lys Gln Glu Ile
145 150 155 160 Asp Pro Gln Arg Leu Asp Thr Asp Ser Gln Leu Leu Ser
Val Asn Gly 165 170 175 Val Lys Pro Ile Thr Pro Glu Gln Glu Glu Leu
Ile His Arg Leu Val 180 185 190 Tyr Phe Gln Asn Glu Tyr Glu His Pro
Ser Pro Glu Asp Ile Lys Arg 195 200 205 Ile Val Asn Ala Ala Pro Glu
Glu Glu Asn Val Ala Glu Glu Arg Phe 210 215 220 Arg His Ile Thr Glu
Ile Thr Ile Leu Thr Val Gln Leu Ile Val Glu 225 230 235 240 Phe Ser
Lys Arg Leu Pro Gly Phe Asp Lys Leu Ile Arg Glu Asp Gln 245 250 255
Ile Ala Leu Leu Lys Ala Cys Ser Ser Glu Val Met Met Phe Arg Met 260
265 270 Ala Arg Arg Tyr Asp Ala Glu Thr Asp Ser Ile Leu Phe Ala Thr
Asn 275 280 285 Gln Pro Tyr Thr Arg Glu Ser Tyr Thr Val Ala Gly Met
Gly Asp Thr 290 295 300 Val Glu Asp Leu Leu Arg Phe Cys Arg His Met
Cys Ala Met Lys Val 305 310 315 320 Asp Asn Ala Glu Tyr Ala Leu Leu
Thr Ala Ile Val Ile Phe Ser Glu 325 330 335 Arg Pro Ser Leu Ser Glu
Gly Trp Lys Val Glu Lys Ile Gln Glu Ile 340 345 350 Tyr Ile Glu Ala
Leu Lys Ala Tyr Val Glu Asn Arg Arg Lys Pro Tyr 355 360 365 Ala Thr
Thr Ile Phe Ala Lys Leu Leu Ser Val Leu Thr Glu Leu Arg 370 375 380
Thr Leu Gly Asn Met Asn Ser Glu Thr Cys Phe Ser Leu Lys Leu Lys 385
390 395 400 Asn Arg Lys Val Pro Ser Phe Leu Glu Glu Ile Trp Asp Val
Val Ser 405 410 415 3 24 DNA Artificial Sequence Degenerate EcR PCR
primer misc_feature (3)..(3) n = a or g misc_feature (6)..(6) n = a
or g misc_feature (9)..(9) n = t or c misc_feature (12)..(12) n =
t, c, a or g misc_feature (15)..(15) n = t or c misc_feature
(18)..(18) n = t, c, a or g misc_feature (21)..(21) n = t, c, a or
g 3 aanaantgnc tnagngtngg natg 24 4 24 DNA Artificial Sequence
Degenerate EcR PCR primer misc_feature (1)..(1) n = a, g or t
misc_feature (4)..(4) n = t or c misc_feature (7)..(7) n = a or g
misc_feature (10)..(10) n = t or c misc_feature (13)..(13) n = t,
a, c or g misc_feature (16)..(16) n = a, g or t misc_feature
(19)..(19) n = t, c, a or g misc_feature (22)..(22) n = t or c 4
natntgntcn tcncgnatna gntt 24 5 8 PRT Artificial Sequence Conserved
EcR C region 5 Lys Lys Cys Leu Ser Val Gly Met 1 5 6 8 PRT
Artificial Sequence Conserved EcR E region 6 Lys Leu Ile Arg Glu
Asp Gln Ile 1 5 7 441 DNA Bamecia argentifoli 7 aagaagtgtc
tcagcgttgg catgaggcca gaatgtgtag ttcccgaatt ccagtgtgct 60
gtgaagcgaa aagagaaaaa agcgcaaaag gacaaagata aacctaactc aacgacgagt
120 tgttctccag atggaatcaa acaagagata gatcctcaaa ggctggatac
agattcgcag 180 ctattgtctg taaatggagt taaacccatt actccagagc
aagaagagct catccatagg 240 ctagtttatt ttcaaaatga atatgaacat
ccatccccag aggatatcaa aaggatagtt 300 aatgctgcac cagaagaaga
aaatgtagct gaagaaaggt ttaggcatat tacagaaatt 360 acaattctca
ctgtacagtt aattgtggaa ttttctaagc gattacctgg ttttgacaaa 420
ctaattcgtg aagatcaaat a 441 8 90 PRT herpes simplex virus 7 8 Met
Gly Pro Lys Lys Lys Arg Lys Val Ala Pro Pro Thr Asp Val Ser 1 5 10
15 Leu Gly Asp Glu Leu His Leu Asp Gly Glu Asp Val Ala Met Ala His
20 25 30 Ala Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Asp
Gly Asp 35 40 45 Ser Pro Gly Pro Gly Phe Thr Pro His Asp Ser Ala
Pro Tyr Gly Ala 50 55 60 Leu Asp Met Ala Asp Phe Glu Phe Glu Gln
Met Phe Thr Asp Ala Leu 65 70 75 80 Gly Ile Asp Glu Tyr Gly Gly Glu
Phe Pro 85 90 9 681 DNA herpes simplex virus 7 9 atgggcccta
aaaagaagaa gcgtaaggtc aaagcgttaa cggccaggct tgaattaatt 60
ccgggcggaa tgaaagcgtt aacggccagg caacaagagg tgtttgatct catccgtgat
120 cacatcagcc agacaggtat gccgccgacg cgtgcggaaa tcgcgcagcg
tttggggttc 180 cgttccccaa acgcggctga agaacatctg aaggcgctgg
cacgcaaagg cgttattgaa 240 attgtttccg gcgcatcacg cgggattcgt
ctgttgcagg aagaggaaga agggttgccg 300 ctggtaggtc gtgtggctgc
cggtgaacca cttctggcgc aacagcatat tgaaggtcat 360 tatcaggtcg
atccttcctt attcaagccg aatgctgatt tcctgctgcg cgtcagcggg 420
atgtcgatga aagatatcgg cattatggat ggtgacttgc tggcagtgca taaaactcag
480 gatgtacgta acggtcaggt cgttgtcgca cgtattgatg acgaagttac
cgttaagcgc 540 ctgaaaaaac agggcaataa agtcgaactg ttgccagaaa
atagcgagtt taaaccaatt 600 gtcgtagatc ttcgtcagca gagcttcacc
attgaagggc tggcggttgg ggttattcgc 660 aacggcgact ggctggaatt c 681 10
703 DNA Baculovirus 10 catatgtatc ccgggccagt tgcacaacac tattatcgat
ttgcagttcg ggacataaat 60 gtttaaatat atcgatgtct ttgtgatgcg
cgcgacattt ttgtaggtta ttgataaaat 120 gaacggatac gttgcccgac
attatcatta aatccttggc gtagaatttg tcgggtccat 180 tgtccgtgtg
cgctagcatg cccgtaacgg acctcgtact tttggcttca aaggttttgc 240
gcacagacaa aatgtgccac acttgcagct ctgcatgtgt gcgcgttacc acaaatccca
300 acggcgcagt gtacttgttg tatgcaaata aatctcgata aaggcgcggc
gcgcgaatgc 360 agctgatcac gtacgctcct cgtgttccgt tcaaggacgg
tgttatcgac ctcagattaa 420 tgtttatcgg ccgactgttt tcgtatccgc
tcaccaaacg cgtttttgca ttaacattgt 480 atgtcggcgg atgttctata
tctaatttga ataaataaac gataaccgcg ttggttttag 540 agggcataat
aaaagaaata ttgttatcgt gttcgccatt agggcagtat aaattgacgt 600
tcatgttgga tattgtttca gttgcaagtt gacactggcg gcgacaagat cgtgaacaac
660 caagtgacta tagaattcac tcgaggctag cataagatct aag 703 11 30 DNA
Drosophila melanogaster 11 gagacaaggg ttcaatgcac ttgtccaatg 30 12
3157 DNA Escherichia coli 12 atggggggtt ctcatcatca tcatcatcat
ggtatggcta gcatgactgg tggacagcaa 60 atgggtcggg atctgtacga
cgatgacgat aaggtaccta aggatcagct tggagttgat 120 cccgtcgttt
tacaacgtcg tgactgggaa aaccctggcg ttacccaact taatcgcctt 180
gcagcacatc cccctttcgc cagctggcgt aatagcgaag aggcccgcac cgatcgccct
240 tcccaacagt tgcgcagcct gaatggcgaa tggcgctttg cctggtttcc
ggcaccagaa 300 gcggtgccgg aaagctggct ggagtgcgat cttcctgagg
ccgatactgt cgtcgtcccc 360 tcaaactggc agatgcacgg ttacgatgcg
cccatctaca ccaacgtaac ctatcccatt 420 acggtcaatc cgccgtttgt
tcccacggag aatccgacgg gttgttactc gctcacattt 480 aatgttgatg
aaagctggct acaggaaggc cagacgcgaa ttatttttga tggcgttaac 540
tcggcgtttc atctgtggtg caacgggcgc tgggtcggtt acggccagga cagtcgtttg
600 ccgtctgaat ttgacctgag cgcattttta cgcgccggag aaaaccgcct
cgcggtgatg 660 gtgctgcgtt ggagtgacgg cagttatctg gaagatcagg
atatgtggcg gatgagcggc 720 attttccgtg acgtctcgtt gctgcataaa
ccgactacac aaatcagcga tttccatgtt 780 gccactcgct ttaatgatga
tttcagccgc gctgtactgg aggctgaagt tcagatgtgc 840 ggcgagttgc
gtgactacct acgggtaaca gtttctttat ggcagggtga aacgcaggtc 900
gccagcggca ccgcgccttt cggcggtgaa attatcgatg agcgtggtgg ttatgccgat
960 cgcgtcacac tacgtctgaa cgtcgaaaac ccgaaactgt ggagcgccga
aatcccgaat 1020 ctctatcgtg cggtggttga actgcacacc gccgacggca
cgctgattga agcagaagcc 1080 tgcgatgtcg gtttccgcga ggtgcggatt
gaaaatggtc tgctgctgct gaacggcaag 1140 ccgttgctga ttcgaggcgt
taaccgtcac gagcatcatc ctctgcatgg tcaggtcatg 1200 gatgagcaga
cgatggtgca ggatatcctg ctgatgaagc agaacaactt taacgccgtg 1260
cgctgttcgc attatccgaa ccatccgctg tggtacacgc tgtgcgaccg ctacggcctg
1320 tatgtggtgg atgaagccaa tattgaaacc cacggcatgg tgccaatgaa
tcgtctgacc 1380 gatgatccgc gctggctacc ggcgatgagc gaacgcgtaa
cgcgaatggt gcagcgcgat 1440 cgtaatcacc cgagtgtgat catctggtcg
ctggggaatg aatcaggcca cggcgctaat 1500 cacgacgcgc tgtatcgctg
gatcaaatct gtcgatcctt cccgcccggt gcagtatgaa 1560 ggcggcggag
ccgacaccac ggccaccgat attatttgcc cgatgtacgc gcgcgtggat 1620
gaagaccagc ccttcccggc tgtgccgaaa tggtccatca aaaaatggct ttcgctacct
1680 ggagagacgc gcccgctgat cctttgcgaa tacgcccacg cgatgggtaa
cagtcttggc 1740 ggtttcgcta aatactggca ggcgtttcgt cagtatcccc
gtttacaggg cggcttcgtc 1800 tgggactggg tggatcagtc gctgattaaa
tatgatgaaa acggcaaccc gtggtcggct 1860 tacggcggtg attttggcga
tacgccgaac gatcgccagt tctgtatgaa cggtctggtc 1920 tttgccgacc
gcacgccgca tccagcgctg acggaagcaa aacaccagca gcagtttttc 1980
cagttccgtt tatccgggca aaccatcgaa gtgaccagcg aatacctgtt ccgtcatagc
2040 gataacgagc tcctgcactg gatggtggcg ctggatggta agccgctggc
aagcggtgaa 2100 gtgcctctgg atgtcgctcc acaaggtaaa cagttgattg
aactgcctga actaccgcag 2160 ccggagagcg ccgggcaact ctggctcaca
gtacgcgtag tgcaaccgaa cgcgaccgca 2220 tggtcagaag ccgggcacat
cagcgcctgg cagcagtggc gtctggcgga aaacctcagt 2280 gtgacgctcc
ccgccgcgtc ccacgccatc ccgcatctga ccaccagcga aatggatttt 2340
tgcatcgagc tgggtaataa gcgttggcaa tttaaccgcc agtcaggctt tctttcacag
2400 atgtggattg gcgataaaaa acaactgctg acgccgctgc gcgatcagtt
cacccgtgca 2460 ccgctggata acgacattgg cgtaagtgaa gcgacccgca
ttgaccctaa cgcctgggtc 2520 gaacgctgga aggcggcggg ccattaccag
gccgaagcag cgttgttgca gtgcacggca 2580 gatacacttg ctgatgcggt
gctgattacg accgctcacg cgtggcagca tcaggggaaa 2640 accttattta
tcagccggaa aacctaccgg attgatggta gtggtcaaat ggcgattacc 2700
gttgatgttg aagtggcgag cgatacaccg catccggcgc ggattggcct gaactgccag
2760 ctggcgcagg tagcagagcg ggtaaactgg ctcggattag ggccgcaaga
aaactatccc 2820 gaccgcctta ctgccgcctg ttttgaccgc tgggatctgc
cattgtcaga catgtatacc 2880 ccgtacgtct tcccgagcga aaacggtctg
cgctgcggga cgcgcgaatt gaattatggc 2940 ccacaccagt ggcgcggcga
cttccagttc aacatcagcc gctacagtca acagcaactg 3000 atggaaacca
gccatcgcca tctgctgcac gcggaagaag gcacatggct gaatatcgac 3060
ggtttccata tggggattgg tggcgacgac tcctggagcc cgtcagtatc ggcggaatta
3120 cagctgagcg ccggtcgcta ccattaccag ttggtct 3157 13 147 PRT
Saccharomyces cerevisiae 13 Met Lys Leu Leu Ser Ser Ile Glu Gln Ala
Cys Asp Ile Cys Arg Leu 1 5 10 15 Lys Lys Leu Lys Cys Ser Lys Glu
Lys Pro Lys Cys Ala Lys Cys Leu 20 25 30 Lys Asn Asn Trp Glu Cys
Arg Tyr Ser Pro Lys Thr Lys Arg Ser Pro 35 40 45 Leu Thr Arg Ala
His Leu Thr Glu Val Glu Ser Arg Leu Glu Arg Leu 50 55 60 Glu Gln
Leu Phe Leu Leu Ile Phe Pro Arg Glu Asp Leu Asp Met Ile 65 70 75 80
Leu Lys Met Asp Ser Leu Gln Asp Ile Lys Ala Leu Leu Thr Gly Leu 85
90 95 Phe Val Gln Asp Asn Val Asn Lys Asp Ala Val Thr Asp Arg Leu
Ala 100 105 110 Ser Val Glu Thr Asp Met Pro Leu Thr Leu Arg Gln His
Arg Ile Ser 115 120 125 Ala Thr Ser Ser Ser Glu Glu Ser Ser Asn Lys
Gly Gln Arg Gln Leu 130 135 140 Thr Val Ser 145 14 441 DNA
Saccharomyces cerevisiae 14 atgaagctac tgtcttctat cgaacaagca
tgcgatattt gccgacttaa aaagctcaag 60 tgctccaaag aaaaaccgaa
gtgcgccaag tgtctgaaga acaactggga gtgtcgctac 120 tctcccaaaa
ccaaaaggtc tccgctgact agggcacatc tgacagaagt ggaatcaagg 180
ctagaaagac tggaacagct atttctactg atttttcctc gagaagacct tgacatgatt
240 ttgaaaatgg attctttaca ggatataaaa gcattgttaa caggattatt
tgtacaagat 300 aatgtgaata aagatgccgt cacagataga ttggcttcag
tggagactga tatgcctcta 360 acattgagac agcatagaat aagtgcgaca
tcatcatcgg aagagagtag taacaaaggt 420 caaagacagt tgactgtatc g 441 15
750 DNA Cytomegalovirus 15 tcaatattgg ccattagcca tattattcat
tggttatata gcataaatca atattggcta 60 ttggccattg catacgttgt
atctatatca taatatgtac atttatattg gctcatgtcc 120 aatatgaccg
ccatgttggc attgattatt gactagttat taatagtaat caattacggg 180
gtcattagtt catagcccat atatggagtt ccgcgttaca taacttacgg taaatggccc
240 gcctggctga ccgcccaacg acccccgccc attgacgtca ataatgacgt
atgttcccat 300 agtaacgcca atagggactt tccattgacg tcaatgggtg
gagtatttac ggtaaactgc 360 ccacttggca gtacatcaag tgtatcatat
gccaagtccg ccccctattg acgtcaatga 420 cggtaaatgg cccgcctggc
attatgccca gtacatgacc ttacgggact ttcctacttg 480 gcagtacatc
tacgtattag tcatcgctat taccatggtg atgcggtttt ggcagtacac 540
caatgggcgt ggatagcggt ttgactcacg gggatttcca agtctccacc ccattgacgt
600 caatgggagt ttgttttggc accaaaatca acgggacttt ccaaaatgtc
gtaacaactg 660 cgatcgcccg ccccgttgac gcaaatgggc ggtaggcgtg
tacggtggga ggtctatata 720 agcagagctc gtttagtgaa ccgtcagatc 750 16
798 DNA Choristoneura fumiferana 16 tcggtgcagg taagcgatga
gctgtcaatc gagcgcctaa cggagatgga gtctttggtg 60 gcagatccca
gcgaggagtt ccagttcctc cgcgtggggc ctgacagcaa cgtgcctcca 120
cgttaccgcg cgcccgtctc ctccctctgc caaataggca acaagcaaat agcggcgttg
180 gtggtatggg cgcgcgacat ccctcatttc gggcagctgg agctggacga
tcaagtggta 240 ctcatcaagg cctcctggaa tgagctgcta ctcttcgcca
tcgcctggcg ctctatggag 300 tatttggaag atgagaggga gaacggggac
ggaacgcgga gcaccactca gccacaactg 360 atgtgtctca tgcctggcat
gacgttgcac cgcaactcgg cgcagcaggc gggcgtgggc 420 gccatcttcg
accgcgtgct gtccgagctc agtctgaaga tgcgcacctt gcgcatggac 480
caggccgagt acgtcgcgct caaagccatc gtgctgctca accctgatgt gaaaggactg
540 aagaatcggc aagaagttga cgttttgcga gaaaaaatgt tctcttgcct
ggacgactac 600 tgccggcggt cgcgaagcaa cgaggaaggc cggtttgcgt
ccttgctgct gcggctgcca 660 gctctccgct ccatctcgct caagagcttc
gaacacctct acttcttcca cctcgtggcc 720 gaaggctcca tcagcggata
catacgagag gcgctccgaa accacgcgcc tccgatcgac 780 gtcaatgcca tgatgtaa
798 17 799 DNA Drosophila melanogaster 17 catagaggcc gagcagcgag
cggagaccca atgcggcgat cgtgcactga cgttcctgcg 60 cgttggtccc
tattccacag tccagccgga ctacaagggt gccgtgtcgg ccctgtgcca 120
agtggtcaac aaacagctct tccagatggt cgaatacgcg cgcatgatgc cgcactttgc
180 ccaggtgccg ctggacgacc aggtgattct gctgaaagcc gcttggatcg
agctgctcat 240 tgcgaacgtg gcctggtgca gcatcgtttc gctggatgac
ggcggtgccg gcggcggggg 300 cggtggacta ggccacgatg gctcctttga
gcgacgatca ccgggccttc agccccagca 360 gctgttcctc aaccagagct
tctcgtacca tcgcaacagt gcgatcaaag ccggtgtgtc 420 agccatcttc
gaccgcatat tgtcggagct gagtgtaaag atgaagcggc tgaatctcga 480
ccgacgcgag ctgtcctgct tgaaggccat catactgtac aacccggaca tacgcgggat
540 caagagccgg gcggagatcg agatgtgccg cgagaaggtg tacgcttgcc
tggacgagca 600 ctgccgcctg gaacatccgg gcgacgatgg acgctttgcg
caactgctgc tgcgtctgcc 660 cgctttgcga tcgatcagcc tgaagtgcca
ggatcacctg ttcctcttcc gcattaccag 720 cgaccggccg ctggaggagc
tctttctcga gcagctggag gcgccgccgc cacccggcct 780 ggcgatgaaa
ctggagtag 799 18 635 DNA Locusta migratoria 18
tgcatacaga catgcctgtt gaacgcatac ttgaagctga aaaacgagtg gagtgcaaag
60 cagaaaacca agtggaatat gagctggtgg agtgggctaa acacatcccg
cacttcacat 120 ccctacctct ggaggaccag gttctcctcc tcagagcagg
ttggaatgaa ctgctaattg 180 cagcattttc acatcgatct gtagatgtta
aagatggcat agtacttgcc actggtctca 240 cagtgcatcg aaattctgcc
catcaagctg gagtcggcac aatatttgac agagttttga 300 cagaactggt
agcaaagatg agagaaatga aaatggataa aactgaactt ggctgcttgc 360
gatctgttat tcttttcaat ccagaggtga ggggtttgaa atccgcccag gaagttgaac
420 ttctacgtga aaaagtatat gccgctttgg aagaatatac tagaacaaca
catcccgatg 480 aaccaggaag atttgcaaaa cttttgcttc gtctgccttc
tttacgttcc ataggcctta 540 agtgtttgga gcatttgttt ttctttcgcc
ttattggaga tgttccaatt gatacgttcc 600 tgatggagat gcttgaatca
ccttctgatt cataa 635 19 714 DNA Mus musculus 19 gccaacgagg
acatgcctgt agagaagatt ctggaagccg agcttgctgt cgagcccaag 60
actgagacat acgtggaggc aaacatgggg ctgaacccca gctcaccaaa tgaccctgtt
120 accaacatct gtcaagcagc agacaagcag ctcttcactc ttgtggagtg
ggccaagagg 180 atcccacact tttctgagct gcccctagac gaccaggtca
tcctgctacg ggcaggctgg 240 aacgagctgc tgatcgcctc cttctcccac
cgctccatag ctgtgaaaga tgggattctc 300 ctggccaccg gcctgcacgt
acaccggaac agcgctcaca gtgctggggt gggcgccatc 360 tttgacaggg
tgctaacaga gctggtgtct aagatgcgtg acatgcagat ggacaagacg 420
gagctgggct gcctgcgagc cattgtcctg ttcaaccctg actctaaggg gctctcaaac
480 cctgctgagg tggaggcgtt gagggagaag gtgtatgcgt cactagaagc
gtactgcaaa 540 cacaagtacc ctgagcagcc gggcaggttt gccaagctgc
tgctccgcct gcctgcactg 600 cgttccatcg ggctcaagtg cctggagcac
ctgttcttct tcaagctcat cggggacacg 660 cccatcgaca ccttcctcat
ggagatgctg gaggcaccac atcaagccac ctag 714 20 711 DNA Artificial
Sequence Chimeric MmRXRalpha/LmUSP-EF 20 gccaacgagg acatgcctgt
agagaagatt ctggaagccg agcttgctgt cgagcccaag 60 actgagacat
acgtggaggc aaacatgggg ctgaacccca gctcaccaaa tgaccctgtt 120
accaacatct gtcaagcagc agacaagcag ctcttcactc ttgtggagtg ggccaagagg
180 atcccacact tttctgagct gcccctagac gaccaggtca tcctgctacg
ggcaggctgg 240 aacgagctgc tgatcgcctc cttctcccac cgctccatag
ctgtgaaaga tgggattctc 300 ctggccaccg gcctgcacgt acaccggaac
agcgctcaca gtgctggggt gggcgccatc 360 tttgacaggg tgctaacaga
gctggtgtct aagatgcgtg acatgcagat ggacaagact 420 gaacttggct
gcttgcgatc tgttattctt ttcaatccag aggtgagggg tttgaaatcc 480
gcccaggaag ttgaacttct acgtgaaaaa gtatatgccg ctttggaaga atatactaga
540 acaacacatc ccgatgaacc aggaagattt gcaaaacttt tgcttcgtct
gccttcttta 600 cgttccatag gccttaagtg tttggagcat ttgtttttct
ttcgccttat tggagatgtt 660 ccaattgata cgttcctgat ggagatgctt
gaatcacctt ctgattcata a 711 21 687 DNA Amblyomma americanum 21
cctcctgaga tgcctctgga gcgcatactg gaggcagagc tgcgggttga gtcacagacg
60 gggaccctct cggaaagcgc acagcagcag gatccagtga gcagcatctg
ccaagctgca 120 gaccgacagc tgcaccagct agttcaatgg gccaagcaca
ttccacattt tgaagagctt 180 ccccttgagg accgcatggt gttgctcaag
gctggctgga acgagctgct cattgctgct 240 ttctcccacc gttctgttga
cgtgcgtgat ggcattgtgc tcgctacagg tcttgtggtg 300 cagcggcata
gtgctcatgg ggctggcgtt ggggccatat ttgatagggt tctcactgaa 360
ctggtagcaa agatgcgtga gatgaagatg gaccgcactg agcttggatg cctgcttgct
420 gtggtacttt ttaatcctga ggccaagggg ctgcggacct gcccaagtgg
aggccctgag 480 ggagaaagtg tatctgcctt ggaagagcac tgccggcagc
agtacccaga ccagcctggg 540 cgctttgcca agctgctgct gcggttgcca
gctctgcgca gtattggcct caagtgcctc 600 gaacatctct ttttcttcaa
gctcatcggg gacacgccca tcgacaactt tcttctttcc 660 atgctggagg
ccccctctga cccctaa 687 22 693 DNA Amblyomma americanum 22
tctccggaca tgccactcga acgcattctc gaagccgaga tgcgcgtcga gcagccggca
60 ccgtccgttt tggcgcagac ggccgcatcg ggccgcgacc ccgtcaacag
catgtgccag 120 gctgccccgc cacttcacga gctcgtacag tgggcccggc
gaattccgca cttcgaagag 180 cttcccatcg aggatcgcac cgcgctgctc
aaagccggct ggaacgaact gcttattgcc 240 gccttttcgc accgttctgt
ggcggtgcgc gacggcatcg ttctggccac cgggctggtg 300 gtgcagcggc
acagcgcaca cggcgcaggc gttggcgaca tcttcgaccg cgtactagcc 360
gagctggtgg ccaagatgcg cgacatgaag atggacaaaa cggagctcgg ctgcctgcgc
420 gccgtggtgc tcttcaatcc agacgccaag ggtctccgaa acgccaccag
agtagaggcg 480 ctccgcgaga aggtgtatgc ggcgctggag gagcactgcc
gtcggcacca cccggaccaa 540 ccgggtcgct tcggcaagct gctgctgcgg
ctgcctgcct tgcgcagcat cgggctcaaa 600 tgcctcgagc atctgttctt
cttcaagctc atcggagaca ctcccataga cagcttcctg 660 ctcaacatgc
tggaggcacc ggcagacccc tag 693 23 17 DNA Saccharomyces cerevisiae 23
cggagtactg tcctccg 17 24 30 DNA Artificial Sequence Synthetic TATAA
24 tagagggtat ataatggatc cccgggtacc 30 25 1705 DNA Photinus pyralis
25 atggaagacg ccaaaaacat aaagaaaggc ccggcgccat tctatcctct
agaggatgga 60 accgctggag agcaactgca taaggctatg aagagatacg
ccctggttcc tggaacaatt 120 gcttttacag atgcacatat cgaggtgaac
atcacgtacg cggaatactt cgaaatgtcc 180 gttcggttgg cagaagctat
gaaacgatat gggctgaata caaatcacag aatcgtcgta 240 tgcagtgaaa
actctcttca attctttatg ccggtgttgg gcgcgttatt tatcggagtt 300
gcagttgcgc ccgcgaacga catttataat gaacgtgaat tgctcaacag tatgaacatt
360 tcgcagccta ccgtagtgtt tgtttccaaa aaggggttgc aaaaaatttt
gaacgtgcaa 420 aaaaaattac caataatcca gaaaattatt atcatggatt
ctaaaacgga ttaccaggga 480 tttcagtcga tgtacacgtt cgtcacatct
catctacctc ccggttttaa tgaatacgat 540 tttgtaccag agtcctttga
tcgtgacaaa acaattgcac tgataatgaa ttcctctgga 600 tctactgggt
tacctaaggg tgtggccctt ccgcatagaa ctgcctgcgt cagattctcg 660
catgccagag atcctatttt tggcaatcaa atcattccgg atactgcgat tttaagtgtt
720 gttccattcc atcacggttt tggaatgttt actacactcg gatatttgat
atgtggattt 780 cgagtcgtct taatgtatag atttgaagaa gagctgtttt
tacgatccct tcaggattac 840 aaaattcaaa gtgcgttgct agtaccaacc
ctattttcat tcttcgccaa aagcactctg 900 attgacaaat acgatttatc
taatttacac gaaattgctt ctgggggcgc acctctttcg 960 aaagaagtcg
gggaagcggt tgcaaaacgc ttccatcttc cagggatacg acaaggatat 1020
gggctcactg agactacatc agctattctg attacacccg agggggatga taaaccgggc
1080 gcggtcggta aagttgttcc attttttgaa gcgaaggttg tggatctgga
taccgggaaa 1140 acgctgggcg ttaatcagag aggcgaatta tgtgtcagag
gacctatgat tatgtccggt 1200 tatgtaaaca atccggaagc gaccaacgcc
ttgattgaca aggatggatg gctacattct 1260 ggagacatag cttactggga
cgaagacgaa cacttcttca tagttgaccg cttgaagtct 1320 ttaattaaat
acaaaggata tcaggtggcc cccgctgaat tggaatcgat attgttacaa 1380
caccccaaca tcttcgacgc gggcgtggca ggtcttcccg acgatgacgc cggtgaactt
1440 cccgccgccg ttgttgtttt ggagcacgga aagacgatga cggaaaaaga
gatcgtggat 1500 tacgtcgcca gtcaagtaac aaccgcgaaa aagttgcgcg
gaggagttgt gtttgtggac 1560 gaagtaccga aaggtcttac cggaaaactc
gacgcaagaa aaatcagaga gatcctcata 1620 aaggccaaga agggcggaaa
gtccaaattg taaaatgtaa ctgtattcag cgatgacgaa 1680 attcttagct
attgtaatac tctag 1705
* * * * *
References